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Traditionally, drug discovery programs have focused on prioritising compounds by their 
affinity to a specific target in isolation, which was hypothesised to be the cause of a 
particular disease. Through chemical inhibition, the disease could, thus, be prevented or at 
the very least, controlled. These hypotheses require significant validation before drug 
screening can begin which relates to lengthy and expensive programs. Furthermore, drug 
screening against a single target in isolation is not a realistic model of cellular behaviour and 
is not appropriately tailored to more complex diseases such as cancer. 
Phenotypic drug discovery, on the other hand, bypasses any involvement of known targets, 
instead focusing on the desired outcome – the phenotype. In this way, drugs are biased by 
their potency on the phenotype and not against any particular targets. The molecular 
mechanism of action need not be known at all, however, it can be useful to later reveal the 
target(s) involved by various deconvolution methods. 
This thesis describes a cooperative ligand based phenotypic drug discovery approach, 
undertaken in order to develop more suitable small molecule drugs for cancer treatment. For 
this purpose, the promiscuous pyrazolopyrimidine inhibitor PP1 was chosen as a starting 
model compound. Modification of PP1 on the N1 position allowed a series of water 
solubilising groups to be incorporated into the pyrazolopyrimidine scaffold which created an 
initial 12-membered library. Testing against MCF7 breast cancer cells and looking at 
phenotypic end points such as cell proliferation, cell mobility and cell cycle, generated early 
target-agnostic structure/anti-proliferative activity relationships. These early results, along 
with compounds published in recent literature, were used to generate further libraries. 
Profiling lead compounds against a selection of 18 kinases known to be targeted by PP1, 
showed the compounds were inhibiting either SRC family or mTOR kinases which enabled 
the creation of two, structure specific, groups of inhibitors. Further lead optimisation led to 
the rapid discovery of preclinical candidates with excellent drug-like properties and 
potencies in both cellular assays and against their respective targets. Compounds also 
showed improved selectivity profiles compared to PP1 and commonly known inhibitors of 
SRC and mTOR kinases. Reported, herein, is the discovery of the first sub-nanomolar SRC 
inhibitor which does not inhibit the kinase ABL and shows excellent properties suitable for 





This thesis has been entirely written by me, Craig Fraser.  All experiments and analysis have 
been performed by me unless otherwise stated. All figures, schemes and tables have been 
composed by me unless stated. Permission was sought for any figures not composed by me 
and is indicated in the figure description. This work is not submitted for any other degree or 
professional qualification. A patent was filed on the 21
st
 of May, 2015 protecting the rights 
to the compounds described in this thesis. 








First of all, my upmost gratitude goes to Dr Asier Unciti-Broceta. Your down-to-earth 
attitude and excellent supervision has made my PhD experience a very positive one, and has 
been paramount to the success of this project, and thesis. Your seemingly endless supply of 
ideas and 'wee blue books' will be worth millions someday. 'I have an idea' is a phrase I have 
come to both love, and loath. 
A special mention goes out to Dr Jason Weiss, the other co-founder of the Unciti-Broceta lab 
(who managed to beat me on both publishing, and submitting his thesis). We have worked 
great together from the start and if there ever was an example of excellent team work, we 
would be it. The rest of the Unciti-Broceta group also deserve special thanks - Dr Belén 
Rubio-Ruiz, Dr Teresa Valero, Dr Ana Pérez-López, Sam Myers, Thomas Bray and Richard 
Crispin. The good times we have shared both in the lab and out have made this PhD 
worthwhile.  
I must thank both Dr Neil Carragher and Dr John Dawson for both teaching me your 
knowledge and answering my constant questions regarding biology. John, your hands-on 
experience is second to none and your no-messing-about approach to science is something I 
admire. A particular mention must go to Alison Munro for always pointing me in the right 
direction and keeping tissue culture in tip top condition. I also thank the rest of the Carragher 
group for their guidance, and good times had during the post-lab meeting pub trips. 
The strong collaboration between the Unciti-Broceta and Patton groups deserves a mention 
and I thank Dr Liz Patton and Reece Dowling for their perseverance and patience during the 
zebrafish work. I hope the collaboration will continue to grow. 
Special thanks go to Jan at reception. Your welcoming smile and help during my 3 years 
have made this experience so much easier. 
I must thank my parents, Andrea and John, for their support during, not just my PhD, but all 
through my undergraduate, and also my brother, Stephen, for the collective nodding of your 
heads in agreement when I try to explain what I actually do. My gratitude goes far beyond 
words. To all my friends in Edinburgh, and beyond, I thank you for all the good nights had 
and the accompanying, uncomfortable, hangovers. 
5 
 
Síðast, en ekki síst, vil ég þakka kærustunni minni, Ylfu. Öllu mínu doktorsnámi deildi ég 
með þér og þú hefur umborið allt mitt nöldur meðan á því stóð. Ég hef vaxið mikið á síðustu 
þremur árum og þú hefur verið stór hluti af því. Þú kynntir mig fyrir heimalandi þínu, 
Íslandi, sem ég varð strax mjög hrifin af. Stundirnar sem við höfum átt saman, bæði í 
Edinborg og erlendis mun ég minnast um ókomna tíð og ég hlakka til upplifa enn fleiri 





Abstract ................................................................................................................................... 2 
Declaration .............................................................................................................................. 3 
Acknowledgements ................................................................................................................. 4 
Abbreviations ........................................................................................................................ 10 
1. Introduction ....................................................................................................................... 14 
1.1 Targeted Drug Discovery ............................................................................................ 14 
1.2 Phenotypic Drug Discovery ........................................................................................ 17 
1.3 Pyrazolopyrimidines as Kinase Inhibitors .................................................................. 20 
1.3.1 Pyrazolopyrimidines as Kinase Inhibitors ............................................................ 21 
1.3.2 Pyrazolo[3,4-d]pyrimidines as SRC Family Kinase Inhibitors ............................ 22 
1.4 The Mechanistic Target of Rapamycin ....................................................................... 24 
1.4.1 mTORC1 ............................................................................................................... 24 
1.4.2 mTORC2 ............................................................................................................... 25 
1.4.3 The Role of mTOR in Cancer ................................................................................ 27 
1.4.4 mTOR Inhibitors - Rapalogs ................................................................................. 28 
1.4.5 mTOR Inhibitors – ATP Competitive .................................................................... 30 
1.5 SRC ............................................................................................................................. 33 
1.5.1 The Structure and Function of SRC ...................................................................... 34 
1.5.2 SRC and Cancer .................................................................................................... 35 
1.5.3 SRC Inhibition ....................................................................................................... 37 
1.5.4 SRC Inhibitors in Combination Therapy............................................................... 39 
2. Research Aims and Rationale ........................................................................................... 41 
3. Design and Synthesis of Initial Library .............................................................................. 43 
3.1 Introduction & Aims ......................................................................................................... 43 
3.2 Results .............................................................................................................................. 45 
3.2.1 Library 1 Design and Synthesis ............................................................................ 45 
3.2.2 Cell Proliferation Assay on Library 1 Compounds ............................................... 47 
3.2.3 Apoptosis Assay on Compounds 8, 10, 14, 17, 18 and PP1 .................................. 51 
3.3 Conclusion ........................................................................................................................ 54 
7 
 
4. The Discovery of Potent Anti-Proliferative Compounds and Target Identification ........ 55 
4.1 Introduction & Aims ......................................................................................................... 55 
4.2 Results .............................................................................................................................. 56 
4.2.1 The Design and Synthesis of Library Two ............................................................ 56 
4.2.2 Screening on a Sub-set of Kinases ........................................................................ 60 
4.3 Conclusion ........................................................................................................................ 63 
5. The Development of Novel, Potent and Selective mTOR Inhibitors ............................... 64 
5.1 Introduction & Aims ......................................................................................................... 64 
5.2 Results .............................................................................................................................. 65 
5.2.1 Synthesis and Testing of Analogues of Compound 19 .......................................... 65 
5.2.2 Kinase Inhibition Data .......................................................................................... 67 
5.2.3 Compound 41 Stability Study ................................................................................ 71 
5.2.5 Further Optimisation of Compound 41 to Increase Potency Against mTOR........ 73 
5.2.6 Cell Cycle Assay.................................................................................................... 75 
5.2.7 Kinase Data for Compounds 41, 47, 48 and INK-128 .......................................... 78 
5.2.8 Western Blot Analysis of Compound 41 ................................................................ 79 
5.3 Conclusion ........................................................................................................................ 82 
6. The Development of Novel, Potent and Selective SRC Family Kinase Inhibitors ............ 83 
6.1 Introduction & Aims ......................................................................................................... 83 
6.2 Results .............................................................................................................................. 84 
6.2.1 The Synthesis and Testing of Lead Compound 52 ................................................ 84 
6.2.2 The Anti-Oncogenic Role of c-ABL in Cancer ...................................................... 89 
6.2.3 In Vitro Properties of Compound 52 – Whole Kinome Selectivity ........................ 91 
6.2.4 Compound 52 Inhibits the Migration of MDA-MB-231 Cells in Vitro ................. 94 
6.2.5 Western Blot Analysis of Compound 52 and Dasatinib ........................................ 96 
6.2.6 Zebrafish Cardiotoxicity and Tail Fin Cut Studies ............................................... 98 
6.3 Conclusion ...................................................................................................................... 103 
7. Optimisation of Lead Compound 52 ............................................................................... 104 
7.1 Introduction & Aims ....................................................................................................... 104 
7.2 Results ............................................................................................................................ 105 
7.2.1 Design and Synthesis of Compound 55 and 56 ................................................... 105 
7.2.2 Aryl Group Modifications – Synthesis and Biological Testing ........................... 106 
7.2.3 Further Optimisation of the Aryl Group - Pyridines .......................................... 110 
8 
 
7.2.4 Further Optimisation of the Aryl Group – Phenyl Modifications ....................... 111 
7.2.5 Synthesis of Compounds 99, 100 and 101 to Complete SAR on ‘South’ of Structure
 ..................................................................................................................................... 117 
7.2.6 Kinase Activity of Compounds 55, 56, 66, 76, 84, 86, 87, 94 and 99 ................. 119 
7.2.7 Synthesis of Pyrazole Compound 104 ................................................................. 121 
7.3 Conclusion ...................................................................................................................... 123 
8. Pre-clinical Testing of Lead Compounds ......................................................................... 125 
8.1 Introduction & Aims ....................................................................................................... 125 
8.2 Results ............................................................................................................................ 128 
8.2.1 hERG Liability Study .......................................................................................... 128 
8.2.2 Cytochrome P450 Enzyme Inhibition Assay ....................................................... 129 
8.2.3 Plasma Protein Binding Study ............................................................................ 130 
8.2.4 Human Liver Microsome Stability Assay ............................................................ 131 
8.2.5 Stability in Human, Mouse and Rat Plasma ....................................................... 132 
8.2.6 Hepatocyte Stability of Compounds 52 and 84 ................................................... 133 
8.2.7 Pharmacokinetic Data of Compounds 52 and 84 ............................................... 134 
8.3 Conclusion ...................................................................................................................... 136 
9. Discussion ........................................................................................................................ 137 
10. Experimental ................................................................................................................. 142 
10.1 General Information .................................................................................................... 142 
10.1.1 Chemicals .......................................................................................................... 142 
10.1.2 Chromatography ............................................................................................... 142 
10.1.3 Nuclear Magnetic Resonance ........................................................................... 142 
10.1.4 Mass Spectrometry ............................................................................................ 143 
10.2 Experimental for Chapter 2 .......................................................................................... 144 
10.2.1 Synthesis of Compounds 2-6 ............................................................................. 144 
10.2.2 Synthesis of Compounds 7-18 ........................................................................... 146 
10.3 Experimental for Chapter 3 .......................................................................................... 156 
10.3.1 Synthesis of Compounds 19-27 ......................................................................... 156 
10.3.2 Synthesis of Compound 28 ................................................................................ 161 
10.3.3 Synthesis of Compounds 29-35 ......................................................................... 162 
10.4 Experimental for Chapter 4 .......................................................................................... 169 
10.4.1 Synthesis of Compounds 36-43 ......................................................................... 169 
9 
 
10.4.2 Synthesis of Compound 44 ................................................................................ 176 
10.4.3 Synthesis of Compounds 45-48 ......................................................................... 176 
10.5 Experimental for Chapter 5 .......................................................................................... 180 
10.5.1 Synthesis of Compound 49 ................................................................................ 180 
10.5.2 Synthesis of Compounds 50-52 ......................................................................... 181 
10.6 Experimental for Chapter 6 .......................................................................................... 184 
10.6.1 Synthesis of Compounds 53-56 ......................................................................... 184 
10.6.2 Synthesis of Compounds 57-68 ......................................................................... 188 
10.6.3 Synthesis of Compounds 69-72 ......................................................................... 198 
10.6.4 Synthesis of Compounds 73-95 ......................................................................... 201 
10.6.5 Synthesis of Compounds 96-101 ....................................................................... 221 
10.6.6 Synthesis of Compounds 102-104 ..................................................................... 226 
10.7 Biology Methods .......................................................................................................... 229 
10.7.1 Cell Culture General ......................................................................................... 229 
10.7.2 Cell Viability Assay ........................................................................................... 229 
10.7.3 Apoptosis Assay ................................................................................................ 229 
10.7.4 Cell Cycle Assay................................................................................................ 230 
10.7.5 Western Blotting Protocol ................................................................................. 230 
10.7.6 Cell Migration Assay ........................................................................................ 231 
10.7.7 Zebra Fish Toxicology Assay ............................................................................ 231 
10.7.8 hERG Channel Inhibition .................................................................................. 232 
10.7.9 Cytochrome P450 Enzyme Inhibition ............................................................... 233 
10.7.10 Plasma Protein Binding .................................................................................. 234 
10.7.11 Human Liver Microsome Stability .................................................................. 234 
10.7.12 Human, Mouse and Rat Plasma Stability ....................................................... 235 
10.7.13 Hepatocyte Stability ........................................................................................ 235 
10.7.14 Pharmacokinetic Analysis ............................................................................... 236 
    10.7.15 Kinase Screening Assay ................................................................................... 236 
References ........................................................................................................................... 238 
Appendix 1 ........................................................................................................................... 247 
Appendix 2 ........................................................................................................................... 249 







H NMR  Proton Nuclear Magnetic Resonance 
4E-BP1   eIF4E Binding Protein 1 
5-FU   5-Fluorouracil 
13
C NMR  Carbon-13 Nuclear Magnetic Resonance 
δ   Chemical Shift 
μM   Micro Molar 
ABL   Abelson murine leukaemia viral oncogene homolog 1 
ADMET  Absorption Distribution, Metabolism, Excretion and Toxicology 
AKT   a.k.a Protein Kinase B 
AMPK   Adenosine Monophosphate-activated Protein Kinase 
ATG13   Autophagy-related Gene 13 
ATP   Adenosine Triphosphate 
BCR   Breakpoint Cluster Region 
BLK   B Lymphocyte Kinase 
BRK/PTK6  Breast tumour Kinase/Protein Tyrosine Kinase 6 
BSA   Bovine Serum Albumin 
CAS   CRK-Associated Substrate 
CDCl3   Deuterated Chloroform 
CML   Chronic Myeloid Leukaemia 
CRPC   Castration Resistant Prostate Cancer 
CSK   C-terminal SRC Kinase 
CYP   Cytochrome P450 enzyme 
d   Doublet 
DCM   Dichloromethane 
dd   Doublet of doublets 
ddd   Doublet of doublet of doublet 
DDT   Dichlorodiphenyltrichloroethane 
Deptor   DEP-domain-containing mTOR-interacting protein 
DMEM   Dulbecco's Modified Eagle Medium 
DMF   N,N-Dimethylformamide 
DMPK   Drug Metabolism and Pharmacokinetics 
DMSO   Dimethylsulphoxide 
DNA   Deoxyribonucleic Acid 
dpf   Days Post Fertilisation 
EC50   Half maximal Effective Concentration  
ECM   Extracellular Matrix 
eEF2K   Eukaryotic Elongation Factor-2-Kinase 
EGFR   Epidermal Growth Factor Receptor 
eIF4B   Eukaryotic Initiation Factor 4B 
eIF4E   Eukaryotic Initiation Factor 4E  
eq.   Equivalents 
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ER   Estrogen Receptor or Endoplasmic Reticulum 
ERBB2   a.k.a HER2 
ES   Electrospray Ionisation 
EtOAc   Ethyl Acetate 
FAK   Focal Adhesion Kinase 
FAS   Fatty Acid Synthase 
FBS   Fetal Bovine Serum 
FDA   Food and Drug Administration 
FGR   Gardner-Rasheer Feline sarcoma viral oncogene homolog 
FIP200   Focal adhesion kinase family-Interacting Protein of 200 kDa 
FKBP12  FK506-binding Protein of 12 kDa 
FRB   FKB12-Rapamycin Binding domain 
FRK/PTK5  Fyn-Related Kinase/Protein Tyrosine Kinase 5 
FYN   Proto-oncogene FYN 
g   Grams 
G2    Gap 2   
GPCR   G-Protein Coupled Receptor 
HCK   Proto-oncogene HCK 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hERG   Human Ether-a-go-go-Related Gene 
HER2   Human Epidermal Growth factor Receptor 2 
HIF1α   Hypoxia-Inducible Factor 1 Alpha 
HLM   Human Liver Microsomes 
HRMS   High Resolution Mass Spectrometry 
HRP   Horseradish Peroxidase 
HTS   High Throughput Screening 
Hz   Hertz 
IC50   Half maximal Inhibitory Concentration 
IGF   Insulin Growth Factor 
IV   Intravenous 
c-KIT   a.k.a. Mast/stem cell growth factor receptor 
J   Coupling Constant  
LCK   Lymphocyte-specific protein tyrosine Kinase 
LC-MS/MS  Liquid Chromatography Mass Spectrometry 
LYN   Lck/Yes Novel tyrosine kinase 
LRMS   Low Resolution Mass Spectrometry 
m   Multiplet 
M   Mitosis 
mg   Milligram 
M+H   Mass + Proton 
ml   Millilitre 
mmol   Millimoles 
m/z   Mass to charge ratio 
MCF7   Michigan Cancer Foundation-7 (Origin of cell line) 
MDA-MB-231  Breast adenocarcinoma cell line 
MeOD   Deuterated Methanol 
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MeOH   Methanol 
MIPDD  Mechanism Informed Phenotypic Drug Discovery 
MHz   Mega Hertz 
mLST8   Mammalian Lethal with Sec13 protein 8 
MOA   Mechanism Of Action 
mRNA   Messenger Ribonucleic Acid 
MS   Mass Spectrometry 
mSIN1   Mammalian Stress activated protein kinase Interacting protein 
mTOR   Mammalian Target of Rapamycin 
mTORC  mTOR Complex 
mw   Microwave 
MW   Molecular Weight 
NADPH  Nicotinamide Adenine Dinucleotide Phosphate-oxidase 
NIS   N-iodosuccinimide 
nm   Nanometer 
NME   New Molecular Entity 
NMR   Nuclear Magnetic Resonance 
NSCLC  Non-Small Cell Lung Cancer 
PAGE   Polyacrylamide Gel Electrophoresis 
PBS   Phosphate Buffered Saline 
PC3   Prostate Cancer 3 
PDCD4   Programmed Cell Death protein 4 
PDGFR  Platelet-Derived Growth Factor Receptor 
PFA   Poly Formaldehyde 
pHH3   Phospho-Histone H3 
PI3K   Phosphatidylinositol 3-Kinase 
PK   Pharmacokinetic 
PKCα   Protein Kinase C-alpha 
POD ECL  Peroxidase Enhanced Chemiluminescence 
PPAR-γ  Peroxisome Proliferator-Activated Receptor-gamma 
PPB   Plasma Protein Binding 
PRAS40  Proline Rich AKT Substrate 40 kDa 
PTEN   Phosphatase and Tensin homolog 
Protor-1  Protein Observed with Rictor-1 
PVDF   Polyvinyllidene Fluoride 
q   Quartet 
Rac1   Ras-related C3 botulinum toxin substrate 1 
Raptor   Regulatory Associated Protein of mTOR 
RED   Rapid Equilibrium Dialysis 
RET   Rearranged during Transfection 
Rf   Retention Factor 
RhoA   Ras Homolog family member A 
Rictor   Rapamycin Insensitive Companion of mTOR 
RLU   Relative Light Units 
RNA   Ribonucleic Acid 
RPMI   Roswell Park Memorial Institute 
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RPPA   Reverse Phase Protein Micro Array 
r.t.   Room Temperature 
s   Singlet 
S6   Ribosomal protein S6 
S6K1   p70 ribosomal S6 Kinase 1 
SAR   Structure Activity Relationship 
SDS   Sodium Dodecyl Sulphate 
SFK   SRC Family Kinase 
SH   SRC Homology 
SMO   Smoothened Receptor 
SREBP1  Sterol Regulatory Element Binding Protein 1 
SRC   Sarcoma 
STAT3   Signal Transducer and Activator of Transcription 3 
SYF   SRC, YES and FYN deficient mouse embryonic fibroblasts 
TBS/T   Tris Buffered Saline/Tween 
TFA   Trifluoroacetic Acid 
THF   Tetrahydrofuran 
TLC    Thin Layer Chromatography 
TSC1/2   Tuberous Sclerosis 1/2 
td   Triplet of Doublets 
Tyr   Tyrosine 
ULK1   Unc-51-Like Kinase 1 
VEGF   Vascular Endothelial Growth Factor 
YES   Proto-Oncogene YES 




1.1 Targeted Drug Discovery 
 
Traditional drug discovery programs begin with a target based hypothesis.[1-5] That is, a 
single biological target (e.g. Enzyme, GPCR, ion channel, DNA/mRNA etc.) is hypothesised 
to cause an undesired effect and so inhibiting or blocking said target should render the 
pathophysiological effect mute and regain normal function, in an organism. Such hypotheses 
require extensive biological validation before the onset of drug screening. This represents the 
first problem associated with traditional target based drug discovery; target validation is 
often challenging due to a lack of disease relevant preclinical model systems and typically 
involves months of work, with knockout mice commonly required. This can prove to be very 
expensive and often the target hypothesis does not correlate well in vivo. Additionally, 
diseases caused by multiple factors/genes, such as cancer, are not appropriately tailored to 
this approach.[6-8] That is not to say that the targeted drug discovery approach is ineffective. 
Indeed, it has proven itself several times over in the later stages of the 20th and early 21st 
century of drug discovery. However, the increased costs associated with target directed drug 
discovery and high attrition rates have contributed to an overall decline in pharmaceutical 
productivity.[9] 































Figure 1.1: New molecular entities approved between 1999 and 2008 arranged by their 
discovery stategy. 
 
As described in a recent review by David C. Swinney and Jason Anthony, targeted drug 
discovery programs accounted for 43% of new molecular entities (NME) approved between 
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1999 and 2008 with phenotypic based drug discovery programs producing 25%, figure 
1.1.[10] 
This is by no means a fair comparison of both routes as neither attrition rates nor costs were 
taken into consideration. It is also worthy to note that target-directed drug discovery was less 
successful in the production of first in class drugs but far superior in ‘follow on’ drugs. 
These analyses may be expected as ‘follow on’ drugs have the target pre-validated and new 
drugs are simply developed to offer incremental improvements in potency, or 
pharmacokinetic properties, over the original drug. 
Shown in figure 1.2 is a schematic representation of the traditional drug discovery route. 
Priority is placed on validating a molecular target corresponding to a particular disease. Once 
the target has been validated and one is confident that inhibition of the target will reduce the 
effects of the disease, priority is then shifted to developing a drug against the target. There 
are many methods for discovering a starting compound, listed below: 
1. High throughput screening (HTS) 
2. Structure based techniques (eg. X-ray, NMR) 
3. Improving previous drugs (follow on drug) 
4. Modification of natural ligands 
5. Modification of natural inhibitors  
 
Figure 1.2: Traditional target-directed drug project operating model from target identification 
to clinical candidate. 
 
However, when it comes to the treatment of cancer, disappointing results in recent clinical 
trials have shown that even compounds showing promising results in vitro often translate 
poorly when taken into the clinic. An important point to consider when advancing a drug 
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candidate is the emergence of drug resistance in patients. In many cancers, the major issue 
when administering chemotherapy is overcoming heterogeneity within patients. 
Consequently, more effective targeted drug therapies are still very much sought after.[11, 12] 
When drugs do get approved for use in humans, targeted drug discovery does have one 
strong advantage. That is the ability to pair up the patient with the correct drug. If the drug 
has a well-defined target, patients can be selected by predictive biomarkers of target 
expression or activity and tailored to the correct therapy. This enables more personalised 
therapy rather than a ‘stab in the dark’ approach where generic drugs are prescribed to 
groups of patients with ‘similar’ cancers. 
One must be careful, however, as there have been a few reported cases of drugs assigned to 
the wrong targets – although the drug may inhibit the target, its true mechanism of action 
exerts through another, perhaps unknown, pathway. Such an example is Sorafenib, thought 
to be a Raf inhibitor but later shown to exert it's clinical effects through VEGFR 
inhibition.[13] This can lead to the selection of the wrong population of patients in trials and, 
consequently, apparent failed efficacy of the drug.[13-16] Even drugs with well validated 
targets may present significant problems when taken into the clinic as complex signalling 
pathways and feedback mechanisms within cells coupled with intricate resistance 
mechanisms may prove overwhelming for the drug, contrary to the success observed in more 
basic preclinical cellular studies.  
In order to break away from the resistance prone targeted drug discovery approach, one may 
take a variety of steps. For example, phenotypic drug discovery is an alternative route which 
frontloads the phenotype of the disease model rather than the genotype, therefore, biasing the 
development on the desired therapeutic outcome regardless of the molecular targets 
involved.[17] Adopting pro-drug therapies for administering drugs to specific disease areas 
permits the safer use of cytotoxic agents and helps to reduce the side effects associated with 
them.[18] The pre-clinical use of advanced imaging techniques coupled with clinically 
relevant in vitro models may also steer drug development towards more successful outcomes  
by informing chemical selection and design strategies based upon robust biological 
evidence.[19] Although perhaps not appropriately tailored for more complex diseases such 
as neurodegeneration and the majority of cancers, which do not fall into molecular subtypes 
characterised by defined genetic mutations, targeted drug discovery remains a valuable route 





1.2 Phenotypic Drug Discovery 
 
As an alternative to the current targeted drug discovery route, modern phenotypic drug 
discovery offers promise in overcoming the difficult transition from lab to clinic. Drugs 
developed on the basis of selectivity to one target only, often do not possess known 
mechanisms of action. That is to say that although the target may be validated via knockout 
mice etc., and the drug does indeed inhibit the target effectively, the exact mechanism by 
which it exerts its phenotypic response (i.e. cell death, reduced cell mobility/division) is 
unknown. Many cases of failed clinical programs may be caused by gaps in the knowledge 
of molecular pathways. On the other hand, phenotypic drug discovery offers the advantage 
of not being constrained by target selectivity and instead, focuses on the desired outcome. 
Drugs produced from such a technique are, therefore, more likely to possess validated and 
clinically relevant mechanisms of action.[20] 
Classic phenotypic endpoints in cancer drug discovery include: reduced cell proliferation, 
reduced cell migration/invasion, induction of apoptosis, cell cycle arrest and changes in cell 
morphology. These classical ‘hallmarks of cancer’ are relatively simple to measure in in 
vitro assays. Consequently, whether a drug can reduce cancer cell viability in culture has 
become the bedrock of cancer drug discovery. Indeed, this phenotypical based technique has 
outdated any knowledge of the mechanisms of action of drugs or the targets involved.[21] 
However, there are many phenotypes which are not so easily measured (e.g. inhibition of 
angiogenesis, cell motility, and evasion of the immune system) as they require more complex 
modelling and assay formats than simply cultured cancer cells in a monolayer. 
Figure 1.3 shows how phenotypic screening bypasses biased knowledge of a compound's 
target. Starting at the ‘hit screening’ stage, one can progress a compound right through to the 
clinic without any prior knowledge of the target involved. In essence, the route is shorter, 
however, knowing the target can often help the optimisation of a drug and will prove more 
useful in a preclinical setting. In practice, it is often wise to deconvolute the target after an 
early lead compound has been identified (lead optimisation stage). There are various ways to 
deconvolute a target including: reverse protein micro arrays (RPPA), screening against 
members of a target family (e.g. the kinome for a suspected kinase inhibitor), affinity 
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chromatography, phage display, mRNA display, yeast/mammalian three hybrid system, 
reverse transfected cell microarrays etc.[22] 
 
 
Figure 1.3: Adapted schematic diagram from figure 1.1 showing the typical phenotypic 
approach. 
 
As an extension to the two sided, black or white argument (targeted or phenotypic), John G. 
Moffat et Al. described a more fluid classification on the origins of NMEs.[23] They 
analysed drugs approved for cancer treatment between 1999 and 2013 and categorised them 
according to a ‘matrix system’, table 1.1.  
It is clear from the data that the majority of drugs were discovered solely via a targeted 
approach where both the initial hit and further development was based upon on-target 
potency alone. Interestingly, most of these drugs (21 out of 29) were kinase inhibitors. The 
well-established ATP assays available for determining kinase inhibition and their ease of 
expression in bacterial systems along with the ability to create X-ray crystal structures 































Inhibition of Known Target 29 4 3 
Mechanism Informed 
Phenotypic Assay 
2 2 3* 
Unbiased Phenotypic Assay 0 1 4 
Table 1.1: Origins of cancer drugs approved between 1999 and 2013 by Moffat et al.[23] 
*Compounds discussed in this thesis belong to this category. 
 
This study, most importantly, included an ‘in-between’ category which Moffat et al. have 
termed ‘mechanism-informed phenotypic drug discovery (MIPDD)’.[23] This category 
comprises drugs that have either been initially discovered or optimised by a phenotypic 
screen but the main target(s) of the compounds are known. Knowing the target involved 
allows further development of novel compounds with both well-defined molecular 
mechanisms of action and proven phenotypic properties, at least in vitro.  
The compounds discussed in this thesis belong to the MIPDD category because the core 
structure is derived from a known promiscuous kinase inhibitor (PP1) and, therefore, any 
phenotypic hit should be expected to target one or more proteins of the human kinome. 
However, apart from their biased starting design, the initial hits were discovered solely 
through a phenotypic screen with no regard to the target involved. Thus, they belong to a 
further novel category halfway in between MIPDD and unbiased phenotypic screen: 
discovered by an unbiased phenotypic screen but subsequently optimised by mechanism 













1.3 Pyrazolopyrimidines as Kinase Inhibitors 
 
Pyrazolopyrimidines are the fused heterocyclic system comprising a 5-membered pyrazole 
moiety joined to a 6-membered pyrimidine, figure 1.4. Different orientations of the rings 
leads to different isomers, however, this chapter only focuses on pyrazolo[3,4-
d]pyrimindines as the drugs described later contain only this isomer. 
 
Figure 1.4: Structures of the different isomers of pyrazolopyrimidines. 
 
The first reported compound containing the pyrazolo[3,4-d]pyrimidine system was in 1938 
by Justoni and Fusco.[24] They synthesised the compound 6-methyl-1,3-diphenyl-
pyrazolo[3,4-d]pyrimidin-4-ol from 5-acetamido-1,3-diphenyl-pyrazole-4-carboxamide as 
shown in figure 1.5. 
 




Commonly reported pyrazolopyrimidines are substituted pyrazolo[3,4-d]pyrimidin-4-amine 
compounds. The similarity of this group to the purines, most importantly to adenine, allows 
the development of compounds which show similar properties to the natural nucleobases etc. 
and indeed some of the earliest pyrazolopyrimidines were shown to be adenosine receptor 
antagonists.[25-27] As early as the 1980s, pyrazolopyrimidines were being substituted for 
adenine in ribonucleosides in order to mimic adenosine and create synthetic drugs.[28] 
Cottam et Al. synthesised 3,4-disubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides in 
order to treat parasitic infections. The unique metabolic pathways of the parasites allowed 
the incorporation of the synthetic ribonucleosides into RNA, whereas, this process did not 
occur in mammals. 
 
1.3.1 Pyrazolopyrimidines as Kinase Inhibitors 
Kinases are an important class of enzyme contained within cells. Kinases, by definition, are 
enzymes which use adenosine triphosphate (ATP) to transfer phosphate groups to other 
molecules, thereby, phosphorylating them. These phosphorylation sites of proteins, and other 
cellular substrates such as lipids and carbohydrates, act as on/off switches governing enzyme 
activity or protein-protein interactions and the presence or absence of a phosphate group on a 
key site (amino acids such as tyrosine, serine, threonine or histidine may be phosphorylated 
in proteins) determines the function and activity within cells. Kinases are, therefore, highly 
involved in the signalling networks that exist within cells. Kinases not only control basic 
pathways within and across cells but they also contribute to the dynamic signalling that 
exists between cells and the extracellular matrix (ECM) by regulating the functions of 
adhesion complexes and transmitting signals from extracellular ligands. This influences the 
dynamics of the cell and controls cellular movement and overall tissue physiology. Due to 
their important role in cell functions, unnaturally high or low levels of kinase expression can 
lead to a variety of diseases including cancer and inflammation of various tissues.[29]
  
The high importance of kinases within cells has prompted a search for tools in order to study 
their function or even control their activity. One of the earliest reported cases of synthetic 
pyrazolopyrimidine kinase inhibitors was by Cottam et. Al. in 1993.[30] They synthesised 
pyrazolo[3,4-d]pyrimidine analogues of 5-iodotubercidin, shown in figure 1.6, as inhibitors 




Figure 1.6: Pyrazolo[3,4-d]pyrimidine analogues of 5-iodotubercidin synthesised by  Cottam 
et Al. for use as adenosine inhibitors. 
 
The first clinically approved kinase inhibitor for cancer was Imatinib in May 2001. In terms 
of medicinal chemistry this is relatively recent and so kinase inhibition for cancer therapy 
remains a fresh and exciting area of drug discovery. Currently, the only pyrazolopyrimidine 
kinase inhibitor approved by the FDA is Ibrutinib which was approved in November 2013 
for the treatment of mantle cell lymphoma. 
 
1.3.2 Pyrazolo[3,4-d]pyrimidines as SRC Family Kinase Inhibitors 
SRC is short for ‘sarcoma’. Cellular-SRC (c-SRC) and the constitutively active avian viral 
form (v-SRC) are two of the oldest oncogenes reported.[31] SRC is, therefore, one of the 
most studied and familiar human proto-oncogenes.[32] The SRC family of proteins are non-
receptor tyrosine kinases and contain the following members: BLK, FGR, FRK, FYN, HCK, 
LCK, LYN, YES and c-SRC. These proteins are all structurally similar and so inhibition of 
one usually results in some off-target binding to the other members. Due to increasing 
examples of acquired drug resistance in patients, however, multi-targeted kinase inhibitors 
are often sought after. SRC has been shown to be involved in many cellular pathways and is 
responsible for a variety of cell phenotypes including adhesion, migration and invasion, 
proliferation, angiogenesis and metastasis.[32] 
The earliest reported SRC family inhibitors were the pyrazolo[3,4-d]pyrimidines, PP1 and 
PP2, figure 1.7.[33] Synthesised in 1996 by J. H. Hanke et Al., PP1 and PP2 were designed 
to be inhibitors of LCK and FYN. IC50 values of 5 and 6 nM against LCK and FYN, 
respectively, were reported for PP1 and values of 4 and 5 nM for PP2.[33] Although, these 
compounds are still both widely used as biological tools for studying SRC family kinases 
(SFKs), neither of them have made it into clinical studies. Recent studies have also shown 
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PP1 and PP2 to be non-selective towards the SRC family which further limits their 
usefulness. 
One of the earliest reported specific SRC inhibitors is 1-naphthyl-PP1 (1-NA-PP1), very 
similar to PP1. Designed in 1998, by Anthony C. Bishop et. Al., 1-NA-PP1  selectively 
inhibits a mutant form of v-SRC (Ile338Gly v-Src) over wild-type SRC, however, 1-NA-PP1 
is still non-selective to other kinases.[34] 
      











1.4 The Mechanistic Target of Rapamycin  
 
The mechanistic target of rapamycin (mTOR), also known as the mammalian target of 
rapamycin, is a key serine/threonine protein kinase with roles in many cellular mechanisms 
and pathways such as protein synthesis, cell cycle, survival, proliferation and even 
migration/invasion.[35] Consequently, mTOR is highly involved in cancer, metabolic 
diseases such as obesity and type-2 diabetes, neurodegenerative diseases and even aging.[36] 
mTOR belongs to the phosphatidylinositol 3-kinase (PI3K)-related family and shares many 
pathways with the PI3Ks. Their interaction in pathways is critical to mTOR’s function. 
mTOR exists as part of a complex of proteins in which there are two forms – mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 and 2 behave 
differently in cells and also function as separate multi-protein complexes.[36] 
 
1.4.1 mTORC1 
mTORC1 consists of 5 proteins: mTOR, Raptor (regulatory associated protein of mTOR), 
mLST8 (mammalian lethal with Sec13 protein 8, aka GβL), PRAS40 (proline rich AKT 
substrate 40 kDa) and Deptor (DEP-domain-containing mTOR-interacting protein).[37] Of 
these proteins, mTOR is the main component containing the catalytically active site; little is 
known about the function of the other 4 proteins, although many experiments suggest they 
may function as regulators of mTOR kinase activity.[37] 
The functions of mTORC1 are much better defined than those of mTORC2 and many of 
these discoveries can be credited to the fact that one of the first discovered inhibitors of 
mTOR, Rapamycin (a macrolide isolated from the bacterium Streptomyces hygroscopicus), 
inhibits mTORC1 but not mTORC2, in general. Rapamycin binds to the FK506-binding 
protein of 12 kDa (FKBP12) which then binds to the FKB12-rapamycin binding domain 
(FRB) of mTOR.[38] This inhibits mTORC1, however, FKBP12 and rapamycin cannot 
inhibit mTORC2.[39, 40]  
mTORC1 has been termed “a master regulator of cell growth and metabolism” as it is 
involved in many pathways and interacts with many different proteins concerning cell 
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growth and cell cycle.[37] The synthesis of proteins and lipids within the cell are all 
controlled by mTOR which is highly sensitive to nutrients such as glucose and amino acids 
and also to hormones such as insulin and growth factors. By far the most important aspect of 
mTORC1 is the control of protein synthesis. Downstream of mTORC1 is the eukaryotic 
initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) and the p70 ribosomal S6 kinase 1 
(S6K1) which are phosphorylated by mTORC1 to initiate protein synthesis. Phosphorylated 
4E-BP1 cannot bind to its partner, eIF4E, which enables eIF4E promotion of cap-dependent 
translation.[41] Phosphorylation of S6K1 leads to cap-dependent translocation, translation 
elongation, mRNA biogenesis and ribosome biogenesis via the proteins eIF4B, PDCD4, 
eEF2K, SKAR and S6, respectively, figure 1.8.[42] 
mTORC1 has also been shown to control autophagy, whereby, mTOR inhibition increases 
autophagy and mTOR stimulation reduces it.[43] These mechanisms are less well known 
compared to the protein synthesis pathways, however, interaction with a complex of unc-51-
like kinase 1 (ULK1), autophagy-related gene 13 (ATG13) and focal adhesion kinase family-
interacting protein of 200 kDa (FIP200) has been shown to regulate autophagy.[44-46]  
Lipid synthesis is also controlled by mTORC1 through the regulation of sterol regulatory 
element binding protein 1 (SREBP1) and peroxisome proliferator-activated receptor-γ 
(PPAR-γ), although, again, this mechanism is not entirely clear.[37, 47, 48]  
Many factors contribute to the activity of mTORC1 including: ATP (energy) levels which 
are regulated via AMP-activated protein kinase (AMPK); oxygen levels via multiple 
pathways; various growth factors, such as insulin, via Ras and the canonical insulin pathway; 
amino acid levels via the Rag proteins; DNA stress via p53/AMPK regulated mechanisms; 
and inflammation via the TSC1/2 complex.[37, 38, 49-54] All these interactions are mapped 
in figure 1.8. 
 
1.4.2 mTORC2 
mTORC2 consists of 6 members: mTOR, Rictor (Rapamycin insensitive companion of 
mTOR), mSIN1 (mammalian stress activated protein kinase interacting protein, Protor-1 
(protein observed with Rictor-1), mLST8 and Deptor. Many of these proteins were 
discovered via experimental evidence and are, thus, named arbitrarily. mTOR, mLST8 and 





Figure 1.8: mTOR signalling pathway. Reprinted with permission from Cold Spring Harbor 
Laboratory Press (2012).[53] 
 
Unlike mTORC1, little is known about the functions of mTORC2 or it may, simply, not play 
as significant a role as mTORC1. mTORC2 is not sensitive to nutrients, as mTORC1 is, but 
it is sensitive to some growth factors such as insulin.[36] mTORC2 is generally reported to 
be insensitive to Rapamycin treatment, and from a broad perspective this is mostly the case. 
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However, long term treatment with Rapamycin has been shown to reduce the signalling of 
mTORC2 in certain cell types.[40, 55]  
mTORC2 has been shown to be involved in cell survival and growth through its interaction 
with AKT.[56]  AKT is another serine/threonine kinase that is highly involved in many 
important pathways associated with cell metabolism, proliferation, migration, apoptosis and 
protein synthesis, thus, mTORC2 is also indirectly involved in these processes.[57] It has 
also been shown that mTORC2 is involved in regulation of the actin cytoskeleton through 
interaction with proteins Paxillin, RhoA, Rac1 and PKCα.[39, 40] 
 
1.4.3 The Role of mTOR in Cancer 
Since there are many examples of the importance of mTOR in cancer described in the 
literature, and being a ‘master regulator’ of cell growth, it is not surprising that faults 
associated with the mTOR pathway can eventually lead to cancer. Mutations of proteins 
upstream of mTOR such as the PI3Ks are common in many human cancers.[36] In fact, data 
shows that changes in expression levels of the PI3Ks, AKT and PTEN are the most common 
alterations found in cancers, all proteins associated with mTOR.[58] PI3K, PTEN and AKT 
are all upstream of mTOR (AKT is downstream of mTORC2) and so mutations in these 
proteins directly affect the function of mTOR, figure 1.8. 4E-BP1, downstream of mTORC1, 
has also been increasingly thought to be involved in cancer formation. Reduction in 4E-BP1 
activity leads to the activation of cap-dependent translation which promotes cell proliferation 
and progression of the cell cycle.[36, 59, 60]  
As mentioned previously, mTOR also controls lipid synthesis via sterol regulatory element 
binding protein 1 (SREBP1). An increase in lipid biosynthesis is one of the classical 
hallmarks of cancer as rapidly dividing cells require lipids for cell membrane production. An 
increase in PI3K signalling to mTORC1 results in activation of SREBP1 which causes an 
increase of lipid biosynthesis via the transcription target fatty acid synthase (FAS) and 
promotes the proliferation of cancer cells.[36, 59, 61]  
Further, mTOR may have a part to play in tumour growth through involvement in 
autophagy. Increased activation of mTOR by mutations in upstream proteins suppress 
autophagy and may promote cancer growth, although, again, this mechanism is not entirely 
clear and the full effect autophagy plays in cancer is yet to be known.[36, 59] Additionally, 
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mTOR is able to promote angiogenesis through its interaction with hypoxia-inducible factor 
1α (HIF1α), thereby, allowing the tumour access to fresh nutrients and oxygen.[62] 
Most of the pathways discussed above feature mTORC1, however, there are increasing 
indications that mTORC2 also plays an important part in cancer formation and growth. AKT 
and SGK1 are downstream targets of mTORC2 and so, through activation, they may 
promote tumour growth. Also, loss of PTEN, commonly observed in a variety of cancers, 
promotes AKT signalling resulting in increased cell proliferation and survival.[63] Further, 
the mTORC2 component RICTOR is required for the growth of certain cell lines derived 
from PTEN deficient mice, thereby, cementing the importance of mTORC2 in cancer.[63, 
64] Thus, through its interaction with AKT, PI3Ks and PTEN, mTORC2 is highly involved 
in cancer, arguably more so than mTORC1.  
 
1.4.4 mTOR Inhibitors - Rapalogs  
Due to the evidence led involvement of mTOR with cancer, targeting the pathway has been 
of great interest. Targeting mTOR for cancer treatment is relatively recent, however, with the 
first inhibitor being approved by the FDA in 2007. Rapamycin, also known as Sirolimus, 
was previously approved in 1999 for organ transplant rejection due to its observed 
immunosuppressant properties. 
mTOR is an unusual kinase target as Rapamycin is a natural product whose phenotypic 
properties were discovered before any knowledge of the mTOR kinase existed and, thus, led 
to the discovery of the functions of mTOR itself. With a natural inhibitor already at hand, the 
first tested, and approved, inhibitors of mTOR for cancer treatment were analogs of 
Rapamycin, collectively named Rapalogs. The first approved inhibitor of mTOR for cancer 
treatment was Temsirolimus, approved for treatment against advanced renal cell carcinoma. 
Everolimus, approved in 2009 for advanced kidney cancer, and Ridaforolimus, currently 
unapproved but in clinical trials, soon followed suite. Their structures, as well as the 




Figure 1.9: Chemical Structure of Rapamycin (left, R = H), Temsirolmius, the first approved 
mTOR inhibitor for cancer therapy, Everolimus and Ridaforolimus (right). 
 
These rapalogs work in the same way as Rapamycin. Their modifications are mostly for 
improving pharmacokinetic properties. For example, the modification of Temsirolimus is to 
increase water solubility so it can be given by intravenous injection. Afterwards, it is 
converted into Rapamycin in the body which is responsible for most of its effect; therefore, it 
is essentially a prodrug of Rapamycin.[65] Likewise with Everolimus, however, 
Ridaforolimus (Deforolimus), which contains a dimethyl phosphine oxide group, is not a 
prodrug. The mechanisms of rapalogs are the same as Rapamycin: binding to FKBP12 prior 
to interaction with the FRB domain of mTOR.  
Currently, Temsirolimus and Everolimus are the only two rapalogs approved for use in 
cancer treatment. Rapamycin, which is given orally, has a very low bioavailability limiting 
its usefulness in therapy.[65] Everolimus was designed to have higher bioavailability, given 
orally, and both Rapamycin and Everolimus are used as immunosuppressants in organ 
transplant patients. Temsirolimus and Ridaforolimus are both given intravenously for cancer 
treatment, although Ridaforolimus has yet to be approved by the FDA. 
Although Rapalogs have shown promise in the lab and some success in the clinic, only 
moderate efficacy has been observed in a lot of tumours. This disappointing realisation has 
been attributed to a variety of reasons. Previous work had suggested that sensitivity to 
Rapalogs could be correlated with loss of PTEN.[66] However, in the clinic this was not the 
case and biomarkers which suggest sensitivity to rapalog treatment remain unknown.[36] 
mTOR, being such an important regulator of cell metabolism and growth, is linked to many 
30 
 
complex pathways and negative feedback mechanisms may limit the efficacy of rapalogs in a 
clinical setting, especially since only one of the mTOR complexes is being inhibited.  
Recently, it has been discovered that the phosphorylation of 4E-BP1, downstream of 
mTORC1, is only partially blocked by Rapamycin treatment.[36] Due to the high 
involvement of 4E-BP1 in cancer progression this may explain why treatment with Rapalogs 
has failed to show the expected effects in the clinic. Further, mTORC2 cannot be ignored. 
Although, little is known about the functions of this complex, its involvement in cancer 
progression is apparent and by only inhibiting one of two mTOR complexes it is reasonable 
to see why rapalog treatment failed to hold up to the early promising results. Most 
importantly, Rapamycin is able to activate AKT via feedback mechanisms associated with 
insulin growth factors (IGFs) and mTOR/S6K inhibition.[67] 
More recently, focus has been on developing ATP site inhibitors of mTOR. These inhibitors 
do not discriminate against mTORC1 or mTORC2 and inhibit both equally with the rationale 
being of overcoming the feedback mechanisms and partial inhibition of downstream targets 
seen with the rapalogs. 
 
1.4.5 mTOR Inhibitors – ATP Competitive 
ATP competitive inhibitors of mTOR, sometimes called second generation mTOR inhibitors, 
are dual inhibitors of mTORC1 and mTORC2 due to their interaction with the active site of 
mTOR directly. By inhibiting both complexes, the phosphorylation of all downstream targets 
of mTOR is reduced resulting in less negative feedback and greater effect over cell growth. 
In practice, these dual inhibitors have resulted in the reduced cell proliferation and greater 
potency in in vivo models, more extensively, than treatment with rapalogs.[36] By 
completely inhibiting the phosphorylation of downstream targets such as 4E-BP1, cap 
dependant translation is greatly reduced and cell growth is impaired to a much higher degree 
than Rapamycin treatment. Further, many transcription events are only affected with 
complete inhibition of mTOR and not by partial inhibition.[68] By blocking not only 
mTORC1 but also mTORC2, the phosphorylation of AKT and SGK1 is reduced resulting in 
impaired cell growth. mTORC2 inhibition also has the added benefit of reducing feedback 
mechanisms associated with only blocking mTORC1. mTORC2 has also been shown to be 
involved in angiogenesis and so, through inhibition, tumour formation may be reduced by 
blocking the formation of vascular systems.[69]  
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Many of these 2
nd
 generation inhibitors target both mTOR and the PI3K enzymes as their 
kinase domains are closely related, and so, are known as dual mTOR/PI3K inhibitors.[70] 
Shown in figure 1.10 are the structures of some 2
nd
 generation mTOR inhibitors. PI103 was 
the first potent and synthetic ATP site inhibitor of mTOR and many compounds are based 
around its structure, however, poor pharmacokinetic properties prevented its use in humans. 
The compounds AZD8055/2014, PI540, PI620, PKI402 and WAY132/354/600/687, shown 
in figure 1.10, all have their structures based around PI103. 
 
Figure 1.10: Chemical structures of 2
nd
 generation mTOR inhibitors targeting the ATP site. 
Compounds in the top box represent dual mTOR/PI3K inhibitors while compounds in the 
bottom box represent dual mTOR inhibitors (mTORC1/2). 
 
Many of the compounds shown in figure 1.10 are in clinical trials as anti-cancer drugs, 
however, as of now there are no 2
nd
 generation mTOR inhibitors approved by the FDA. 
Many of the early dual mTOR/PI3K inhibitors shared similar structures involving 4-
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morpholinylpyrimidine ring systems, whereas, the mTORC1/2 inhibitors mostly feature the 
pyrazolopyrimidine scaffold. With so many 2
nd
 generation mTOR inhibitors currently in 
clinical trials the success of one over another may depend on other properties than mTOR 
inhibition such as PK properties or off-target induced toxicity. 
mTOR inhibitors show great promise in cancer therapy and results in preclinical settings 
look promising, however, their success may be limited by a lack of sufficient biomarkers 
indicating patients which would benefit from therapy. Another area of concern with mTOR 
inhibition is the effect on the immune system. Suppression of the immune system is not 
something to be encouraged during chemotherapy and should be examined carefully, 
especially since most in vivo models involve immunodeficient mice. 
Further, mTOR’s involvement with cell metabolism should be noted as, although mTOR is 
upregulated in a majority of cancers, it is also found all over the body and heavy inhibition 
may have adverse side effects on patients. Only long term studies will tell, however, in terms 







SRC is the first, and perhaps most studied, known oncogene. However, we still do not know 
everything about its mechanisms or its full involvement in the development of cancer. SRC 
was discovered over 100 years ago by Peyton Rous when he described an agent that could 
cause cancer in chickens. This ‘agent’ turned out to be a virus, now named the Rous 
Sarcoma Virus, and advances in molecular biology in the 1960s and 70s enabled the 
identification of the viral oncogene responsible for tumour transformation seen in chickens 
by Rous – v-SRC. Bishop and Varmus later found a proto-oncogene in cells which 
corresponded to the viral oncogene, v-SRC, and appropriately named it c-SRC.[32, 71] They 
were later rewarded with the Nobel Prize for their work in proto-oncogenes. 
c-SRC encodes a non-receptor tyrosine kinase which belongs to a family of 8 kinases – 
BLK, FGR, FYN, HCK, LCK, LYN, SRC and YES. There are a few related ‘sub-family’ 
members such as BRK/PTK6, FRK/PTK5 and YRK.[72, 73]  However, c-SRC is the one 
most commonly associated with cancer and, consequently, the most studied of all the 
members. 
Resistance is a commonly observed, and troublesome, feature in cancer treatment. Therapy 
involving cytotoxic agents such as gemcitabine, oxaliplatin and cetuximab has led to 
acquired resistance involving disrupted SRC signalling.[32] As such, SRC may represent a 
common resistance mechanism and, thus, inhibition of SRC may re-sensitise cancers towards 
treatment. This creates the opportunity for combination therapies whereby SRC inhibition is 
combined with the drugs to which tumours have developed resistance, to provide an 
alternative line of therapy for patients. 
The strong correlation between SRC activity and cancer progression supports the premise 
that SRC signifies an important target for cancer treatment. And several compounds have 






1.5.1 The Structure and Function of SRC 
The SRC family members all have conserved SRC homology (SH) domains and a regulatory 
tyrosine residue (Tyr530) at the C-terminus, figure 1.11.[32] The four SH domains are 
conserved across species and also in v-SRC, figure 1a, however, the C-terminal region 
differs. In particular, Rous Sarcoma Virus SRC (v-SRC) lacks the regulatory C-terminal 
domain, leading to constitutive activity and oncogenic transformation.[72] Human and 
chicken c-SRC, however, both possess this regulatory domain that maintains the enzyme in a 
constitutively inactive conformation until upstream activation. The kinase domain is found in 
SH1, as is a conserved tyrosine autophosphorylation site – Y419 in human and Y416 in 
chicken. 
SRC is activated by dephosphorylation of Y530 resulting in opening of the complex and 
consequent access to the kinase domain, figure 1.11b. Further, autophosphorylation of Y419 
in the kinase domain (Y416 in chicken) is required for full activity of SRC. Deactivation 
occurs via phosphorylation of Y530 which allows binding to the SH2 domain, locking the 
complex in a closed conformation. C-terminal SRC kinase (CSK) phosphorylates this region, 
thus, inactivating SRC. Certain cancers have reduced levels of CSK which leads to higher 
SRC activation.[74] 
 
Figure 1.11: a) Structure of human and chicken c-SRC, and chicken v-SRC showing the 
conserved SRC homology regions. b) Method of SRC activation/inactivation. Inactivation of 
SRC occurs via phosphorylation of Tyr530 which results in a closed complex with restricted 
access to the kinase domain. Reprinted by permission from Macmillan Publishers Ltd: 




There are many other methods of SRC activation. Activation via receptor tyrosine kinases 
such as EGFR, PDGFR, ERBB2, fibroblast growth factor receptor, colony-stimulating factor 
1 and hepatocyte growth factors represent a few.[72] 
One of the major interacting proteins which binds to SRC is focal adhesion kinase (FAK) 
which has an important role in cell migration/invasion.[75] FAK binds to the SH2 and SH3 
domains of SRC, thus, resulting in the open, active conformation. CRK-associated substrate 
(CAS) also binds similarly, and both FAK and CAS are key regulators of the focal adhesion 
complex and actin, which are essential for cell movement.[76]  
 
1.5.2 SRC and Cancer 
SRC has been shown to be important in driving certain cancers, and given that it is one of the 
most studied proto-oncogenes, there is considerable evidence of its role in tumour 
progression. The classical ‘Hallmarks of Cancer’ include: increased cell proliferation, 
ignorance of growth suppressor signals, increased cell migration and invasion, infinite 
replication, induction of angiogenesis and the resistance of apoptosis.[77] SRC is involved in 
all of these processes.[32, 72] 
Increased Cell Proliferation 
Evidence exists showing SRC is involved in the cell cycle to some extent, primarily the G2 to 
M phase transition.[78] However, targets downstream of SRC may be more involved in 
control of the cell cycle rather than SRC itself.  
Cell Migration and Invasion 
SRC is more involved with cell-cell and cell-ECM adhesion dynamics than cell growth and 
so, increased activation of SRC in cancer is associated with increased cell migration and 
invasion leading to metastasis in the patient.[79] When activated, SRC translocates to areas 
of the cell membrane where the cytoskeleton is associated and interacts with the adherens 
junctions and focal adhesions.[80] Adherens junctions, which bind cells to cells, and focal 
adhesions, which bind cells to the extracellular matrix, are in a dynamic state of assembly 
and disassembly enabling natural cell movement, and transmission of extracellularly derived 
growth signals. SRC is involved in the regulation of the assembly of these components.[72]  
Adherens junctions involve the binding of E-cadherin moieties located on the extracellular 
membranes of cells. SRC is highly involved in the complex array of proteins required to 
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regulate this process and increased SRC activation results in decreased E-cadherin 
expression.[81, 82] In turn, this leads to loss of cell-cell binding and an increase in tumour 
metastasis. 
 
Figure 1.12: The function of SRC in adherens junctions and focal adhesion. Reprinted by 
permission from Macmillan Publishers Ltd: [Nature Reviews] [72], copyright (2004).  
 
Similarly, SRC is involved in the mass complex of proteins involved in focal adhesion, 
ultimately, through integrin binding to the extracellular matrix. FAK is highly involved in 
this process through its interaction with SRC and together they interact with a multitude of 
proteins involved in focal adhesion turnover and actin remodelling.[83] Focal adhesions are 
involved in the control of cancer metastasis and their dysregulation results in increased 
patient death.[84] 
Angiogenesis 
Angiogenesis is a process required for tumour growth as a consequence of the need for more 
nutrients and oxygen. Cancer cells are able to promote angiogenesis to fulfil their energy 
needs. SRC has been shown to be associated with the increased expression of vascular 
endothelial growth factor (VEGF) via signal transducer and activator of transcription 3 
(STAT3) activation.[85, 86] PP2, a non-selective SRC inhibitor, inhibits the growth of 
endothelial and vascular smooth muscle cells in vivo, thus, reducing angiogenesis.[87] The 




SRC activity is also involved in bone metastasis, which represents the primary metastatic site 
for breast cancer and is also a site for lung, prostate and colorectal cancer. Bone remodelling 
is the process of bone reabsorption by osteoclasts and bone formation by osteoblasts and 
SRC is a key protein in the regulation of such a process. Bone metastases disrupt this 
balanced process and cause pain and morbidity to the patient. SRC inhibition decreases bone 
reabsorption by reducing osteoclast activity.[89] Thus, SRC inhibition can induce net bone 
formation and prevent the symptoms of bone metastases.[90] 
 
1.5.3 SRC Inhibition 
With all the evidence highlighting the role SRC plays in cancer growth and metastasis, it has 
become an increasingly important drug target. There are currently only three SRC inhibitors 
approved by the FDA for cancer therapy – Dasatinib, Bosutinib and Ponatinib – however, 
many are in clinical trials. All three drugs are approved for Imatinib resistant chronic 
myeloid leukaemia (CML). However, these drugs are considered to owe their clinical 
success to inhibition of the BCR-ABL fusion protein (genetic abnormality and main 
proliferation driver of CML) and not to SRC inhibition. Surprisingly though, given that SRC 
is one of the most studied oncogenes, there are relatively few examples of selective SRC 
inhibitors and the vast majority also inhibit c-ABL, a target which I and others have found to 
be have paradoxical roles in cancer.  
Two of the earliest SRC inhibitors are the pyrazolo[3,4-d]pyrimidines, PP1 and PP2, figure 
1.13.[91] Originally designed as inhibitors of SRC family members LCK and FYN, with IC50 
values of 5 and 6 nM, PP1, and 4 and 5 nM, PP2, respectively, they are non-selective SRC 
family kinase inhibitors that are widely used as biological tools but have not made it into the 
clinic. PP20, figure 1.13, is a relatively recent SRC/ABL inhibitor with sub-nano molar 
potency. It is also non-selective and, thus, has not made it into the clinic.[92]  
Many of these SRC inhibitors, particularly Dasatinib, Saracatinib and Bosutinib, have shown 
promising preclinical activity towards a number of solid tumours such as prostate, colon 
breast and lung and have been taken forward for evaluation in clinical trials, however, their 
preclinical successes have not translated well in the clinic.[32] Most commonly, patients did 
not respond to treatment, contradictory to preclinical indications.[93] Further, severe toxicity 
occurred in several patients causing an abrupt end to their trials.[ClinicalTrials.gov]  
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A reason for their lack of success in solid tumours may be due, again, to the lack of suitable 
biomarkers to predict patient response to the drugs. Targeted therapies usually benefit from 
suitable clinical biomarkers that highlight what targets are driving the patients' cancer and, 
thus, if they are likely to benefit from targeted drug therapy. Even similar cancers in a group 
of patients may respond differently to the same treatment.  
 
 
Figure 1.13: Examples of SRC inhibitors as tools (top) and in clinical development (bottom). 
Remarkably, all of the inhibitors also potently target Abl. Even KX2-391 which is not an ATP-






1.5.4 SRC Inhibitors in Combination Therapy 
Due to the disappointing results in single agent therapy with Dasatinib, Saracatinib and 
Bosutinib, and the premise that SRC is involved in a multitude of pathways within the cell, 
many of which drive cancer progression, several trials involving combinations of a SRC 
inhibitor plus a cytotoxic or targeted drug have taken place.  
SRC may be involved in acquired resistance mechanisms against cytotoxic therapies such as 
gemcitabine and oxaliplatin.[94, 95] Combination studies in vitro showed that Dasatinib can 
increase sensitivity towards oxaliplatin and paclitaxel treatment in ovarian and colon cancer 
cells.[95, 96] Further, 5-FU and gemcitabine treatment against pancreatic cancer cells was 
shown to be more effective combined with SRC inhibition.[32] There is also evidence for the 
combination of a SRC inhibitor with tamoxifen for breast cancer treatment given SRC’s 
ability to promote cell proliferation in association with the estrogen receptor (ER) and 
commonly seen resistance to tamoxifen therapy.[97] Similarly, combination of Dasatinib or 
Saracatinib with cetuximab, a monoclonal antibody against epidermal growth factor receptor 
(EGFR), inhibits colorectal cancer cell growth in a synergistic manner.[98]  
According to ClinicalTrials.gov, there have been 255 trials involving Dasatinib, of which, 87 
were combination therapies with 28 ongoing as of March 2015. Similarly, Saracatinib and 
Bosutinib have 30 and 34 trials, respectively, with 8 and 5 being combination therapies. 
These studies involve several solid tumours such as non-small cell lung cancer (NSCLC), 
breast, ovarian, colorectal, castration resistance prostate cancer (CRPC) and pancreatic 
cancer as well as leukaemia. Table 1.2 shows completed combination trials involving 
Dasatinib. 
Overall, Dasatinib performed rather poorly. Many patients experienced severe toxicity or did 
not benefit from the combination over single agent therapy. However, as discussed, the issue 
may not be with SRC inhibition but with selecting the correct patients to benefit from such a 
therapy. Further, all 3 SRC inhibitors approved for use in cancer therapy inhibit ABL with 
the same potency, a factor which we later show to be non-beneficial or even detrimental in 
cancer treatment. Incredibly, during SRC’s century long journey there has still not been a 







Target Cancer Phase ClinicalTrials.gov 
Identifier 
BMS-833923 SMO Chronic myeloid leukaemia 1/2 NCT01218477 
Revlimid 
(+Dexamethasone) 
Broad MOA Multiple myeloma 1 NCT00560391 
















Proteasome inhibitor Multiple myeloma 1 NCT00560352 
Nilutamide Androgen receptor Metastatic castration resistant 
prostate cancer 
 NCT00918385 
Cetuximab EGFR Colorectal cancer 0 NCT00835679 
Cediranib Maleate VEGF Hormone resistant prostate cancer 2 NCT01260688 
Docetaxel Anti-mitotic agent Castration resistant prostate 
cancer 
3 NCT00744497 
Dacarbazine DNA alkylating agent Metastatic melanoma 1/2 NCT00597038 
Docetaxel Anti-mitotic agent Metastatic hormone refractory 
prostate cancer 
1/2 NCT00439270 
Capecitabine 5-FU prodrug, 
thymidylate synthase 
inhibitor 
Advanced breast cancer 1 NCT00452673 
Table 1.2: Completed clinical trials involving Dasatinib in combination with another agent. 
SMO: Smoothened receptor; MOA: Mechanism of action; IGF-1: Insulin-like growth factor 1; 
EGFR: Epidermal growth factor receptor; VEGF: Vascular endothelial growth factor. 
 
Having such an important, and well-studied, role in cancer pathophysiology, SRC is 
undoubtedly a relevant target for cancer therapy. Selection of relevant biomarkers will no 
doubt improve patient selection and increase the success of SRC inhibitors, whether it be 





2. Research Aims and Rationale 
 
Advances in combinatorial chemistry and high throughput screening have undoubtedly 
improved the quality of novel compounds on the basis of target potency and target 
selectivity. However, increasing research and development costs associated with the 
widespread adoption of high-throughput target directed screening strategies have not 
translated into increased clinical success rates. High attrition of candidate drugs during the 
later stages of preclinical and clinical development, and the lack of any significant 
improvement in the appearance of novel targets to FDA approved drugs, suggest that current 
drug discovery strategies are sub-optimal.[99, 100] Disappointing results in recent clinical 
trials with promising targeted agents underline that a major challenge to the development of 
successful targeted therapies for treating the majority of cancer types is overcoming 
heterogeneity across patients and inherent or acquired drug resistance.[8, 11, 100] Most drug 
discovery programs begin with a screening campaign for inhibitors against a single protein 
target. Subsequent chemical and target selectivity optimisation is typically based upon "on-
target" potency. While this approach may be optimal for diseases caused by single-gene 
defects, it is, however, not appropriately tailored to health disorders with complex 
mechanisms and genetic heterogeneity such as cancer.[11] This reflects the fact that in most 
solid tumours, no single molecular event drives continued proliferation and tumour 
progression, and that redundancy in signalling pathways limits the efficacy of therapies 
targeting single molecular pathways.[8, 11] 
Acknowledging the limitations of target-centric drug discovery, many research groups, 
including ours, are frontloading the search of robust empirical data to progress anticancer 
drug development programs away from classical black-and-white anticancer hypotheses. 
Following that paradigm, we aim to explore whether cooperative ligand-based design and 
phenotypic screening, complemented with biochemical assays and the use of published data 
(literature, patents, databases, etc.), could be effectively applied to accelerate the generation 
of preclinical drug candidates. The study of my thesis is founded on three wide-ranging 
hypotheses: (i) the use of phenotypic screening in designated models of cancer can be used 
to generate target-agnostic structure-bioactivity relationships and guide ligand optimisation 
tailored to particular cancer types/subtypes; (ii) targeting the kinase ATP pocket with 
compounds derived from promiscuous kinase inhibitors can enable 'rationally-biased' 
serendipitous discoveries; and (iii) early improvement of drug likeness on promiscuous 
42 
 
ligands can be concurrently used to explore pharmacodynamic diversity. By means of this 
pragmatic approach to anticancer kinase inhibitor discovery, target deconvolution of 
identified hits and leads would be largely simplified (= focused kinome screening), thereby, 




3. Design and Synthesis of Initial Library 
3.1 Introduction & Aims 
 
Protein kinases are integral components of cell-to-cell communication as regulators in signal 
transduction cascades, thus, governing a wide range of basic cellular functions and 
coordinating cellular actions. As a result, kinases are directly involved in progressive 
diseases including cancer and inflammation.[14, 101] The approval of a number of small 
molecule kinase inhibitors for the treatment of several types of cancer has shown that they 
can be effective drugs.[14, 101] The vast majority of kinase inhibitors target the kinase ATP 
site and because all kinases (>500) necessarily possess this catalytic site there is great 
potential for cross-reactivity. This disadvantage may, however, become a competitive 
advantage in anti-cancer therapy as such off-target activities may circumvent issues of 
molecular heterogeneity and resistance mechanisms. Indeed, a number of kinase inhibitors 
approved as anti-cancer agents display broad selectivity profiles (e.g. Sunitinib, Sorafenib 
and Dasatanib). However, the target selectivity profiles of such multi-targeting kinase 
inhibitors were neither selected nor optimised by rational design. 
 
Figure 3.1: Structure of ATP (left) and PP1 (right). 
 
To overcome the disadvantages of orthodox target-centric drug discovery strategies and 
promote a more empirical, evidence led, approach to targeted therapy, we aimed to explore a 
ligand-based drug design strategy, which frontloads phenotypic analysis in disease-relevant 
assays. Potency would be calculated across primary phenotypic endpoints from cell based 
assays (e.g. anti-proliferation, apoptosis, and inhibition of cell migration) and used to rapidly 
distil compounds according to their degree and type of anticancer activity to inform 
subsequent chemical design. To take advantage from prospective poly-pharmacological 
effects provided by small molecule inhibitors targeting the ATP binding site, novel 
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compounds were designed based on the ATP molecule and the promiscuous kinase inhibitor, 
PP1 (4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), figure 3.1, a 
highly potent c-SRC family inhibitor that also targets additional tyrosine kinases such as Ret, 
























3. Design and Synthesis of Initial Library 
3.2 Results 
 
3.2.1 Library 1 Design and Synthesis 
The first library of compounds was based on a core aldehyde molecule, figure 3.2, derived 
from ATP and PP1. A selection of various amines would then enable access to an easily 
synthesised library via reductive amination.  
 
Figure 3.2: The core aldehyde scaffold derived from ATP and PP1. 
 
The core aldehyde was synthesised following scheme 3.1. 5-amino-1H-pyrazole-4-
carbonitrile (1) was heated, under microwave irradiation, in neat formamide giving core 
heterocycle (2) in excellent yield. Selective iodination was facilitated using N-
iodosuccinimide and alkylation of 3 with bromoacetaldehyde diethyl acetal gave the 
protected aldehyde intermediate 4. Suzuki reaction with p-tolylboronic acid gave compound 
5 which was then deprotected to give the core aldehyde (6) using TFA and water (1:1). The 
core synthesis was overall high yielding (41.8% over 5 steps) and straightforward. No 
purification was attempted on compound 6 due to the reactiveness of the aldehyde. Further, 
compound 6 was not characterised by NMR as multiple adducts of the aldehyde (hemiacetal, 
geminal diol and the TFA salt) were all visualised in mass spectra resulting in complex and 




Scheme 3.1: Core synthesis. a) Formamide, 180 
o
C, mw; b) NIS, 180 
o
C, DMF, mw; c) NaH, 
bromoacetaldehyde diethyl acetal, 150 
o
C, mw; d) p-tolylboronic acid, K2CO3, Pd(OAc)2, 
PPh3, 1,4-dioxane/water (10:1), 120 
o




Following on from the core synthesis, a 10 membered library was made by reductive 
amination, scheme 3.1. Solubility is a major factor in determining the success of a drug as 
many compounds with low aqueous solubility possess poor pharmacokinetic properties 
limiting their effectiveness in the clinic. These libraries were, therefore, designed to produce 
aqueous soluble compounds from the start. Chemical diversity was introduced on these 
water-solubilising motifs in the search for unanticipated pharmacodynamic profiles. As such, 
the ten amines chosen initially were substituted piperidines, piperazines and morpholine, all 




Scheme 3.2: Synthesis of library 1 members 7-16. a) 1 eq. of  amine, AcOH, NaBH(OAc)3, 
DCM, r.t. 
 
3.2.2 Cell Proliferation Assay on Library 1 Compounds 
To assess the anti-proliferative effect mediated by library 1 compounds in cancer cells, a 
single dose cell proliferation assay was set up using the IncuCyte-ZOOM
TM 
system from 
Essen BioScience, figure 3.3. The IncuCyte-ZOOM
TM
 is a microscope capable of bright field 
and fluorescence microscopy, situated in an incubator. This allows the real time imaging of 
cells across indefinite time points in a range of formats – multi-well plates, cell culture 
flasks/dishes etc. In addition, the software accompanying the IncuCyte is capable of 
calculating cell density, as percentage confluence, and so provides kinetic cell growth data. 
By imaging cells across the time course of an experiment, one not only obtains the optimal 
time points for an assay but also confirms that apparent reduced cell viability is indeed 
occurring due to cell death and not due to inhibition of metabolic pathways, which may 
occur when using a cell viability reagent. 
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Figure 3.3: Image of the IncuCyte-ZOOM
TM 
system from Essen BioScience (left).Example of 
a cell confluence graph produced by the IncuCyte software comparing DMSO (navy blue) to 
drug treated cells (light blue) over 5 days treatment. The kink in the graph (20 hours) 
indicates at which point the drug was added (right). 
 
MCF7 cells, which are estrogen receptor (ER) positive breast cancer cells, were chosen as 
the initial cell line as they are readily available and have a strong literature presence. Of 
course, the choice of cell line is important and different cell lines may have led to different 
results, however, MCF7 cells, being a commonly used and well established breast cancer cell 
model, were considered as an excellent starting point to steer the drug discovery program 
towards breast cancer indications. Compounds were tested at a single dose of 100 µM in 
triplicate for 5 days with 0.1 % DMSO as negative control. 






















Figure 3.4: IncuCyte single time-point analysis of MCF7 cell growth. % cell confluence 
normalised to DMSO on MCF7 cells after incubation with compounds 7-16 at 100 μM for 5 




The results, figure 3.4, revealed compounds 10 and 14 to be the two most potent compounds 
(cell confluence <20%). It was important to note, however, that 20% confluence does not 
correlate to 20% of the cells remaining alive as the software maps confluence based on 
differing contrasts between cells (or cell debris) and background (see figure 3.6), therefore, it 
is important to also observe the morphology of the cells and also to perform a cell 
proliferation assay using a reagent for measuring viability. From the structures of 10 and 14, 
it was essential to make compounds 17 and 18 also, figure 3.5a, synthesised in the same way 
as described in scheme 3.2.  
 

















































Figure 3.5: a) Compounds 17 and 18 designed from 10 and 14. b) IncuCyte experiment with 
% confluence of MCF7 cells after 5 day treatment of compounds at 100 µM, relative to 
DMSO (n = 3, error bars denote standard deviation). c) PrestoBlue cell viability assay - Half-
log dose response assay using MCF7 cells. Curves were generated using GraphPad Prism 
and EC50 values calculated for compounds 8, 10, 14, 17, 18 and PP1. (n = 3; error bars 





Compounds 17 and 18 proved to be even slightly more potent than 10 and 14 from the 
IncuCyte cell confluence assay, each with confluence <10%, figure 3.5b. Following the 
single dose IncuCyte experiment, a cell viability assay was set up, using MCF7 cells, for 
compounds 8, 10, 14, 17 and 18 and PP1 as a comparison, figure 3.5c. Compounds were 
tested across a 10-point concentration gradient starting at 100 µM down to 0.03 µM using a 
half-log scale in order to obtain EC50 values against cell proliferation. The experiment was 
performed in triplicate (n = 3) using DMSO (0.1 %) as negative control and cell viability 
measured after 5 days of  incubation with drugs using PrestoBlue® reagent.  
The dose response and resulting EC50 values are shown in figure 3.5c. Both compound 17 
and 18 share similar values of 12 µM, while analogous compound 10 had an EC50 of 18 µM. 
Due to the structural similarities between compound 18 and compound 10 it was concluded 
that the piperazine nitrogen at the 4-position was not essential for activity, thus, future 
compounds contained only piperidine moieties – 4-dimethylamino piperidines based on 
compounds 14, 17 and 18. 
 
 
Figure 3.6: Images obtained from IncuCyte experiment discussed above after 5 days of 
treatment with drug or DMSO. a) Compound 17 (100 µM) phase image. b) Compound 17 
(100 µM) phase image with applied confluence mask. c) DMSO (0.1 %) phase image. d) 
DMSO (0.1 %) phase image with applied confluence mask. 
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The above mentioned limitations of the Incucyte experiment are shown in figure 3.6. Images 
from the IncuCyte experiment described above with compound 17, figure 3.5b, are shown in 
figure 3.6. Cells following 5 days of drug (17) treatment at 100 µM have shrunk, are very 
round and few in number indicating the induction of apoptosis, figure 3.6a. It is apparent that 
at this concentration, all cells undergo apoptosis and die, however, the IncuCyte’s software 
includes them in the confluence mask, figure 3.6b, and consequently there is a ‘minimum’ 
cell confluence achievable when using this system. Figure 3.6c and 3.6d show cells in the 
absence of drug (0.1 % DMSO) without and with the confluence mask, respectively, for 
comparison.  
 
3.2.3 Apoptosis Assay on Compounds 8, 10, 14, 17, 18 and PP1 
NucView™ 488, which is a caspase-3/7 substrate, was used to detect apoptosis in MCF7 
cells treated with compounds 8, 10, 14, 17, 18 and PP1. Upon cell damage caused by 
compound treatment, many pathways may be activated eventually instructing the cell to kill 
itself – apoptosis. However, the cascade of pathways instructing the induction of apoptosis 
all filter down to one final mechanism involving a group of proteases called caspases. Two 
types of caspases exist: initiator and effector caspases. Caspase-3 is an effector caspase and 
when activated by an initiator caspase it proteolytically begins to break down numerous 
protein substrates within the cell to cause the cell to die. NucView™ 488, being a caspase-
3/7 substrate, thus, is degraded by caspase-3 or 7, binds to DNA becoming fluorescent and 
indicates the induction of caspase dependent apoptosis.  
MCF7 cells were plated on optical imaging plates and compounds (8, 10, 14, 17, 18 and 
PP1) added as a concentration gradient. NucView™ 488 was added at 1 µM at the time of 
compound addition. Cells were incubated for 5 days and imaged using the IncuCyte. Shown 
in figure 3.7 is an example of the images obtained from the experiment. Drug treated cells 
(figure 3.7a) are small and rounded indicating apoptosis which is confirmed from the 
NucView™ 488 fluorescence image in figure 3.7b. At this concentration (100 µM) all cells 
are apoptotic and dead. Similarly to cell confluence, the IncuCyte software applies a ‘green 
mask’ over the green cells, figure 3.7c, which enables the quantification of apoptotic cells. 





Figure 3.7: Example phase and fluorescence images obtained from the IncuCyte apoptosis 
experiment discussed above after 5 days treatment with drug or DMSO and the addition of 
NucView™ 488 at 1 µM. a) Compound 17 (100 µM) phase image. b) Compound 17 (100 µM) 
green fluorescence image showing caspase-3 activity. c) Green count mask applied by 
IncuCyte software on image b. d) DMSO (0.1 %) phase image. e) DMSO (0.1%) green 
fluorescence image. f) Green count mask on image e. 
 
The numbers generated from the applied confluence and green (NucView) masks were 
divided so as to create a ratio of number of apoptotic cells to cell confluence. The data were 
then normalised to DMSO to account for the decreased number of cells found in higher 
concentrations of drug treatment. The results are shown in figure 3.8 – only values down to 
10 µM are graphed as no further effect was seen below this concentration. Compound 17 
showed the greatest effect on inducing apoptosis, slightly greater than compound 18, with 
ratios of 31 and 27 at 100 µM compared to DMSO, respectively. This follows the same trend 
as in the cell viability assays. For this reason compound 17 was progressed through to the 
next stage, forming the basis of the library 2 compounds – section 4. So far, the target of the 
compounds and the mechanisms by which apoptosis and reduced viability are being induced 
were unknown, however, enough early structural activity relationships (SARs) were 





Figure 3.8: Apoptotic ratios of MCF7 cells caused by 5 day treatment with compounds 8, 10, 
14, 17, 18 and PP1 normalised to DMSO (0.1 %), (p<0.001, ***; n = 3; error bars denote 
























































3. Design and Synthesis of Initial Library 
3.3 Conclusion 
 
In an attempt to promote a more pragmatic approach to drug discovery, the non-selective 
small molecule inhibitor PP1 was used as a model for the generation of a 10-membered 
library. Aiming to create novel kinase inhibitors, the structure of ATP was also taken into 
consideration when designing the library, as were major factors which determine the fate of a 
drug such as solubility. 
Compounds 7-16 were synthesised in a 6-step process and their activity tested against HER-
2 positive MCF7 breast cancer cells. Cell viability was used as a phenotypic end point in 
which to rank compound activity. Using the IncuCyte-ZOOM™ system from Essen 
BioScience, 3 compounds (8, 10 and 14), bearing similar structures, were identified as early 
‘hits’ leading to the design and synthesis of a further 2 members – compounds 17 and 18. 
The EC50 values against MCF7 cell proliferation were determined for these 5 compounds, 
along with PP1. Compounds 17 and 18 generated EC50 values of 12.36 and 12.44 µM, 
respectively, against proliferation. 
Further, the mechanisms by which the compounds were reducing cell proliferation were 
determined by phase-contrast and fluorescence microscopy. The rounding up of cells upon 
compound treatment suggested that apoptosis was being induced and incubation with the 
caspase-3/7 substrate, NucView™ 488 concluded this was the case. Compounds 10, 17 and 
18 were able to induce apoptosis at statistically significant levels down to 30 µM. 
Given that an appropriate ‘south part’ of the molecules had been identified, thoughts turned 
to improving the compounds’ potency against cell proliferation. Chapter 4 discusses the 
optimisation of the aryl group of the structures and investigates the mechanism of action by 







4. The Discovery of Potent Anti-Proliferative 
Compounds and Target Identification 
4.1 Introduction & Aims 
 
The second library of compounds was based on the anti-proliferative hit 17. Using the 
piperidinyl group of compound 17, library 2 focuses on the modification of the aryl group of 
the molecule (‘north’ part) in order to generate more potent compounds and give some early 
structure activity relationships. The putative kinase targets by which the hit compounds exert 
their activity were also discovered via an initial 14-membered kinase panel screen by 

















4. The Discovery of Potent Anti-Proliferative 
Compounds and Target Identification 
4.2 Results 
 
4.2.1 The Design and Synthesis of Library Two 
Library 2 members were synthesised in the same way as library 1 with diversity added, this 
time, during the Suzuki reaction step using different boronic acids/esters. 10 members were 
originally planned with the iodo group (compound 35) taking the 11
th
 place to assess the 
needs of an aryl group at all. The 10 aryl groups chosen are shown in scheme 4.1. These 
groups were chosen from examples in the literature, as they had previously shown potency 
against kinases, and they would also provide some structure activity relationships regarding 
the best aryl groups.[92, 105] PP121, shown in scheme 4.1, was used as a model compound 
for compounds 19 and 29 as it had previously shown good activity against a sub-set of 
kinases.[92] It must be noted, however, that the target of previous members, and of the 
projected new compounds, was still unknown so the choice of aryl group was solely to 
improve potency in cellular assays. 
Core intermediate 4, discussed previously in scheme 3.1, was used again for the synthesis of 
library 2. Suzuki reaction with 4 and corresponding commercial boronic acid/ester resulted 
in high to excellent yields of acetal intermediates 19-27. Compound 28 was synthesised via a 
Sonogashira reaction using phenyl acetylene as the alkyne reactant. The conditions are 
shown as a*) in scheme 4.1, below. 
Following on from the acetal intermediates, final compounds 29-35 were made via acetal 
deprotection using TFA/water then reduction amination with N,N-dimethyl-1-(4-
piperidyl)methanamine, previously shown to be the best amine (compound 17). Unlike the 
synthesis of library 1 members, however, the core aldehydes in this case were not isolated. 
Instead, after each deprotection reaction, the product was dried under vacuum and used 
immediately in the reductive amination step. This was to try and improve the yields by not 




Scheme 4.1: Library 2 synthesis. a) Boronic acid/ester, K2CO3, Pd(OAc)2, PPh3, 1,4-
dioxane/water (10:1), 120 
o
C, mw. a*) Phenylacetylene, Et3N, Pd(OAc)2, CuI, PPh3, THF, 70 
o
C. b) TFA/water (1:1), 100 
o
C, mw. c) N,N-dimethyl-1-(4-piperidyl)methanamine, AcOH, 
NaBH(OAc)3, DCM, r.t. PP121 (bottom right) was used as an inspirational molecule. 
 
Only 7 of the projected 11 final compounds (29-35) were successfully synthesised, however. 
The yields of these reactions varied from low 8 % to high 76 %. Problems arose when 
deprotecting the acetal intermediates of compounds 20 and 25-27. Upon concentration of the 
samples under vacuum to remove the excess TFA/water, unusual polymers appeared in the 
flasks which were insoluble in any of the following solvents: acetone, acetonitrile, DMF, 
DMSO, hexane, TFA, toluene and water; even upon boiling of the samples. As the products 
were insoluble, mass and NMR spectra were unobtainable and the products (likely to be 
some kind of polymeric structures) were discarded. It is unclear to why the polymerisation 
occurred but looking at the structures, all examples had either an endocyclic NH or NH2, and 
so this was hypothesised to be involved. Other compounds containing OH or endocyclic NH 
groups, such as 32 and 29, were successfully synthesised, although at low yields (8 and 15 
%, respectively), indicating that protic groups interfered with the reductive amination 
process. Nonetheless, the 7 successful compounds were tested as before in MCF7 cell 
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viability assays to assess their potency against cell proliferation. As well as the final 7 amine 
compounds (29-35), the corresponding acetal intermediates (19-28), as well as core 
intermediate 4, were tested also. Compound 5, section 3.2.1, was also tested to compare the 
original p-toluyl group with the library 2 members. Compounds were tested along a half-log 
dose response in triplicate from 100 µM to 0.03 µM and compared against DMSO (0.1 %). 
Curves were fitted using GraphPad Prism software to generate EC50 values. EC50 values 
above 100 µM were estimates only and compounds were assumed non-active.  

















Figure 4.1: EC50 values against MCF7 cell proliferation of library 2 compounds (n=3, error 
bars denote standard deviation). 
 
Interestingly, compounds 19 and 29 were the most potent with EC50 values of 1.32 and 2.69 
µM, respectively, figure 4.1. Both these compounds shared the same aryl group, the 1H-
pyrrolo[2,3-b]pyridine group. Comparing compound 20 with compound 21, the small change 
from an indole to a quinoline group creates a drop in potency from 4.42 µM to >100 µM 
highlighting the need for a hydrogen bond donor. 
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Even more interestingly, all the acetal compounds were more potent than their respective 
amine compounds i.e. the presence of a acetal at the south part of the molecule led to 
superior phenotypic effect than the N,N-dimethyl-1-(4-piperidyl)methanamine group, 
previously shown to be optimum. Indeed, this was the case with all the compounds except 
for the related compounds 21 and 30. At this point, two hypotheses were considered: (i) 
acetal compounds could improve cell penetrability or (2) the acetal compounds and their 
amine equivalents were exerting a different molecular mechanism of action. 
 
 
Figure 4.2: Images from IncuCyte-ZOOM™ MCF7 cell viability experiment after 5 days of 
treatment with compounds 19 and 29 at 100 µM. a) Compound 19 phase image. b) 
Compound 19 green mask. c) Compound 29 phase image. d) Compound 29 green mask. e) 
DMSO control phase image. f) DMSO control green mask. 
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Due to their superior potency in the MCF7 cell viability assay, compounds 19 and 29 were 
subjected to the IncuCyte-ZOOM™ cell growth assay discussed previously, section 3.2.2, so 
that the compounds’ effects on cells could be observed over the incubation period. 
NucView™ 488 was added to cells at time of drug addition so the induction of apoptosis, if 
any, could be monitored.  
The experiment suggested that the compounds were exerting different effects on the cells 
due to the different phenotypes observed after incubation. Both compounds reduced cell 
proliferation, however, compound 19 appeared to slow the cells’ growth without causing cell 
death (suggesting cell cycle inhibition), whereas, compound 29 was inducing apoptosis 
resulting in cell death, figure 4.2. Images a) and c), figure 4.2, show MCF7 cells after 5 days 
of treatment with both compounds, at 100 µM. The cells in image a) look relatively healthy, 
whereas, the cells in image c) are very rounded indicating apoptosis and cell death. Looking 
at images b) and d), the green mask applied by the IncuCyte from NucView™ activity 
confirms that  compound 29 is inducing apoptosis more so than compound 19. There is a 
small amount of apoptosis seen in image b), however, cells naturally undergo apoptosis and 
after 5 days of treatment with a compound at high concentration this is expected - images e) 
and f) show comparison with DMSO as negative control. On observation of time-lapse 
movies created from the IncuCyte images it was clear that the cells treated with compound 
29 immediately started to round up after compound addition, whereas, cells treated with 
compound 19 simply stopped growing. 
 
4.2.2 Screening on a Sub-set of Kinases  
To shed some light over the mechanism of action and selectivity profile of the compounds, 
IC50 values were determined for PP1, 14, 17, 18, 19 and 29 against a selection of protein 
kinases known to be targeted by PP1 and based on published literature.[91, 92, 102-106] Not 
only would this give some insight to the mechanisms of these compounds but knowing their 
respective targets would also allow for further optimisation and ‘tuning in’ selectivity. IC50 
values were determined from 10-point, 1:3 dilution curves starting at 100 µM down to 5.08 
nM with 10µM ATP by Reaction Biology Corp. using a radioactive ATP substrate 
incorporation assay. 
The results, shown in table 4.1, revealed that compounds 14 and 29 are moderately potent c-
SRC family (BLK, FGR, FRK, FYN, HCK, LCK, LYN and SRC) inhibitors with IC50 values 
of 126 and 27 nM, respectively. Not surprising since PP121, containing the same aryl group 
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1H-pyrrolo[2,3-b]pyridine, is also a moderately potent SRC inhibitor (IC50 14 nM). What is 
surprising is the difference in potency between compounds 14, 17 and 18, however. 
Compound 14 was far more potent against the kinases tested than 17 or 18. This is in 
contrast to their anti-proliferative properties against MCF7 cells – compounds 17 and 18 
displayed EC50 values of around 12 µM, whereas, 14 had a value of 51 µM. These 
contradictory results may be explained by slight differences in physicochemical properties of 
the molecules, leading to variations in solubility, cell permeability or their roles in active 
transport mechanisms etc. On the other hand, the superior effects against cell proliferation 
seen with compounds 17 and 18 may be simply explained by effects on targets not tested 
amongst the 14 kinases shown here.  
 
















c-ABL 147.2 6323 7525 7249 1207 115.7 
BLK 268.3 1545 2846 7072 >10
5
 110.1 
FGR 7.6 115 399.6 600.8 2127 45.3 
FRK/PTK5 63.0 915.8 1635 3700 2691 105.6 
FYN 27.5 311.1 913 1964 1226 37.8 
HCK 167.4 1523 6009 11630 6774 36.1 





LCK 173.8 727 1542 4344 8598 232.8 







 328.4 8565 









RET 11.6 6584 22590 10840 598.2 288.9 
c-SRC 16.6 126 302.7 1040 2453 26.9 
YES/YES1 36.3 71.4 344.5 696.5 565.6 12.3 
Table 4.1: Kinase IC50 data (nM) for compounds PP1, 14, 17, 18, 19 and 29. Data 
highlighted in red indicates IC50 values of below 100 nM. Data highlighted in green indicates 




Due to the nature of phenotypic drug discovery, specific target inhibition or physicochemical 
properties of molecules are not independently considered, only the overall phenotypic effect 
resulting from the sum of all the physicochemical and pharmacological properties of each 
compound, which in this case is reduced cell proliferation. 
All of the new compounds differentiated from PP1 in terms of selectivity towards the kinases 
tested. Compounds 14, 17, 18 and 29 did not inhibit c-KIT, PDGFRα or mTOR and only 
compound 29 showed moderate activity against RET. The piperidine moiety of compound 
14, 17 and 18 was particularly effective in reducing inhibition of the RET protein leading to 
>500 times reduction in activity, compared to PP1. These results show that small changes to 
the PP1 molecule can be used to generate lead compounds with better physicochemical 
properties and selectivity. 
Most interesting of all was compound 19, which turned out to be a moderately potent mTOR 
inhibitor (328 nM), with much reduced activity against all other kinases tested. The acetal 
moiety was clearly the reason for this selectivity and compared to compound 29, it is 
remarkable how such a small change led to such a vast difference in target selectivity, while 
both having similar anti-proliferative potency. This unanticipated result is in agreement, 
however, with the phenotypic effect mediated by 19, as the previous IncuCyte experiment, 
figure 4.2, showed that compound 19 halted the growth of MCF7 cells, a common 
observation of mTOR inhibition due to its strong involvement in the cell cycle.[107]  
Furthermore, the shared 1H-pyrrolo[2,3-b]pyridine group of compounds 19 and 29 seemed 
to aid the potency of both compounds against their respective targets (mTOR and SRC 
family), whereas, selectivity was governed through the ‘south part’ of the molecule through 
the use of the diethyl acetal or piperidine groups. PP121, on the other hand, was both a 






4. The Discovery of Potent Anti-Proliferative 
Compounds and Target Identification 
4.3 Conclusion 
 
Using the N,N-dimethyl-1-(4-piperidyl)methanamine moiety from compound 17, found to be 
the most potent out of a series of 14 amines tested, 'chapter 1', a second library of 10 
members was designed  to contain varying aryl groups. The aryl groups were all 
commercially available, making synthesis of the library quick and straight forward, and were 
chosen based on their presence in recent literature, highlighting them as important groups for 
kinase inhibition. The acetal intermediates, compounds 19-28 were synthesised and tested 
also against MCF7 cell proliferation. The transformation from acetal intermediate to final 
compound proved troublesome for 4 out of the 10 designed compounds due to 
polymerisation during the TFA mediated deprotection of the acetal. As such, only 6 of the 
final amine containing compounds were produced. Compounds 4 and 35, containing no aryl 
group but iodine only, were included in the MCF7 cell viability study. 
Compounds 19 and 29, sharing the same 1H-pyrrolo[2,3-b]pyridine group, turned out to be 
the most potent compounds with EC50 values of 1.32 and 2.69 µM, respectively. The two 
compounds were subjected to analysis by incubation with NucView™ 488 in the IncuCyte-
ZOOM™ system revealing differing mechanisms of action of the 2 compounds.  
The kinase targets, to which compounds 14, 17, 18, 19 and 29 inhibitied, were discovered 
via a 14-membered panel screen, based on targets inhibited by PP1. It was discovered that 
compound 29, containing the amine moiety, was a potent SRC family kinase (SFK) 
inhibitor, whereas, compound 19, containing the diethyl acetal, was a moderately potent 
mTOR inhibitor with reduced activity towards the SFKs. 
This evidence led to the hypothesis that modifications on the current structures could be used 
to create novel and selective SRC family and mTOR inhibitors. As such, the thesis now 
splits into two separate chapters, one discussing the development of SRC family inhibitors 




5. The Development of Novel, Potent and 
Selective mTOR Inhibitors 
5.1 Introduction & Aims 
 
The mini review on mTOR, chapter 1.4, highlights the increasing evidence for the 
involvement of mTOR in cancer. Current Rapalogs approved for cancer treatment are sub-
standard owing to the lack of sufficient clinical biomarkers, partial inhibition of downstream 
targets, such as 4E-BP1, and inhibition of only one of the two mTOR complexes causing 
negative feedback resulting in the activation of AKT. Efforts have turned instead to 
producing selective ATP site inhibitors which inhibit both of the mTOR complexes. As such, 
the development of small molecule ATP site mTOR inhibitors is highly sought after and 
several have entered clinical trials.  
Compound 19, being a moderately potent mTOR inhibitor, created an ideal starting point for 
the development of a potent and more selective mTOR inhibitor than current standards and 
given the rational need for such therapies in cancer treatment, the progression of compound 
19 seemed a logical step.  
Based upon the clinical candidate INK-128, several new compounds were designed and 
synthesised. Their EC50 values against cell proliferation are discussed along with their 
selectivity and potency for mTOR in vitro. Whole kinome profiling is discussed for lead 
compound 41, highlighting its excellent selectivity for mTOR, and comparing it with current 
gold standard, INK-128. 
Further, the effects on the cell cycle by lead compounds, generated from the library of 
mTOR inhibitors, are analysed and discussed as is compound 41’s effects on downstream 








5. The Development of Novel, Potent and 
Selective mTOR Inhibitors 
5.2 Results 
 
5.2.1 Synthesis and Testing of Analogues of Compound 19 
In order to improve compound 19 in terms of potency and selectivity for mTOR, different 
acetal groups were tried, using the same north motif known to target mTOR potently and 
selectively.[35] The aryl group was based on the developmental compound INK-128, 
currently in Phase 1 and 2 clinical trials. INK-128 is a fairly selective mTOR kinase inhibitor 
with an IC50 of 1.4 nM and some off-target activity for PI3Kα, β, γ (152, 4700 and 165 nM, 




Scheme 5.1: mTOR inhibitor optimisation. a) Bromoacetaldehyde diethyl acetal (4) or 2-
bromomethyl-1,3-dioxolane (36) or bromoacetaldehyde dimethyl acetal (37), NaH, DMF, 150 
o
C, mw. b) 1H-pyrrolo[2,3-b]pyridine-5-boronic acid pinicol ester (19, 39, 40) or 5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzoxazol-2-amine (41, 42, 43), K2CO3, Pd(OAc)2, 
PPh3, 1,4-dioxane/water (10:1), 120 
o
C, mw. b’) Bis(pinacolato)diboron, K2CO3, Pd(OAc)2, 





Each acetal intermediate was synthesised as before: treatment of 3 with sodium hydride 
followed by the addition of the corresponding alkyl bromide compound gave compounds 36 
and 37 in moderate yields upon heating in the microwave, scheme 5.1 
The aryl group corresponding to compounds 41, 42 and 43 was non-commercially available 
so was synthesised from the bromo precursor, scheme 5.1, b’), in excellent yield. The 
following Suzuki reactions then gave the final compounds in moderate to excellent yields. 


































Figure 5.1: EC50 values of mTOR inhibitors against MCF7 cell proliferation in PrestoBlue cell 
viability assay (n=3, error bars denote standard deviation). 
 
As before, compounds were tested against MCF7 cells to assess their anti-proliferative 
effects. The determined EC50 values from the experiment are shown in figure 5.1. The 6 
compounds were tested along with Rapamycin, Everolimus, INK-128 and AZD2014, all 
previously reported mTOR inhibitors.[35, 108] Our compounds are highly suspected to be 
ATP-site competitive inhibitors, like INK-128 and AZD2014, whereas, Rapamycin and 
Everolimus are allosteric inhibitors and inhibit only one of the two mTOR complexes.  
The results reveal that although compound 40 is slightly more potent than 19, compounds 
41-43 are extremely potent against cell proliferation with EC50 values in the low nano-molar 
range. Clearly, the 2-aminobenzoxazole aryl group is driving the potency against cell 
viability and presumably, against mTOR. INK-128 shared a similarly low EC50 value of 1.8 
nM which is not surprising given the similarity in their structures and the ‘driving force’ of 
the 2-aminobenoxazole group. As discussed previously, Rapalogs such as Rapamycin and 
Everolimus only inhibit one of the two mTOR complexes – mTORC1 – so although they 













gave sub-nano-molar EC50 values in this assay, they are incapable of causing 100 % cell 
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Figure 5.2: MCF7 cell viability dose response curves and corresponding EC50 values 
comparing compound 41, Rapamycin and Everolimus (n=3, error bars denote standard 
deviation). 
 
5.2.2 Kinase Inhibition Data 
Following the cell viability results, the IC50 values against the same 14 kinases tested before, 
and 4 new kinases, were determined for compounds 41, 42 and 43. The new kinases were 
phosphoinositide 3-kinase (PI3K) alpha, beta, gamma and delta; Lipid kinases similar to, and 
closely associated with the mTOR pathway, and AKT. Commonly, inhibitors which target 
mTOR also show some off-target effects on the PI3Ks.[70]  
All 3 compounds showed superior potency against mTOR with values of 15, 29 and 25 nM, 
respectively, table 5.1. Most interesting was the selectivity for mTOR. All of the compounds 
showed >130x selectivity over the previously tested kinases with the majority of kinases 
having no inhibition, indicated by a blank box in table 5.1. It is also interesting that the most 
potent compound, 41, also showed the most selectivity over the 14 original kinases and the 4 
PI3Ks. Comparing the PI3Ks, compound 41 was the weakest inhibitor of the 3 with >60x 
loss in potency over mTOR. Compound 43 had a moderate IC50 value of 98.9 nM against 
PI3K-γ. These results showed promise that modifications to the lower half of the molecule 
could be used to achieve potent mTOR and PI3K inhibitors with selectivity equal to or even 



















 8630 9920 
BLK >10
5
    
FGR 2127  7940 >10
5
 
FRK/PTK5 2691    
FYN 1226    
HCK 6774    
c-KIT >10
5
    
LCK 8598  9400  
LYN 2298    
mTOR/FRAP1 328.4 15.3 58.9 25.3 
PDGFRa >10
5
    
RET 598.2    
c-SRC 2453    
YES/YES1 565.6  >10
5
  
PI3K-α ND 981 115 300 
PI3K-β ND >10
5
 3850 5600 
PI3K-γ ND 1340 302 98.9 
PI3K-δ ND 1840 271 505 
Table 5.1: Kinase IC50 data (nM) for compounds 19, 41, 42, and 43. Data highlighted in red 
indicates IC50 values of below 100 nM. Data highlighted in green indicates mTOR inhibition 
below 1 µM. Blank boxes indicate no inhibition. 
 
The ethyl acetal moiety was optimum for binding to the mTOR ATP pocket over the methyl 
and 1,3-dioxolane and for this reason compound 41 was screened against the whole kinome 
to determine its kinome wide selectivity. The compound was screened against 340 wild-type 
kinases, 19 atypical kinases and 17 lipid kinases (listed in appendix 1a, 1b and 1c, 
respectively) at a single dose of 10 µM in duplicate with 10 µM of ATP by Reaction Biology 
Corp. 
The data was then averaged and plotted as percentage enzyme activity relative to DMSO, as 
negative control, using DiscoverRX TREEspot™ software. Compound 41 was very selective 
for mTOR, even at the high concentration of 10 µM only 5 enzymes were inhibited greater 
than 35 % compared to DMSO, figure 5.3, which included DDR1, DNA-PK, mTOR, PI3K-
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α and PI3K-γ. PI3K-α and γ previously had their IC50 values determined, with compound 41 
showing greater than 64x and 87x selectivity for mTOR over either, respectively, table 5.1.  
 
Figure 5.3: Kinome screen tree map showing percentage enzyme activity with compound 41 
at 10 µM after 35 % cut-off. The 5 interactions mapped include DDR1, DNA-PK, mTOR, 




Figure 5.4: Kinome screen tree map showing percentage enzyme activity with INK-128 at 1 
µM after 35 % cut-off. The interactions mapped include CK1-δ, CK1-ε, FMS, FGR, FLT3, 




DNA-PK (DNA-dependant protein kinase) is another enzyme closely related to the 
AKT/PI3K/mTOR family.[109] As such, it is not surprising that compound 41 had some 
activity. DNA-PK is a serine/threonine protein kinase that is involved in repairing damaged 
DNA by re-joining double strand breaks and, consequently, inhibition of DNA-PK has been 
shown to be beneficial to cancer treatment.[110] DDR1 (Discoidin domain receptor family, 
member 1) was the fifth kinase to show some inhibition in the study. DDR1 is a receptor 
tyrosine kinase not related to the PI3K family members so its inhibition was surprising; 
however, it has been shown to be over regulated in several cancers and is proposed as a 
therapeutic target, thus, inhibition may be helpful.[111] 
As a comparison, the percentage enzyme activities for a panel of kinases was plotted in the 
same manner for INK-128, figure 5.4. These data were taken from Hsieh et Al.’s study 
described in Nature, 2012, 485, p 55-61, supplementary data page 16.[35] This study only 
tested 243 kinases, using the Invitrogen SelectScreen™ kinase profiling service 
(fluorescence based assay rather than the gold standard radioactive assay we opted for), 
compared to our broader panel of 340, however, the most important kinases for comparison 
were included (see appendix 2 for list). Even more noteworthy is the difference in 
concentration used. We opted for the higher concentration of 10 µM to highlight any off-
target effects while 1 µM was chosen for the study of INK-128. Although INK-128 is more 
potent against mTOR with an IC50 of 1.4 nM, it also has more off-target effects, figure 5.4, 
with 10 interactions mapped after a 35 % cut-off, albeit, much weaker than mTOR. The 
interactions mapped include CK1-δ, CK1-ε, FMS, FGR, FLT3, LCK, LYN, mTOR, TRKC 
and PI3KC2-α. Included in this list are 3 members of the SRC family – FGR, LCK and LYN 
– these are not targeted at all by compound 41. Modification of the lower half of the 
molecule by an ethyl acetal group enabled greater selectivity for mTOR over SRC family 
members and afforded a more selective inhibitor than current standards. 
 
5.2.3 Compound 41 Stability Study  
Due to similarities in the EC50 values of compounds 41, 42 and 43 (ethyl acetal, 1,3-
dioxolane and methyl acetyl) an important hypothesis to test was whether the compounds 
were being hydrolysed to the corresponding aldehyde compound during the cell viability 
assay and whether the active compound was, in fact, the aldehyde. Treatment of compound 
43 with TFA/water at 100 
o
C in the microwave yielded the corresponding aldehyde 
compound, 44, figure 5.5a. A cell viability assay with MCF7 cells was set up and 
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compounds 41 and 44 tested. The results shown in figure 5.5b showed this not to be the case, 
however. Compound 41 gave an EC50 value of 9.3 nM, in agreement with the previous 
viability assays, whereas compound 44 was non active with only an estimated EC50 value of 
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Figure 5.5: a) Structure of compound 44. b) MCF7 cell viability dose response curves and 
corresponding EC50 values comparing compounds 41 and 44 (n=3, error bars denote 
standard deviation). 
 
To further back up the evidence that the compounds were not being hydrolysed, a non-cell 
conversion assay was set up where compound 41 was incubated with water at 37 
o
C and 
0.1M HCl at 37 
o
C to imitate the extreme gastric acid conditions. The Eppendorfs containing 
the solutions were shaken on a thermoshaker and aliquots taken after 0, 0.5, 1 and 2 hours. 
Compound stability was determined by mass spectrometry. Shown in figure 5.6 are two mass 
spectra from the water only experiment at time 0 (a) and 2 h (b), respectively, each showing 
the unaltered compound 41 mass (M+1 = 384.2). The same was observed for the 0.1M HCl 
experiment, thus, confirming that no hydrolysis was occurring, even under moderately acidic 






Figure 5.6: Non-cell conversion assay of compound 41 to determine stability of acetal in 
water at 37 
o
C. a) Mass spectrum of compound 41 immediately after dissolving in water at 
0.5 mg/ml. b) Mass spectrum of compound 41 after incubation in water at 37 
o
C for 2 hours. 
 
5.2.5 Further Optimisation of Compound 41 to Increase Potency Against mTOR 
In order to explore some more SARs around the south part of the mTOR inhibitors, a couple 
of more compounds were synthesised implementing small changes to try and gain some 
potency over mTOR and perhaps the PI3K enzymes. Methylcyclopentyl and 2-
methyltetrahydrofuran moieties were chosen for the south part of the new compounds. Their 
synthesis was identical to before and is shown in scheme 5.2 along with the new compounds’ 
structures, 47 and 48. 
 
Scheme 5.2: mTOR inhibitor further optimisation. a) (iodomethyl)cyclopentane (47) or 2-
(bromomethyl)tetrahydrofuran  (48), NaH, DMF, 150 
o
C, mw. b) 5-(4,4,5,5-tetramethyl-1,3,2-






The new compounds were tested alongside compound 41 and INK-128 for comparison 
against MCF7, MDA-MB-231 and PC3 cell proliferation. MDA-MB-231 cells are triple 
negative breast cancer cells and PC3 are prostate cancer cells. The results, shown in figure 
5.7, revealed compound 47 had excellent potency against all three cell types, exceeding that 
of the original compound, 41, and the ‘gold standard’, INK-128. Compound 48 was 
equivalent in terms of EC50 values, to compound 41. INK-128 showed EC50 values in 
agreement with literature (PC3 cells EC50 = 17 nM).[35]  
All 4 of the compounds showed greater potency against the HER2 positive MCF7 cells than 
the triple negative MDA-MB-231 cells. This could suggest some preclinical indication as to 
which patient population would be eligible for treatment using these therapies. It was 
important to test their potency against the targets, in isolation, and to test in further assays, in 
order to determine their differences. 



















Compound\Cell Type MCF7 MDA-MB-231 PC3 
41 8.40 71.87 36.71 
47 1.67 11.71 4.31 
48 8.62 113.25 51.16 
INK-128 1.81 29.95 11.21 
 
Figure 5.7: EC50 values (nM) against MCF7, MDA-MB-231 and PC3 cell proliferation over 5 
days of compound treatment determined from half-log dose response curves. Error bars 





5.2.6 Cell Cycle Assay 
With mTOR being heavily involved in protein synthesis and the cell cycle it was important 
to check what effects the compounds were exerting on the cell cycle.[35] It was already 
previously noticed on the IncuCyte that MCF7 cells appeared to stop growing in response to 
treatment with compound 19 so an assay was designed to look at whether, after treatment 
with our compounds, stages of the cell cycle were being altered. For this purpose cells were 
seeded at higher density (5000 cells/well) and treated with compounds for 24 hours as a 
concentration gradient with DMSO (0.1 %) as negative control. The cells were then fixed 
with 4 % PFA in PBS and stained for DNA (DAPI or Hoechst), phospho-histone H3 (anti-
pHH3 rabbit antibody with AlexaFluor®-594 goat anti-rabbit IgG) and cyclin B1 (anti-
cyclin B1 antibody with AlexaFluor®-488 donkey anti-mouse IgG). Images were then taken 
using either the Scan^R fluorescence microscope from Olympus or the ImageXpress System 
from Molecular Devices and analysed using scan^R or ImageXpress software. 
Cells were classified according to their DNA content into G1, S or G2 stages. Early or late 
mitotic cells were classified according to their cyclin B1 or phospho-histone H3 expression 
levels within the nuclear compartment, respectively. The compounds were tested against 
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Figure 5.8: Effects of compounds 41, 47, 48 and INK-128, across a concentration gradient, 
on the cell cycle of MCF7 cells (top), MDA-MB-231 cells (middle) and PC3 cells (bottom) 
following 24 hours treatment. Cell cycle stage was determined by DNA content and mitotic 
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All compounds, in all cell types, caused an arrest in the G0/1 stage of the cycle, the longest 
phase and, consequently, most abundant in cells. More likely, is that there is an increase in 
the number of cells in the G0 or resting phase which have simply halted the cell cycle 
process and are no longer dividing due to the disruption of key pathways downstream of 
mTOR and essential for cell growth. Consequently, there is a decrease in the number of cells 
in the synthesis, S, and G2 stages. Rather than the compounds decreasing the number of cells 
in the S and G2 stages by mTOR inhibition, these stages have, more than likely, gone down 
due to the lagging effect from G0/1 arrest.  
The compounds follow a similar trend in terms of potency of that seen in the cell viability 
assay. Compounds 47 and INK-128 show the greatest effect with cell disruption occurring as 
low as 3 nM concentration. Compounds 41 and 48 share similar trends and generally affect 
the cell cycle around 10 nM. Arrest of the cell in the G0/1 phase by INK-128 is in agreement 
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s Compound\Cell Type MCF7 MDA-MB-231 PC3
41 13.30 19.70 45.25
47 1.45 2.66 2.06
48 14.92 13.00 83.97
INK-128 3.10 2.52 9.68
 Figure 5.9: Curve fits of percentage of MCF7 (top left), MDA-MB-231 (top right) and PC3 
(bottom left) cells in G0/1 stage after treatment with compounds 41, 47, 48 and INK-128 and 
their corresponding EC50 values (nM, bottom right). (n=3, error bars denote standard 
deviation). 
 
Figure 5.9 shows the G0/1 data from the cell cycle experiment plotted as concentration 
against percentage of cells and the corresponding calculated EC50 values. This allows for a 
clearer comparison of compound and cell type. From these values it is evident that the 
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compounds are affecting MCF7 cells slightly more so than the other types. Again, this 
follows the same trend seen in the viability experiment. Further, compounds 41 and 48 share 
similar values as do 47 and INK-128. Structurally, these pairs are more alike which can 
explain their shared potency values. More than likely this pattern was arising from selectivity 
and potency against their kinase targets – namely mTOR, but also the PI3K enzymes, 
structurally similar to mTOR and known to be inhibited by INK-128.[35] It was, again, 
essential to calculate IC50 values against kinase inhibition in vitro. 
 
5.2.7 Kinase Data for Compounds 41, 47, 48 and INK-128 
The kinome screen had revealed that compound 41 was inhibiting DDR1, DNA-PK, PI3K-α 
and PI3K-γ along with mTOR and so the IC50 values were determined for these enzymes 
along with PI3K-β and PI3K-δ. Compounds 47, 48 and INK-128 were also tested against 
these kinases, table 5.2.  












DDR1 2106 4.7 137.0 ND 
DNA-PK 320.1 3.1 47.7 10.0 
mTOR/FRAP1 15.3 1.8 1.8 1.4 
PI3K-α 980.9 3.5 44.2 152.0 
PI3K-β >105 88.7 1118 4700 
PI3K-γ 1336 4.9 76.8 156.0 
PI3K-δ 1841 7.3 149.0 ND 
 
Table 5.2: Kinase screening data for compounds 41, 47, 48 and INK-128 (nM). INK-128 data 
was obtained from published data.[35] Data highlighted in green indicates mTOR inhibition 
below 1 µM. ND: Not determined. 
 
The results revealed the extent of compound 41’s selectivity, with the next most inhibited 
enzyme being DNA-PK (IC50 of 320.1 nM) – 20 times greater than that of mTOR. All other 
targets tested had IC50 values greater than 60 times compared with mTOR, quite a 
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remarkable selectivity profile for a compound that was fundamentally designed by 
phenotypic screening. 
It is noteworthy that compound 47 had gained a magnitude of potency with an IC50 of 1.8 
nM against mTOR, compared with 41, figure 5.10. This is in great correlation with the 
similar pattern observed in the cell viability and cell cycle assays. 47 was also very potent 
against all 7 kinases tested showing low nano-molar IC50 values in all but PI3K-β. This dual 
PI3K/mTOR inhibition is not new and, indeed, many compounds discovered previously have 
shown dual inhibition of these targets.[70, 92] Compared to INK-128, compound 47 is 
equally potent against mTOR, however, more potent against all other targets tested.  
Compound 48 gave the most interesting results from this study. Although it has equal 
potency against cell viability as 41, 48 was 8 times more potent against mTOR than 41 with 
an IC50 of 1.8 nM, comparable to 47. Compound 48 also showed increased potency against 
all other kinases tested in this assay, compared with 41, but still retained the same selectivity 
for mTOR with >20 times selectivity for mTOR over the other tested kinases. The difference 
in potency seen in the cell viability and cell cycle assays may, therefore, be due to the 
compounds’ pharmacokinetic properties rather than their activities against their targets. 
 
5.2.8 Western Blot Analysis of Compound 41 
To test whether the compounds were able to inhibit mTOR to the same degree in cells as in 
the isolated target, a Western blot experiment was set up using MCF7 cells treated with 
compound 41 or INK-128. MCF7 cells were seeded at 1 x 10
6
 cells per well in a 6-well plate 
then serum starved (0.1% FBS v/v) for 24 hours. Cells were incubated with drug for 30 
minutes at varying concentration, with DMSO (0.1% v/v) as negative control, then 
stimulated with FBS for an hour, lysed and Western blots run as described in section 10.7.5. 
To test for mTOR inhibition, antibodies corresponding to targets downstream of the mTOR 
complexes were incubated with the blot. mTOR is not activated via auto-phosphorylation 
like many other proteins found in the cell and so antibodies corresponding to mTOR 
phosphorylation sites would not prove that the compounds were inhibiting mTOR but only, 
perhaps, upstream targets.[112] That being said, by inhibiting mTOR, and therefore, its 
downstream targets, complex feedback mechanisms may, ultimately, result in a decrease of 




It is, perhaps, easier to look at the AKT signalling pathway in order to simplify the 
downstream targets of mTOR, figure 5.10. There is still little known about mTORC2, 
however, it has been shown to activate AKT by phosphorylation at serine 473.[36] 
Downstream of mTORC1 are the proteins P70S6K and S6K, phosphorylated by mTOR at 
sites threonine 389 and serine 235/236, respectively, figure 5.10. The intensity of 
phosphorylation of these three proteins was determined in the Western blot. 
 
Figure 5.10: PI3K/AKT signalling pathway. Key proteins involved in the downstream 
pathway of mTOR are highlighted in yellow. Illustration reproduced courtesy of Cell Signaling 
Technology, Inc. (www.cellsignal.com). 
 
The inhibition of pAKT at serine 473, along with pP70S6K and pS6K, may prove that both 
mTORC1 and mTORC2 are being targeted by the compounds as pAKT is only 
phosphorylated by mTORC2 (Rapamycin treatment, which only targets mTORC1, does not 
inhibit pAKT). However, it is important to take into account that PI3K activity also leads to 
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AKT phosphorylation. Therefore, inhibition of pAKT can result from both mTOR and PI3K 
inhibition. In addition, with longer treatment, feedback mechanisms and the complexity of 
signalling pathways may result in a reduction of the phosphorylation of AKT with 
Rapamycin. 
To study the inhibition of mTOR by the compounds, antibodies corresponding to the 
phosphorylation sites of P70S6K, S6K and AKT were used. The developed blot is shown in 
figure 5.11, below. 
 
Figure 5.11: Western blot of MCF7 cells treated with compound 41 or INK-128 at varying 
concentrations with DMSO (0.1% v/v) as negative control. Concentrations are in nM. 
 
The Western blot data are in agreement with the inhibition of mTOR at the ATP site. 
Compound 41 inhibits the phosphorylation of downstream targets of mTOR roughly ten 
times less than INK-128. This observation is in good correlation to the IC50 values calculated 
against the target in isolation. The inclusion of total P70S6K, total S6 and total AKT 
antibodies show that only the phosphorylation of these targets was being effected and not 
their overall levels of expression. This is to be expected with such a short incubation period. 
GAPDH was used as a loading control. 
The data show that compound 41 is capable of inhibiting mTOR in vitro at therapeutically 




5. The Development of Novel, Potent and 
Selective mTOR Inhibitors 
5.3 Conclusion 
 
Using the clinical candidate compound, INK-128 as a model, and varying the type of acetal 
group found in compound 19, 3 new compounds were developed with low nano-molar 
activities against MCF7 cell proliferation. Compounds 41-43 had their inhibition against 
mTOR determined by kinase screening which revealed them to be very selective mTOR 
inhibitors with IC50 values of 15.3, 58.9 and 25.3 nM, respectively. The compounds showed 
no other inhibition over the original 14 kinases tested, however, slight inhibition was 
observed with compound 43 against PI3K-δ with an IC50 of 98.9 nM. 
Lead compound 41 had its selectivity towards mTOR determined by whole kinome screen 
revealing it to be extremely selective towards mTOR with only DNA-PK, DDR1, PI3K-α 
and PI3K-γ being the other kinases inhibited. This was superior over current gold standard, 
INK-128. Further, compound 41 was shown to be stable in aqueous and acidic conditions 
concluding that the acetal group was, indeed, responsible for activity and selectivity. 
Further optimisation led to compounds 47 and 48 which showed very potent inhibitory 
properties over cell proliferation. Cell cycle analysis showed compound 47 was capable of 
arresting the G0/1 stage at concentrations as low as 3 nM with 41 and 48 being slightly 
weaker at 10 nM. 
Western blot confirmed the effects seen on the cell cycle and proliferation were in fact due to 
inhibition of mTOR as confirmed by decreased phosphorylation of downstream targets of 
mTOR. 
Compound 41 represents the most selective mTOR inhibitor to date. Although only having 
an IC50 of 15.3 nM, its extreme selectivity suggests that higher concentrations may be used 
to achieve the desired anti-tumoral effects in vivo. However, due to the similarities in their 
structures to INK-128 (lack of freedom to operate), the progression of these series of mTOR 





6. The Development of Novel, Potent and 
Selective SRC Family Kinase Inhibitors 
6.1 Introduction & Aims 
 
Compound 29 was shown to be a potent SRC family inhibitor (IC50 = 27 nM) and it was 
hypothesised that through modification of the structure the potency and selectivity towards 
SRC and its members could be improved over such drugs as PP1 and other SRC family 
inhibitors. Examples of highly selective SRC inhibitors have been reported previously, 
however, the most selective of which (compound 4) only inhibited SRC with an IC50 of 86 
nM which is 3x less potent than compound 29.[114] Further to its modest potency against 
SRC, compound 4 had an EC50 against MCF7 cell proliferation of 11 µM which is relatively 
high, even compared with our early ‘hit’ compound’s (29) value of 2 µM.[114]  
 
Figure 6.1: Structure of PP2, a non-selective SRC family inhibitor similar to PP1; a highly 
selective, but not potent, SRC inhibitor derived from PP2; PP20, a potent SRC family 
inhibitor; compound 29 and Dasatinib, a potent SRC/ABL inhibitor approved for Imatinib 





6. The Development of Novel, Potent and 
Selective SRC Family Kinase Inhibitors 
6.2 Results 
 
6.2.1 The Synthesis and Testing of Lead Compound 52 
Looking back to compounds 14, 17 and 18 it was evident that on-target potency was 
favoured on the shorter amine groups over the longer chains i.e. compound 14 was >8x more 
potent against SRC than compound 18, table 6.1. To corroborate this, compound 49 was 
synthesised, scheme 6.1, with 4-dimethylaminopiperidine, and tested against MCF7 cell 
proliferation then screened against the kinases tested previously, table 6.1. Compound 49 had 
an EC50 against MCF7 proliferation of 1.35 µM comparing equally to compound 29’s value 
of 1.94 µM. 
 
 
Scheme 6.1: Compound 49 synthesis. a) TFA/water (1:1), 100 
o
C, mw. b) N,N-
dimethylpiperidine-4-amine, AcOH, NaBH(OAc)3, DCM, r.t.  
 
Interestingly, the kinase results showed the opposite trend as seen with compounds 14, 17 
and 18 with the 4-(dimethylamino)piperidine compound (49) being less potent against the 
SRC family members than the 4-((dimethylamino)methyl)piperidine compound (29). 


















c-ABL 6323 7525 7249 115.7 283.0 
BLK 1545 2846 7072 110.1 321.0 
FGR 115.0 399.6 600.8 45.3 31.8 
FRK/PTK5 915.8 1635 3700 105.6 147.0 
FYN 311.1 913.0 1964 37.8 67.6 
HCK 1523 6009 11630 36.1 1660 





LCK 727.0 1542 4344 232.8 321.0 

















RET 6584 22590 10840 288.9 465.0 
c-SRC 126.0 302.7 1040 26.9 67.0 
YES/YES1 71.4 344.5 696.5 12.3 28.9 
Table 6.1: IC50 values (nM) of compounds 14, 17 and 18 against various kinases showing 
decreasing potency with longer chain length against SRC. Compound 29 compared with 
compound 49 shows smaller amine had an opposite effect in this case. Values in red 
indicate an IC50 below 100 nM. 
 
In order to increase the potency of compounds 29 and 49, thoughts turned to modifying the 
aryl group further as previous evidence suggested that potency was delivered from the aryl 
group and selectivity from the amine moiety. The breakthrough paper by Beth Aspel et. Al. 
published in Nature Chemical Biology, 2008, provided inspiration. Through their work, they 
discovered a series of new compounds which inhibited kinases, both selectively, and dual 
inhibitors of PI3Ks and tyrosine kinases.[92] As well as many other compounds, they 
discovered compound PP20, figure 6.1, a very potent (< 1 nM) SRC inhibitor which also 
targets ABL (< 1 nM), HCK (< 1 nM) and EGFR (168 nM). PP20 is also based around the 
pyrazolopyrimidine scaffold and was derived from two compounds (S1 and S2) which have 
very similar structures to PP1/2.   
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Based on PP20’s aryl motif, compounds 51 and 52 were synthesised to represent both amine 
moieties found in compounds 29 and 49, scheme 6.2. This time, in order to protect the Boc 
protected amine group, and avoid the polymerisation issues found with some derivatives 
discussed during chapter 3, the synthesis steps were reversed so that the reductive amination 
to introduce the amine occurred before the Suzuki reaction to introduce the aryl group. 
 
Scheme 6.2: Synthesis of compounds 51 and 52. a) TFA/water (1:1), 100 
o
C, mw. b) N,N-
dimethylpiperidine-4-amine (50) or N,N-dimethyl-1-(4-piperidyl)methanamine (35), AcOH, 
NaBH(OAc)3, DCM, r.t. c) [4-(tert-butoxycarbonylamino)-3-methoxy-phenyl]boronic acid, 




As before, compounds 51 and 52 were tested in an MCF7 cell viability assay to assess their 
anti-proliferative potency. As the founding paradigm of this thesis work, compounds are 
only progressed after corroborating the induction of strong phenotypic effects. The 
compounds were also tested in another cancer cell line, MDA-MB-231, which are triple 
negative breast cancer cells. Dasatinib, a potent SRC/c-ABL inhibitor used for the treatment 
of chronic myeloid leukaemia (CML), was tested alongside compounds 51 and 52 in the 
viability assay. PP20 was synthesised (scheme shown in appendix 3) and tested also. 
The results of the viability assay showed compound 52 to be much more potent than 
previous compounds with EC50 values of 40.35 and 10.09 nM in MCF7 and MDA-MB-231 
cells, respectively. Compound 52 was also much more potent in both cell types compared 
with 51. This is contradictory to the order of observed potencies against SRC kinase with 
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compounds 29 and 49 when comparing the ‘south’ amine moiety. Compared with Dasatinib, 
compound 52 showed superior potency in the MCF7 cells but both were equal, and much 
more potent, in MDA-MB-231 cells. This was an early suggestion of a possible indication 
area for the compounds – triple negative breast cancer is currently poorly treated and in need 
of much better therapies. An EC50 value of 10 nM is very potent in terms of cell proliferation 
and a very acceptable value to begin thinking about further pre-clinical development and 
clinical applications for the compounds, although, the properties of these compounds 
required much more evaluation. Regardless of their structural similarities, PP20 displayed 
lower anti-proliferative properties against these two cell lines, with EC50 values of 1843.5 
and 155.0 nM, respectively. This poorly correlates with the sub-nanomolar potency against 
the SRC and ABL kinases in vitro and perhaps explains why this compound has never 
attracted much attention by the scientific community (there are no references of studies with 
PP20 apart from the original work from Aspel at Al. previously mentioned).  


















Compound\Cell Type MCF7 MDA-MB-231 
51 520.47 197.45 
52 40.35 10.09 
Dasatinib 451.10 12.82 
PP20 1843.50 155.00 
 
Figure 6.2: EC50 values (nM) of compounds 51, 52, Dasatinib and PP20 against MCF7 and 
MDA-MB-231 cell proliferation. Error bars denote standard deviation; n = 3. 
 
Differences in potency between compound 51 and 52 in this viability assay may be due, 
more so, to physicochemical properties rather than their potency against SRC. To test this 
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hypothesis, again, the two compounds were screened against the 14 previously tested 
kinases, table 6.2. 
The study revealed compounds 51 and 52 to be very potent SRC inhibitors with sub-
nanomolar IC50 values. This potency is comparable to Dasatinib and PP20. Further, the 
compounds were much more selective towards the SRC family members than Dasatinib with 
no activity against c-KIT, PDGFRa or RET. Compounds 51 and 52 were even more selective 
within the SRC family members with sub-nanomolar potency observed in 4 and 3, 
respectively, of the 9 members.  
Most importantly, the compounds show low inhibition of c-ABL, highlighted in blue in table 
5.2, with IC50 values of 189 and 479 nM, respectively. Compared with Dasatinib’s sub-
nanomolar value this is greater than 950-fold difference in inhibition. 
 









c-ABL 189.0 479.0 < 0.5 <0.5 
BLK 3.3 5.4 < 0.5 NR 
FGR < 0.5 < 0.5 < 0.5 NR 
FRK/PTK5 8.8 2.8 < 0.5 NR 
FYN 4.6 2.0 < 0.5 NR 
HCK 1.3 2.8 1.9 <0.5 
c-KIT 7130 6460 39.0 NR 
LCK < 0.5 < 0.5 < 0.5 NR 
LYN 2.5 0.85 < 0.5 NR 
mTOR/FRAP1 >105   NR 
PDGFRa >105  9.9 NR 
RET >105  433.0 <0.5 
c-SRC < 0.5 < 0.5 < 0.5 NR 
YES/YES1 < 0.5 < 0.5 < 0.5 NR 
Table 6.2: IC50 values (nM) of compounds 51, 52 and Dasatinib against the 14 previously 
tested SRC family kinases. Values in red indicate an IC50 below 100 nM. Values in blue 





The importance of ABL inhibition in cancer is discussed in section 6.2.2. Comparing to the 
‘parent’ compound, PP20, the study showed that by incorporation of groups other than 
isopropyl or t-butyl (in the case of PP1) selective inhibition of SRC family kinases over ABL 
was possible, and to this date, compounds 51 and 52 represent the first sub-nanomolar 
inhibitors against SRC which do not inhibit ABL. 
 
6.2.2 The Anti-Oncogenic Role of c-ABL in Cancer 
Quite recently it has emerged that c-ABL may actually have paradoxical roles depending on 
the cancer context. Indeed, there are evidences that it is anti-oncogenic in certain cancers, 
particularly breast cancer.[114, 115] This means that inhibition of ABL in breast cancer can 
actually promote the disease rather than supress it. There is contradictory evidence on the 
exact role of ABL in the promotion or suppression of cancer; however, recent clinical trials 
involving Imatinib, a potent ABL inhibitor, have resulted in either no benefit or disease 
progression and toxicity.[115] To test this hypothesis, we decided to study whether the anti-
proliferative activity of the highly selective SRC inhibitor 52 could be antagonised in the 
presence of a highly selective ABL inhibitor. Therefore, a dose ratio matrix combination 





         
GNF-2 Concentration (nM\µM) 100 30 10 3 1 0.3 0.1 0.03 DMSO 
 
1000 40.00 45.24 45.08 41.90 32.47 27.46 22.86 18.82 21.73 
 
100 56.50 61.09 59.55 56.42 46.01 41.43 34.76 27.36 27.48 
 
10 86.85 86.69 88.87 85.26 74.78 63.55 54.20 49.95 50.18 
 
1 104.75 99.67 105.82 106.12 101.73 97.51 88.11 77.26 79.75 
 
0.1 101.49 85.08 100.27 105.94 100.55 101.28 94.72 89.02 90.93 
 
DMSO 103.83 94.79 102.46 109.44 109.29 108.32 105.38 102.73 100.95 
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Figure 6.3: Combination of compound 52 and GNF-2, a specific ABL inhibitor, in MDA-MB-
231 cells to test the anti-oncogenic role of ABL in breast cancer. a) Combination matrix 
showing the percentage of viable cells compared to DMSO (0.2 % v/v). b) Structure of GNF-
2. c) Concentration gradient of compound 52 with fitted curves and calculated EC50 values at 
varying concentrations of GNF-2. d) EC50 values of compound 52 with varying 
concentrations of GNF-2 plotted as a bar graph showing an exponential increase in EC50 
with increasing concentration of GNF2. 
 
MDA-MB-231 cells were incubated with drug 2 days post seeding, and left for 5 days before 
analysing with PrestoBlue® cell viability reagent. Compound 52 was dosed along a log scale 
concentration gradient ranging from 1000 to 0.1 nM down the inner columns of 96-well 
plates. GNF-2 was dosed along a half-log scale ranging from 100 to 0.03 µM along the inner 
rows of 96-well plates – see the schematic in figure 6.3a. As both compounds were used in 
DMSO, the resulting final concentration was 0.2 % v/v DMSO in the plate. As such, all 
results were normalised to 0.2 % v/v DMSO.  
The assay revealed an antagonistic combination between the two drugs. Compound 52 on its 
own gave an EC50 value in agreement with previous experiments, however, with increasing 
doses of GNF-2 (> 0.03 µM), the EC50 value rose from 12 nM to 330 nM at 10 µM GNF-2. 
This is greater than a 27-fold difference in potency through increasing ABL inhibition. 
Although it did not promote the growth, the effect of GNF-2 on MDA-MB-231 cells was 
minimal, even at 100 µM. This further reinforces the idea that ABL inhibition has no place 
in breast cancer therapy and that breast cancer, in particular, triple negative breast cancer, 
could be an ideal indication area for potent and selective SRC inhibition therapy. 
Remarkably, Dasatinib and GNF-2 also resulted in an antagonistic combination, albeit to a 
much less pronounced effect than compound 52, figure 6.4. This may be the result of GNF-

























2’s allosteric inhibition properties combined with Dasatinib’s ATP-site inhibitory properties 
to give much reduced ABL activity and, thus, increased cell survival. 
 
Figure 6.4: Relative antagonistic combinations of compound 52 and Dasatinib with GNF-2. 
Combination of 52 and GNF-2 showed a strong antagonistic relationship while Dasatinib and 
GNF-2 gave a weaker effect due to Dasatinib’s already potent ABL inhibitory properties. 
 
Due to compound 52’s superior potency in the viability assays and its greater selectivity 
against ABL inhibition, it was chosen as the ideal compound for further study. Its properties 
against cell migration, apoptosis and kinome wide selectivity were assessed and are 
discussed in the next sections. 
 
6.2.3 In Vitro Properties of Compound 52 – Whole Kinome Selectivity 
Up to this point, the selectivity of compounds against targets had only been determined using 
the same 14 kinases, initially chosen as they were shown to be targeted by PP1. Although, 
proven important in determining the potency of compounds against the SRC family members 
and selectivity over others such as ABL, mTOR, PDGFRα and RET, it was essential to 
determine the inhibitory properties of compound 52 over the whole kinome to find any ‘off-
targets’. The kinome of an organism is the whole set of protein kinases found in a cell of 
which there are 518 in humans.[116] Compound 52 was screened against 340 wild type 
kinases by Reaction Biology Corporation – see appendix 1a for list of kinases  (which 
represents the largest available list of kinases currently available in the market for profiling 





























































































with 10 µM of ATP in duplicate, relative to DMSO. The duplicates were averaged and 
plotted using TREEspot™ from DiscoveRx with a 10% cut-off value. The plotted kinome 
tree results are shown in figure 6.5. Red circles denote kinase inhibition greater than 90% 
and SRC is highlighted in blue. The interactions mapped include:  
ARAF, BLK, BMX/ETK, BRK, BTK, c-SRC, CSK, ERBB4/HER4, FGR, FRK/PTK5, FYN, 
HCK, LCK, LYN, LYN B, TXK and YES. 
 









Table 6.3: Percentage inhibition of non-SRC family kinases by compound 52 at a single 
dose of 1 µM, relative to DMSO. 
 
Of these interactions, 10 (including LYN B) belong to the SRC family which is to be 
expected giving the previously calculated IC50 values. The majority of targets inhibited sit on 
the SRC family branch of the kinome tree with only two falling outside - ARAF and HER4 – 
and only ARAF falls out with the tyrosine kinase group into the tyrosine kinase-like (TKL) 
group. 
BRK, also known as protein tyrosine kinase 6 (PTK6) or breast tumour kinase, has recently 
been discovered as an important target in breast cancer.[117-119] As well as promoting cell 
growth via stimulation of the cell cycle, BRK has been shown to be involved in the 
migration and invasion of cancer cells.[117, 119] As compound 52 has been extensively 
tested in breast cancer cells and triple negative in particular, inhibition of BRK can been seen 




Figure 6.5: Map of the kinome (excluding lipid, atypical and mutant kinases) showing the 
selectivity of compound 52 for the SRC family kinases. Red circles denote inhibition greater 
than 90%, SRC is coloured in blue. 17 kinases were inhibited greater than 90%, at 1 µM 
concentration, out of 321 tested.  S-score at 10% cut-off = 0.06. 
 
Inhibition of a target at a single dose (1 µM) in the case of compound 52 is a good indication 
of target activity, however, it was important to consider the IC50 value of inhibition for a 
proper comparison against SRC. The IC50 value against BRK was determined for compound 
52 and Dasatinib by the same conditions described before, table 6.4. 
Both compounds showed good potency against BRK with IC50 values of 17.3 and 41.5 nM, 








BRK/PTK6 17.3 41.5 
Table 6.4: IC50 values (nM) of compound 52 and Dasatinib against BRK/PTK6. 
 
6.2.4 Compound 52 Inhibits the Migration of MDA-MB-231 Cells in Vitro 
The ability of a cell to move is very important in nature to support embryogenesis, wound 
healing and inflammatory response. White blood cells, for example, must find their way to a 
site of infection to fight off unwanted pathogens. To do this, they are able to migrate along 
blood vessels and then invade surrounding tissues. In cancer, however, cell mobility is an 
unwanted property as it is the migration of cancer cells from the primary site to other sites 
(metastasis) that causes the cancer to spread and ultimately, to become lethal. Single tumours 
are a lot easier to treat than multiple tumours spread around the body. For this purpose, drugs 
which inhibit cell migration and invasion are sought after. 
One of the major functions of SRC in cells is the control of mobility – both migration across 
a 2D surface and invasion through a 3D matrix.[72] Several assays have been developed to 
assess the effect of a compound on the mobility of cells.[120] Perhaps the most well-known 
technique is the (scratch) wound healing assay where by cells are seeded at high density then 
a scratch created down the centre of a well and the percentage of cells migrated after a time 
period calculated. One of the drawbacks to this classical assay is the reproducibility of the 
scratch between wells and the ability to calculate accurate cell migration versus the initial 
scratch. To overcome this, the IncuCyte ZOOM system was used to track cell migration over 
a period of 24 hours. MDA-MB-231 cells were seeded at 50000 cells per well in a 96-well 
ImageLock™ plate from Essen BioScience, and left to adhere overnight. A 700-800 µm 
scratch wound was created in each well simultaneously using the WoundMaker™, which 
creates evenly sized wounds across a 96-well plate. The wells were then washed and fresh 
media containing either drug or DMSO added to each well. Images were taken every 30 
minutes for 24 hours and cell migration calculated as relative wound density against time 
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zero by the IncuCyte ZOOM analysis software. Results were normalised to DMSO and are 







































Figure 6.6: Top: Relative migration of MDA-MB-231 cells across a scratch wound over 6, 12 
and 24 hours normalised to DMSO at 24 hours. Graph shows compound 52 and Dasatinib at 
10 nM concentration with statistical significance relative to DMSO; p<0.05, *; p<0.01, **; 
p<0.005, ***. Error bars denote standard deviation, n = 4.  Bottom: Cell migration relative to 
DMSO after 24 hours with compound 52 and Dasatinib along a concentration gradient. 
Curves were plotted and EC50 values calculated using GraphPad Prism 6. 
 
Both compound 52 and Dasatinib were able to reduce migration as early as 2 hours and 
maintain the potency for 24 hours. Dasatinib and 52 showed very similar properties with 
EC50 values against cell migration of 8.4 and 8.6 nM, respectively.  
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6.2.5 Western Blot Analysis of Compound 52 and Dasatinib 
To assess the level of inhibition of SRC and downstream targets in situ a Western blot was 
set up using MCF7 and MDA-MB-231 breast cancer cells. Cells were seeded in 10 cm 
dishes and grown until 80% confluence. Cells were then serum starved (0.1 % FBS) 
overnight and incubated with drug or DMSO (0.1 % v/v) for 30 minutes prior to stimulation 
with FBS (10 %) for an hour. The cells were then lysed and Western blotting carried out as 
described in method section 10.7.5. 
As SRC auto-phosphorylates at tyrosine 416 upon activation, SRC activity/inhibition could 
be determined using an anti-phospho SRC Y416 antibody. Focal adhesion kinase, an 
important protein involved in cell mobility, is phosphorylated by SRC at position Y861. This 
antibody was used to show inhibition of downstream targets of SRC. AKT (Y326) is the 
primary target of BRK/PTK6 and is also phosphorylated by SRC at this position so this was 
included in the blot, along with pAKT (Y473), the common AKT activation site.[121, 122] 
Tubulin was used as a loading control. In order to determine whether pFAK, downstream of 
SRC, was truly being inhibited by SRC and not by off-target or direct inhibition, SYF cells 
(lacking expression of SRC, YES and FYN) were incubated with compound 52 and 
Dasatinib and phospho-FAK levels identified by Western Blot, as described previously. 
Figure 6.7 shows the results as scans of the photographic films used to develop the blots. 
Compound 52 was able to inhibit the auto-phosphorylation of SRC down to 10 nM in both 
MCF7 and MDA-MB-231 cells to an equal or even greater degree than Dasatinib – a more 
profound difference was observed in MCF7 cells. The inhibition of FAK phosphorylation 
was in excellent correlation with that of SRC. Interestingly though, treatment with Dasatinib 
resulted in increased levels of total SRC at higher concentration (100 and 30 nM), whereas, 
treatment with compound 52 seemed to have a lesser effect on total SRC. This may suggest 
that Dasatinib is able to stabilise SRC from degradation, hence, the increased levels. 
Whether this results in increased levels of SRC activation is unknown, however. 






Figure 6.7: Western Blot analysis of compound 52 and Dasatinib on SRC and downstream 
targets in MCF7 (top left), MDA-MB-231 (top right) and SYF cells (bottom). Compound 52 
was able to inhibit the phosphorylation of SRC down to 10 nM in MCF7 and MDA-MB-231 
cells and did not stabilise total SRC as Dasatinib did at higher concentrations. Tubulin was 
used as a loading control. SYF cells (lacking expression of SRC, YES and FYN) confirmed 
the inhibition of pFAK (Y861) was via pSRC inhibition and not through direct or off-target 
effects. 
 
It was hypothesised that via inhibition of BRK/PTK6, phosphorylation of AKT at Y326 
would be reduced as both 52 and Dasatinib inhibit BRK at moderate levels, 17.3 and 41.5 
nM IC50, respectively. This was not observed, however, at the concentrations used (top dose 
100 nM). Compound 52 gave constant levels of pAKT (Y326) indicating that 
phosphorylation at this position was via other proteins (i.e. not SRC or BRK) and basal 
levels of pAKT (Y326) were already high. In the case of Dasatinib, however, levels of 
pAKT (Y326) were increased at higher concentration of drug (100 and 30 nM – even 10 nM 
with MDA-MB-231 cells). This effect is more pronounced in the triple negative MDA-MB-
231 cells. Again, the reason for compensatory increase in AKT signalling is unknown, 
however, it may lead to a negative effect in terms of cancer treatment – phosphorylation of 
AKT at Y326 may lead to a more stable complex with increased catalytic activity. 
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Looking at the results from the SYF cells, it is clear that inhibition of pFAK following 
compound treatment, in the MCF7 and MDA-MB-231 cells, is a result of SRC inhibition as 
there is no effect on pFAK seen in the SYF cells.  
 
6.2.6 Zebrafish Cardiotoxicity and Tail Fin Cut Studies 
The use of zebrafish for in vivo biology studies has gained increasing momentum over the 
past 20 years.[123, 124] Although they do not offer the same comparison to humans as mice 
do, their low costs, rapid growth rate, range of assays/imaging techniques available and ease 
of use make zebrafish a viable alternative for early in vivo studies. In addition, zebrafish 
embryos (less than 5dpf) are not subject to animal regulations. To evaluate the toxicity and 
in vivo efficacy of compound 52 and Dasatinib, both compounds were included in zebrafish 
embryo tail fin regeneration assays.  
Zebrafish embryos are capable of regrowth of damaged tissues after amputation, in 
particular, amputated tails. Evidence has emerged that a member of the SRC family kinases 
(SFK), FYNb, is activated and involved in regeneration of the tail after tissue damage. 
Further, LYN acts as a sensor to detect reactive oxygen species, such as hydrogen peroxide, 
after injury. Activation of FYNb, was responsible for tail regeneration.[125] Yoo et. Al. 
found that incubation of the zebrafish with PP2 (a SFK inhibitor) halted the regrowth of 
amputated tails after only 2 hours treatment (1 hour pre, and post injury).[125] It was 
hypothesised that compound 52, being a potent SFK inhibition, may give similar results. 
Importantly, any off-target toxicity effects would become evident since numerous kinases 
are essential for correct zebrafish embryo development. 
Zebrafish embryos, 2 days post fertilisation (dpf), were treated with compound 52 or 
Dasatinib at 100µM, with DMSO as negative control, for 2 hours prior to tail amputation. 
The tails were then clipped from all fish at the points indicated by the red lines in figure 6.8. 
The fish were incubated with drug for a further 2 hours before being washed off and the fish 
left to develop in E3 embryo media at 28 
o
C for 2 days, after which, they were imaged, 








Figure 6.8: Zebrafish embryos at 4 dpf, 2 days post tail amputation comparing compound 
52, Dasatinib and DMSO. Left: Full regrowth of the tail was observed with DMSO treatment, 
whereas, 2 hours pre and post incubation with compound 52 or Dasatinib halted the 
regrowth. Middle: Dasatinib treated zebrafish showed severe heart toxicity after 2 days post 
4 hours incubation at 100 µM. Compound 52 and DMSO showed normal development and 
no toxicity. Right: Zoomed in images of heart development after 2 days post tail amputation 
and incubation with drug. Compound 52 shows normal growth, as seen with DMSO, while 
Dasatinib treatment resulted in an enlarged heart.  
 
2 days post amputation, zebrafish treated only with DMSO were able to completely grow 
back their tails as shown in figure 6.8, left, whereas, treatment with compound 52 or 
Dasatinib at 100 µM halted tail regeneration. This tail regeneration assay was designed as a 
simple proof of concept experiment to demonstrate that compound 52 was able to inhibit 
SFKs in a basic in vivo model and to assess any obvious toxicity issues associated with the 
drug. Even at 100 µM, zebrafish treated with compound 52 showed no signs of toxicity, 
figure 6.8, top middle and right, and continued to develop normally. Dasatinib, however, 
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caused severe cardiotoxicity as seen in figure 6.8, bottom middle and right, with the fish 
displaying enlarged hearts. 
It was hypothesised that ABL inhibition may be the cause of the observed cardiotoxicity and 
indeed many groups have demonstrated the complications of ABL inhibition and the 
development of adverse cardiac effects.[126-129] In particular, Qui et Al. (PNAS, 2010) 
demonstrated that knock-out of c-ABL causes ‘dramatically enlarged hearts’ in mouse 
embryos which can be rescued by restoring the protein.[129] They showed that reduction in 
ABL activity caused an increase in cardiomyocyte proliferation, thus, resulting in the 
abnormally large hearts observed in the mice; the same effect seen in zebrafish treated with 
Dasatinib. Although their findings show that c-ABL is essential for heart development, in 
mammals, both Dasatinib and Imatinib (a potent ABL inhibitor approved for CML) have 
caused cardiotoxicity in adult patients, with fully developed hearts. These findings, along 
with our own evidence, further back up the premise that inhibition of c-ABL is not only 
harmful in breast cancer treatment but can also instigate severe toxicity in patients taking 
such drugs, particularly in an aging population with heart disease problems. 
To further test this hypothesis, PP20, figure 6.1, was incubated with zebrafish embryos for 2 
hours only, and images taken 3 days later. PP20 (dosed at 100 µM) caused severe toxicity in 
all zebrafish and their development was highly flawed. The embryos shown in figure 6.9a 
show examples of the observed growth retardation, and again, all embryos showed 
significantly enlarged hearts, which is the probable reason for the overall lack of 
development of the embryo.  
PP20 proved to be even more toxic that Dasatinib at only 2 hours incubation with zebrafish 
embryos. Compound 52, Dasatinib and PP20 all inhibit SRC to a similar degree, however, 
only 52 does not inhibit ABL. Although the properties of PP20 have not fully been explored, 
it is likely that the cardiotoxicity and growth retardation are due to ABL inhibition. 
As a simple model of in vivo efficacy, tail fin regeneration assays were set up, as described 
above, and compound 52 compared with Dasatinib and PP20. Many assays were attempted, 
however, the results were generally inconsistent and statistically significant results could not 
be drawn. Figure 6.9b shows the results of one of the assays including a higher sample 
number. In this assay, zebrafish embryos were incubated with DMSO (0.1 %), Dasatinib or 
PP20 (100 μM) 2 hours prior to and after tail amputation and the embryos left to develop for 
two days in fresh E3 media before being imaged. Compound 52 was included at the higher 
concentration of 250 μM, firstly because it had not shown any previous toxicity, as Dasatinib 
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and PP20 had, but also because it inhibits FYN, the kinase responsible for regrowth, to a 
lesser degree than the others. 
 
 
Figure 6.9: a) Zebrafish embryos at 4 dpf after 2 hour treatment with PP20 (100 µM) at 1 
dpf. All 3 fish show growth retardation and cardiotoxicity, highlighted in zoomed in images at 
bottom. b) Embryos were incubated with either 52 (250 µM), Dasatinib (100 µM) or PP20 
(100 µM) for 2 hours prior to and after tail amputation. Tail regrowth was measured after 2 
days, and plotted as a scatter plot. Performed t-tests showed both Dasatinib and PP20 were 
statistically significant (p<0.05, *; p<0.01, **; p<0.005, ***) but not 52. *3 fish were omitted 
from the Dasatinib and PP20 group due to toxicity or death. 
  
Dasatinib and PP20 caused a statistically significant reduction in tail regrowth compared 
with DMSO, figure 6.9b, however, all embryos looked sick and displayed severe toxicity 





or extreme toxicity. It is hypothesised that the reduction in tail regrowth observed with 
Dasatinib and PP20 was caused more so by the general toxicity than with inhibition of 
LYNb. 52, on the other hand, did not show any toxicity, even at the higher concentration of 
250 μM. The reduction in tail regrowth was not deemed statistically significant (p = 0.079), 
however, this result was anticipated due to its lower inhibitory properties over FYN. Most 
importantly, the cardiotoxicity was consistently observed with Dasatinib and PP20, but not 




















6. The Development of Novel, Potent and 
Selective SRC Family Kinase Inhibitors 
6.3 Conclusion 
 
Through the discovery of moderately potent compound 29 and modification of its aryl group, 
using PP20 as inspiration, lead compound 52 was generated showing extraordinary activities 
in cellular assays. Compound 52, which was shown to inhibit the viability of MDA-MB-231 
triple negative breast cancer cells with an EC50 of 10 nM, was revealed to be a sub-
nanomolar potent SRC family kinase inhibitor. Most importantly, 52 did not potently inhibit 
the kinase c-ABL, unlike all other SRC inhibitors, either in the clinic or reported to date. 
Through a combination assay using the specific allosteric site ABL inhibitor GNF-2 and 52, 
it was shown that ABL inhibition was detrimental in combination with SRC inhibition. This 
experimental evidence describing adverse effects of ABL inhibition is backed up thoroughly 
in the literature.[114, 115] 
Not only was 52 extremely potent against SFKs, it was also very selective when tested 
against 341 kinases. Inhibition was generally only observed in the SRC family branch of 
kinases. By exploiting the properties of SFK inhibition, 52 was able to reduce the migration 
of MDA-MB-231 cells to the same degree as Dasatinib and was shown to potently inhibit 
pSRC and pFAK in MCF7 and MDA-MB-231 cells by Western Blot. Further, 52 did not 
show off-target effects, such as increased pAKT levels, as Dasatinib did. 
Most importantly, 52 was shown to be non-toxic when incubated with zebrafish embryos and 
caused no growth defects. Dasatinib and PP20, on the other hand, caused severe 
cardiotoxicity in the embryos, which has previously been reported in the literature. Since 
potent and selective SRC inhibitors have not been developed until now, the study reported 
herein represents the first pharmacological evidence that the cardiotoxicity mediated by dual 
ABL/SRC inhibitors is most likely attributed to ABL inhibition.[126, 127, 129] 
Currently, compound 52 represents the only sub-nanomolar SRC inhibitor that does not 
potently inhibit ABL. Given all the evidence of ABL's anti-oncogenic role in cancers other 
than CML, compound 52 represents promise for the treatment of SRC driven tumours, 
particularly triple negative breast cancer. The optimisation and thorough examination of the 
properties of 52 are discussed in the next chapters.  
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7. Optimisation of Lead Compound 52 
7.1 Introduction & Aims 
 
In order to develop the series of SRC inhibitors into preclinical candidates, compounds 
containing variations of the aryl group of compound 52 were synthesised. This allowed the 
creation of vital structure activity relationships to which the necessity of the current groups 
could be assessed. A structure activity relationship map can be drawn, figure 7.1, to show 
which groups should be addressed in regard to whether they are necessary for potency, 
stability or pharmacokinetic properties. Due to the phenotypic nature of the discovery of the 
previous series of inhibitors, any drugs created via modification of the lead compound were 
to be biased based upon phenotypic endpoints, typically cell proliferation. This would not 
only frontload the most potent compounds but also rule out any which possessed low 
permeability or solubility due to their modifications. Important issues to address regarding 
modifications are shown in figure 7.1. The table highlights some of the modifications made 
to compound 52.  
 
Figure 7.1: Table showing possible modifications for groups around compound 52 (left). 
Structure activity relationship map of compound 52 highlighting which groups should be 






7. Optimisation of Lead Compound 52 
7.2 Results 
 
7.2.1 Design and Synthesis of Compound 55 and 56 
Compound 51 showed an IC50 against SRC inhibition of < 0.5 nM, similar to 52. By this 
reckoning, there is space in the SRC active site to accommodate larger groups to the ‘south’ 
of the molecule. Instead of lengthening the chain, as in compound 51, two new compounds 
were synthesised containing pyrrolidine and piperidine groups, respectively, in order to 
access lipophilic pockets situated near the ‘south’ amine. Firstly, the two intermediates, 53 
and 54, scheme 7.1, were synthesised from the aldehyde intermediate by the same fashion as 
previously. Compounds 55 and 56 were then synthesised, by Suzuki reaction, from the 
intermediates, 53 and 54, respectively, and [4-(tert-butoxycarbonylamino)-3-methoxy-
phenyl]boronic acid.  
 
Scheme 7.1: Synthesis of compounds 55 and 56. a) 4-(1-pyrrolidinyl)piperidine (53) or 1,4-
bipiperidine (54), AcOH, NaBH(OAc)3, DCM, r.t. b) [4-(tert-butoxycarbonylamino)-3-methoxy-




Compounds 55 and 56 were tested in MCF7 and MDA-MB-231 cell viability assays, as 
before, to initially assess the impact of larger, more lipophilic, amine groups on cell 
proliferation, figure 6.2. Both compounds were less potent than 52, however, still had EC50 
values against both cell lines below 250 nM. Again, compounds were more potent in the 
triple negative MDA-MB-231 cells with the ratio of MCF7 to 231 comparing favourably 





52 30.99 9.08 
55 76.52 39.24 




















Figure 7.2: EC50 values against MCF7 and MDA-MB-231 cell proliferation plotted as an 
average of 3 experiments with mean values (right, nM). Error bars denote standard 
deviation, n = 3. 
 
The study suggested that increasing size and/or lipophilicity in the ‘south’ part of the 
structure was not beneficial to activity against cell proliferation and perhaps SRC inhibition. 
Due to this decreasing activity and the pressure of modern small drugs to comply with 
Lipinsk’s rules (molecular weight < 500), the dimethyl amino group, found in compound 52, 
was used for all further structure modifications. Other drug likeness parameters, such as 
ligand efficiency (LE), percentage/potency efficiency index (PEI) and binding efficiency 
index (BEI), also favour lower molecular weight compounds, given similar potencies.  
 
7.2.2 Aryl Group Modifications – Synthesis and Biological Testing 
To fulfil some of the questions raised from the structure activity map in figure 7.1, a series of 
varying aryl groups were synthesised to satisfy concerns over the optimal aryl group for SRC 
inhibition and pharmacokinetic properties. The first group synthesised was aiming to 
determine whether the oxygen, and therefore, carbamate, was required and whether the t-
butyl group could be replaced with a phenyl group. For this purpose, a set of boronic esters 
(57-62) were synthesised from the common precursor 4-Amino-3-methoxyphenylboronic 
acid pinacol ester and various commercially available acetyl chlorides, chloroformates or t-





Compound X = R= Compound X = R= 
57 CH2 t-butyl 63 CH2 t-butyl 
58 NH t-butyl 64 NH t-butyl 
59 O Phenyl 65* O Phenyl 
60* O Benzyl 66* O Benzyl 
61 CH2 Phenyl 67 CH2 Phenyl 
62 CH2 Benzyl 68 CH2 Benzyl 
 
Scheme 7.2: Synthesis of intermediate boronic esters 57-62 and compounds 63-68. a) t-
butylacetal chloride; t-butylisocyanate; phenyl chloroformate; benzyl chloroformate; 
phenylacetyl chloride or hydrocinnamoyl chloride, 4-amino-3-methoxyphenylboronic acid 
pinacol ester, NEt3, DCM, r.t. b) 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-
pyrazolo[3,4-d]pyrimidin-4-amine, K2CO3, Pd(OAc)2, PPh3, 1,4-dioxane/water (10:1), 120 
o
C, 
mw. * Product was not as desired. 
 
Boronic esters 57 and 58 contained an amide and a urea group instead of a carbamate, 
thereby, challenging the requirement of a hydrogen bond acceptor (-O-) with a non-hydrogen 
bonding atom (-CH2-) and a hydrogen bond donor (-NH-). The synthesis of both boronic 
esters and corresponding final compounds, 63 and 64, proceeded in good yield with the 
conditions described in scheme 7.2. 
Boronic ester 59 was designed to challenge the presence of the t-butyl group with a phenyl 
group and, similarly, 60, with a benzyl group. 59 was synthesised successfully, however, the 
product of reaction between 4-amino-3-methoxyphenylboronic acid pinacol ester and benzyl 
chloroformate was the unexpected, benzylated product, 60*, figure 7.3a, rather than the 
desired boronic acid. The rearrangement depicted in figure 7.3a is one possible explanation 
for the by-product. Nonetheless, 60* was isolated and purified, and used to create compound 
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66*, hereby named 66, by Suzuki reaction. Further complications arose when attempting to 
synthesise compound 65 from intermediate 59. Following the Suzuki reaction using the 
standard protocol, desired product 65 was not detected but the free amino compound instead, 
figure 7.3b. The reaction was repeated under the same conditions but the outcome was the 
same with the phenyl formate group of the boronic ester intermediate missing. Perhaps the 
phenyl carbamate was unstable at higher temperatures and degraded during the Suzuki 
reaction. Regardless, the free amino derivate, 65*, hereby known as 65, was isolated and 
purified, and later used in biological testing.  
Figure 7.3: a) Possible rearrangement mechanism during reaction of 4-amino-3-
methoxybenzeneboronic acid pinacol ester and benzyl chloroformate to create 60* and 
corresponding final compound, 66* (66). b) Loss of phenyl formate during Suzuki reaction 
created by-product 65* (65). 
 
Boronic esters 61 and 62 were similar to 59 and 60 in that they have phenyl and benzyl 
groups, respectively, instead of t-butyl. In this case, however, the oxygen was replaced by a 
CH2. This was designed to provide a direct comparison between carbamate and amide 
groups, giving important information on the structural requirements of the hydrogen bond 
acceptor. Due to the complications that arose during the synthesis of final compounds 65 and 
66, however, this direct comparison was could not be carried out. Both intermediates 61 and 
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62, and their corresponding final compounds, 67 and 68 were synthesised following the 
procedure described in scheme 7.2, successfully, and in good yield. 




























































































Compound\Cell Type MCF7 MDA-MB-231 
52 0.031 0.0091 
63 23.44 13.59 
64 35.47 15.23 
65 4.93 6.72 
66 0.58 0.20 
67 11.59 17.21 
68 7.04 12.18 
 
Figure 7.4: Plotted EC50 values (µM) against MCF7 and MDA-MB-231 cell proliferation 
comparing lead compound 52 with aryl modified compounds 63-68. Structures are included 
below the x-axis for convenience. Error bars denote standard deviation, n = 3. 
 
Compounds were tested in MCF7 and MDA-MB-231 cell viability assays, as before, and the 
calculated EC50 values plotted in a bar graph, figure 7.4. Surprisingly, the only compound to 
show sub-micro molar potency was 66, the benzyl amine containing derivative from the 
unexpectedly synthesised boronic acid 60*. Compound 66 had an EC50 value of 583 and 202 
nM against MCF7 and MDA-MB-231 cell proliferation, respectively. Though not as potent 
as lead compound 52, these values represent acceptable potency for further consideration.  
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Even more surprising were compounds 63 and 64. The modification from a carbamate group 
to an amide or urea reduced the compounds' potency >750x relative to lead 52, strongly 
indicating that a hydrogen bond acceptor is essential for activity at this position. It is curious 
as to why compound 66 was more potent given the lack of any hydrogen bond acceptors on 
the aryl groups. However, as 66 is notably different from the other compounds, it may be 
that other targets than SRC were being inhibited.  
 
7.2.3 Further Optimisation of the Aryl Group - Pyridines 
Given the unexpected success of compound 66, two more compounds were designed and 
synthesised based upon its structure. Compounds 71 and 72, based around a pyridine ring 
instead of phenyl, were synthesised from boronic ester intermediates, 69 and 70, scheme 6.3, 
from 4-amino-3-methoxyphenylboronic acid pinacol ester. The more polar pyridine group 
was designed to mimic compound 66 but featured a hydrogen bond acceptor extended 
further to the extremities of the structure. 
 
Scheme 7.3: Synthesis of compounds 71 and 72 from boronic ester intermediates 69 and 
70. a) 2-(bromomethyl)pyridine hydrobromide or 3-(bromomethyl)pyridine hydrobromide, 
NEt3, DCM, r.t. b) 69 or 70, 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine (50), K2CO3, Pd(OAc)2, PPh3, 1,4-dioxane/water (10:1), 120 
o
C, mw. The 
4-(methyl)pyridine equivalent boronic ester was not able to be synthesised. It was thought to 




The synthesis of the 4-(methyl)pyridine boronic ester equivalent was unsuccessful. The 
starting compound, 4-amino-3-methoxybenzeneboronic acid pinacol ester, was sensitive to 
light and although reactions were carried out in the dark, very little product was isolated 
from the reaction with 4-(bromomethyl)pyridine hydrobromide. Nonetheless, compounds 71 
and 72 were successful and taken forward for biological testing. 
The compounds, synthesised in good yields, were tested in a cell viability assay with MDA-
MB-231 cells. Due to the greater effect of compound 52 in the triple negative breast cancer 
cells, all subsequent compound ranking and importance were decided based upon the EC50 
values gathered against MDA-MB-231 cell proliferation. Compound 71 and 72 gave EC50 
values of 40.20 and 4.14 µM, respectively. Comparing with compound 66’s value of 0.20 
µM, compounds 71 and 72 were much weaker and the more polar pyridine group was not 
tolerated. 
 
7.2.4 Further Optimisation of the Aryl Group – Phenyl Modifications 
With the optimum ‘south’ part of the molecule determined, section 7.2.1, and compound 52 
still remaining the best compound in terms of potency against cell proliferation, efforts were 
focused on altering the aryl group associated with 52 to answer some more of the questions 
raised in the SAR map in figure 7.1. More appropriately, was the methoxy group or the -NH- 
from the aryl moiety required for potency? 
To answer these questions, again, a series of boronic acids/esters were synthesised, or were 
commercially available, and were cross-coupled to intermediate 50 by Suzuki reaction, 
scheme 7.4. The table below describes the final compounds synthesised, in which way they 
differ from compound 52, and which issues they will address in terms of SARs. 
Compound Modification SAR 
75 Methoxy to hydroxy H bond acceptor to donor 
76 Methoxy removal Removal of H bond acceptor 
77 Methoxy removal and N-boc at 
2-position 
Determine optimum position for 
 N-boc 
78 Methoxy to pyridine Bring H bond acceptor closer to ring 
79 Methoxy to CH as an indole Fill space with neutral group and force 
carbamate to assume flat position 
81 Methoxy to 3-position, N-boc to 
 2-position 
Challenge optimum group position 
84 Carbamate to ester Removal of H bond donor 
86 Methoxy removal and carbamate Removal of H bond donor and acceptor 
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 to ester 
87 Methoxy removal and carbamate 
 to acid 
Charged group instead of neutral 
90 Carbamate to amide Switch nitrogen position 
94 Carbamate to oxazole Locked position involving aromatic 
group 
95 Methoxy removal and carbamate  
to nitrile 
Removal of all groups with extended  
H bond acceptor 
Table 7.1: Compound modifications relative to 52 and the SARs they will address. 
 
All final compounds were synthesised from their respective intermediates in moderate to 
excellent yields with no complications. Boronic acid/ester synthesis, where appropriate, 
involved starting from either commercially available amino phenyl compounds to which the 
amine was protected with a Boc group or phenyl acetic acid precursors with the conversion 
to acid chlorides using thionyl chloride. Subsequent substitution then proceeded in low to 
good yield. 
All 12 final compounds were assessed in MDA-MB-231 cell viability assays to determine 
their potency relative to compound 52. The results, figure 7.5, varied greatly from totally 
inactive, compounds 87, 90 and 95, to very potent, compounds 84 and 86, with EC50 values 
comparable to 52.  
Compounds 87, 90 and 95 were completely inactive, which is not surprising given their 
drastic changes relative to 52. 87, which features a carboxylic acid moiety, is a highly 
charged molecule, expected to be found in zwitterion form at physiological pH (negatively 
charged on the north of the molecule and positively charged on the south). Although the 
introduction of zwitterions can aid solubility in large or lipophilic compounds, they present 
significant problems with cell permeation unless transported through the cell membrane by 
active transport or other means. It is highly likely that compound 87 struggled to penetrate 
the cell. It is shown in section 7.2.6 that 87 has no effect on SRC family inhibition. Based on 
the target potency data, in this case, I cannot confirm whether cell permeability is also an 
issue, however, the charges associated with the molecule most likely do present the problem. 
Compound 90, which features a ‘reverse amide’ relative to the nitrogen position in the 
carbamate in compound 52, indicates that the nitrogen is not tolerated in this position or the 
restriction in movement in the lipophilic region of the pyrrolidine, presented by the amide, is 




Scheme 7.4: Synthesis of compounds 73-81. a) Di-tertbutyldicarbonate, DMAP, DCM, r.t. b) 
bis(pinacolato)diboron, Pd(OAc)2, PPh3, 1,4-dioxane/water (10:1), 120 
o
C, mw. c) 1-[2-[4-
(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (50), K2CO3, 
Pd(OAc)2, PPh3, 1,4-dioxane/water (10:1), 120 
o




Scheme 7.4 cont.: Synthesis of compounds 82-95. b) bis(pinacolato)diboron, Pd(OAc)2, 
PPh3, 1,4-dioxane/water (10:1), 120 
o
C, mw. c) 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-
iodo-pyrazolo[3,4-d]pyrimidin-4-amine (50), K2CO3, Pd(OAc)2, PPh3, 1,4-dioxane/water 
(10:1), 120 
o
C, mw. d) Thionyl chloride, DMF (cat.), THF, 80 
o
C. e) t-butyl alcohol, NEt3, THF, 
r.t. f) Thionyl chloride, DMF (cat.), toluene, 120 
o
C. g) t-butyl alcohol, NEt3, toluene, r.t. h) 























Compound 75 76 77 78 79 81 84 86 87 90 94 95 
EC50 (µM) 9.71 3.57 26.77 17.74 4.15 28.59 0.036 0.10 >100 >100 0.89 >100 
 
Figure 7.5: Calculated EC50 values (µM) plotted as a bar graph for compounds 75-95 
against MDA-MB-231 cell proliferation. Error bars denote standard deviation, n = 3. 
 
Compound 95, featuring a nitrile group instead of the carbamate and the methoxy group 
removed, also showed no activity against cell proliferation. This compound is drastically 
different from lead compound 52 and features no lipophilic moiety which appears to be 
required for activity. 
Compounds 84 and 86 gave EC50 values of 36 and 100 nM, respectively. This indicates that 
the nitrogen and, hence, carbamate group of 52 is not required for activity but its presence 
does not hinder activity and gives, roughly 3x, greater potency against cell proliferation. 
Whether this difference is down to pharmacokinetics or kinase inhibition is discussed in 
section 7.2.6. Remarkably, the loss of the nitrogen and the methoxy group still produced a 
potent compound (86) indicating that, although beneficial for activity, the methoxy group is 
not essential to produce a potent compound against MDA-MB-231 cell proliferation, at least. 
Comparing with compound 76, which contains the t-butyl carbamate without the methoxy 
group, compound 86 is 35x more potent. This is surprising given that the only difference is 
the substitution from nitrogen to a CH2.  
Compound 94 also gave a sub-micro molar potency with an EC50 of 0.89 µM. At first, an 
oxazole might seem a significantly different group from those in 52, however, by looking at 
an overlay of 94 with 84, one can see how related the structures are and how they might sit 
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in the SRC active site, thus, explaining the reasons for compound 94’s activity. Indeed 
oxazoles are known bioisosteres of ester groups used to increase biochemical stability. 
 
 
Figure 7.6: Compounds 84 and 94 merged together to show the similarities in their 2D 
structures. 
 
Compounds 75-81 all gave micro molar EC50 values against MDA-MB-231 cell 
proliferation. From these low values, important SARs can be derived:   
75: A hydroxyl group and, therefore, a hydrogen bond donor, is not tolerated. 
76: Results suggest that the methoxy is required; however, compound 85 suggests it is not. 
77: The carbamate group is optimum at the para position of the phenyl group. 
78: A pyridine instead of phenyl ring is not well tolerated. 
79: A lipophilic group instead of methoxy, represented by an indole, is not tolerated. 
81: The methoxy and carbamate groups are optimum at meta and para, respectively. 
Given all the data gathered from the compounds it can be summarised that the carbamate 
group must be in the para (4) position but substitution for an ester, by substitution of the -
NH- for a -CH2-, is well tolerated. The methoxy group is not required if an ester is present 
instead of the carbamate, however, adds an extra degree of potency when present. 
Furthermore, the methoxy group is required when the carbamate is present. This can perhaps 
be explained by considering the intramolecular interactions between the NH and methoxy 
group, figure 7.7. 
The use of the indole group not only challenged the requirement of the methoxy but also 
forced the carbamate group to adopt a more rigid position. Further, the introduction of 
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pyridine, indole and nitrile groups are not tolerated, neither is having an amide instead of 
ester. An oxazole is also a good and stable substitution for the ester group. 
 
 
Figure 7.7: Compounds 52, 76, 79 and 86 highlighting the spatial requirements for 
activity.*Perhaps the lone-pair of electrons on the nitrogen are forced perpendicular to the 
phenyl ring to accommodate bonding with the aromatic pi system. 
 
7.2.5 Synthesis of Compounds 99, 100 and 101 to Complete SAR on ‘South’ of Structure 
Through all structural modifications in section 7.2.4, compound 52 remained the most potent 
compound against cell proliferation. As a final nail in the coffin for the optimisation of the 
‘south’ amine part of the structure, 3 more compounds were designed and synthesised, 
scheme 7.5. Previously, in section 3.2.2, compound 8 was shown to be one of the most 
potent of the library one compounds featuring a 4-methylpiperizine group. In contrast, 
compound 11 was non-active, featuring a 4-hydroxypiperidine group. By modifying this 
group to a 4-methoxypiperidine, the properties of the group are changed from a hydrogen 
bond donor to an acceptor which appears to be favourable in these group of inhibitors. The 3 
new compounds designed featured 4-methylpiperizine, 4-methoxypiperidine and 3-
dimethylaminopiperidine groups, thus, challenging the position of the key nitrogen in the 
‘south’ of the molecule. 
The compounds were synthesised as previously by reduction amination using aldehyde 6 and 
one of three amines then Suzuki reaction with [4-(tert-butoxycarbonylamino)-3-methoxy-

















Figure 7.8: Scheme 7.5, top: Synthesis of intermediates 96-98 and final compounds 99-101. 
a) 4-methylpiperizine (96, 99); 4-methoxypiperidine (97, 100); or 3-dimethylaminopiperidine, 
AcOH, NaBH(OAc)3, DCM, r.t. b) [4-(tert-butoxycarbonylamino)-3-methoxy-phenyl]boronic 
acid, K2CO3, Pd(OAc)2, PPh3, 1,4-dioxane/water (10:1), 120 
o
C, mw. Bottom: Plotted EC50 
values against MDA-MB-231 cell proliferation. Error bars denote standard deviation, n=3. 
 
The compounds were tested in cell viability assays using MDA-MB-231 cells. EC50 values 
calculated from curves plotted in GraphPad Prism are shown in figure 7.8, plotted as a bar 
graph. All 3 compounds gave supra-micromolar EC50 values. Compared with lead compound 
52’s value of ~10 nM these compounds were 200x less potent. This drastic difference in 
potency from such a subtle change highlights how sensitive enzymes truly are with regard to 
their inhibitors. Furthermore, this data provides great confidence that the original 4-






dimethylaminopiperidine group is optimum for SRC inhibition and/or compound penetration 
into cells to reduce their proliferation.  
Such is the beauty of phenotypic drug discovery, even the most potent enzyme inhibitor is 
not considered a drug unless it possesses the correct physical properties to enable it to pass 
through the cell membrane and exert its effects. Phenotypic drug discovery supports the 
unearthing of these properties simultaneously, and quickly divides the good from the poor 
compounds by providing rapid proof-of-concepts in functional cell based assays.  From a 
critical point of view, however, using this strategy, compounds with interesting binding 
activities but poor cell penetrability may be discarded as inactive. Those discarded 
compounds, which have the potential to be physicochemically improved in further medicinal 
chemistry campaigns, represent the real collateral damage of this pragmatic approach of drug 
discovery.   
 
7.2.6 Kinase Activity of Compounds 55, 56, 66, 76, 84, 86, 87, 94 and 99 
All compounds that gave EC50 values of less than 1 µM were tested against the SRC family 
kinases to determine their on-target potency and selectivity. Compounds 76 and 87 were 
included in this study to gain a greater insight into why they were less potent than their ester 
equivalents, 86, as was compound 99 to see how SRC inhibition differed by placing the 
nitrogen into the ring. Compounds were tested against the same 14 kinases as before as well 
as BRK/PTK6, previously shown to be inhibited by compound 52. The study was conducted 
by Reaction Biology Corp. as described in section 10.7.15.  
The IC50 values against the 15 kinases are shown in table 7.2. Comparing all compounds 
with the same north of the molecule (compounds 55, 56 and 99) with 52, compound 99 is the 
weakest of the three with an IC50 of 20.9 nM against SRC. This is in good agreement with its 
reduced anti-proliferative effects against MDA-MB-231 cells and provides good 
confirmation that the nitrogen of the 4-dimethylamino group is in the optimum position in 
the other compounds. Nonetheless, 99 is still a very potent inhibitor against SRC family 
members with excellent selectivity over ABL. Compounds 55 and 56, which showed 
excellent potency against cell proliferation, are both very potent SFK inhibitors. Compound 
55 is slightly more potent, leaving 56 to be slightly more selective against ABL. These data 



































BLK 2.7 8.5 452.8 307.0 7.0 378.0 3.7 15.4 
 
49.4 118.0 
BRK/PTK6 22.0 30.4 206.0 198.0 36.5 242.0 20.9 37.3 
 
43.9 34.0 
FGR <0.5 <0.5 53.7 74.00 1.1 9.490 <0.5 <0.5 
 
3.4 1.2 
FRK/PTK5 3.1 7.3 1267.0 1680.0 166.9 730.0 5.1 30.5 
 
192.0 30.7 
FYN 0.8 4.1 787.2 749.0 4.3 342.0 3.1 6.4 
 
156.0 29.8 
HCK 2.3 4.8 344.2 492.0 7.4 308.0 2.5 10.3 
 
102.0 10.0 
c-KIT 4041.0 6302.0  5820.0 514.3 22200.0      
LCK <0.5 3.1 63.0 87.9 1.5 30.8 0.5 1.3 
 
6.9 1.3 










      
RET     7496.0       
c-SRC <0.5 0.9 113.6 194.0 3.5 71.30 1.0 1.0  46.3 20.9 
YES/YES1 <0.5 0.6 30.3 36.4 0.6 7.9 <0.5 <0.5 
 
1.5 0.8 
Table 7.2: IC50 values (nM) against 15 kinases. Values below 100 nM are highlighted in red. Empty boxes indicate no inhibition. 
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Compounds 63 and 64 are much weaker SFK inhibitors, not surprising given their high EC50 
values against cell proliferation, which, again, strongly suggests that a hydrogen bond 
acceptor is essential closer to the t-butyl position. Compound 66, which turned out to be a 
potent SFK inhibitor, remains a mystery as to why it is so potent. It does not possess an 
oxygen to act as a hydrogen bond acceptor as previous results suggest necessary. However, 
perhaps its mode of binding differs from the other compounds and the phenyl ring has access 
to a lipophilic pocket. Structural studies would be needed to support any hypotheses. 
Compounds 76, 84, 86 and 87 had IC50 values which corresponded greatly to their respective 
potencies against cell proliferation. 87 was completely non-active against all kinases tested, 
most likely due to its highly charged nature, explaining its zero effect when tested in cells. 
Again, 76, 84 and 86 follow the same trend seen with the cell viability assay. Compound 76 
is only a moderately potent SFK inhibitor whereas, 84 and 86 are very potent inhibitors, with 
84 being slightly more potent, however, sacrificing on the selectivity over ABL. Both these 
compounds represent leads due to their excellent potency against cell proliferation, inhibition 
of the SFKs, and lower molecular weight (509 and 479, respectively). 
 
7.2.7 Synthesis of Pyrazole Compound 104 
There are many examples in the literature of the binding modes of pyrazolopyrimidine based 
kinase inhibitors through x-ray crystal structures and computational models.[92, 109, 130, 
131] All of these examples show important binding between the NH2 and one of the 
pyrimidine nitrogen's with the enzyme – with glutamic acid commonly binding to the NH2. 
As the pyrazolopyrimidine mimics the adenine of ATP, it is understandable to see why such 
important binding occurs between the amino-pyrimidine ring and the active site. 
Nonetheless, compound 104 was synthesised to prove that the pyrimidine was essential for 
activity from 3-iodo-1H-pyrazole following the route in scheme 7.6. If it turned out that 
compound 104 was equally as active, this would provide a great opportunity to reduce the 
molecular weight of the compounds, thus, increasing their ligand efficiency. 
The compound was synthesised in good yield and tested in a MDA-MB-231 cell viability 
assay. The resulting EC50 against cell proliferation was 32.6 µM, conclusively proving that 
the pyrimidine was essential for compound activity. Given the essential role of this group, 
this result further corroborates that the compounds described in this thesis do bind to the 





Scheme 7.6: Synthesis of intermediates 102 and 103, and final compound 104. a) 
Bromoacetaldehyde dimethyl acetal, NaH, DMF, 150 
o
C, mw. b) TFA/H2O (1:1), 100 
o
C, mw. 
c) 4-dimethylaminopiperidine, AcOH, NaBH(OAc)3, DCM, r.t. d) [4-(tert-
butoxycarbonylamino)-3-methoxy-phenyl]boronic acid, K2CO3, Pd(OAc)2, PPh3, 1,4-
dioxane/water (10:1), 120 
o




7. Optimisation of Lead Compound 52 
7.3 Conclusion 
  
The SAR map, figure 7.1, was created to question which groups, and their positions, were 
essential for compound activity, and whether alteration would improve or supress activity. 
As such, 25 compounds were synthesised to search for the ideal and optimum positions of 
groups belonging to lead compound 52. The ‘answered’ map is shown in figure 7.8 with the 
structure activity relationships of 52 highlighted.  
 
Figure 7.8: Structure activity relationships of compound 52. 
 
Exploration of the aryl group of lead compound 52 and final optimisation of the amine 
moiety of the structure has unveiled a total of 6 compounds with lead-to-candidate drug 
properties. Compounds 52, 55, 56, 66, 84 and 86 all showed excellent potency against triple 
negative breast cancer, MDA-MB-231, cell proliferation and sub-nano molar inhibition of 
one or more of the SFKs with generally excellent selectivity over ABL and other related 
kinases such as c-KIT, PDGFRa and RET. Their properties are summarised in table 7.3. 
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Up until this point, the physicochemical properties of the compounds have been ignored, 
owing to the adaptability of phenotypic drug screening to discriminate between those 
compounds with good or bad properties. However, advancing a compound to the preclinical 














MW 510.63 536.67 550.7 500.64 509.64 479.62 
clogP 2.693 3.096 3.601 3.057 3.027 3.043 
TPSA 123.675 123.675 123.675 97.37 111.648 102.414 
H-bond Donor 2 2 2 2 1 1 
H-bond Acceptor 9 9 9 7 9 8 
EC50 - 231 (nM) 9.08 39.24 80.63 201.77 35.85 100.27 
EC50 - MCF7 (nM) 30.99 76.52 208.95 583.2 414.9 2581.7 
IC50 - ABL (nM) 479.0 406.7 808.2 1204.0 370.0 2950.0 
IC50 - SRC (nM) < 0.5 < 0.5 < 0.5 3.5 1.0 1.0 
Ratio ABL:SRC 958 813 1616 344 370 2950 
Table 7.3: Summary of key properties of 6 lead compounds. MW: molecular weight. clogP: 
Calculated logP (Molinspiration Cheminformatics). TPSA: Topological polar surface area 
(Molinspiration Cheminformatics). *For compounds with <0.5 nM IC50, the ratio of ABL to 
SRC was calculated using 0.5 as a value for SRC. 
 
All compounds possess properties which conform to Lipinski’s rule of five (MW <500, logP 
<5, H-bond donor <5 and H-bond acceptor <10), albeit the molecular weight is slightly 
above the Lipinski’s limit of 500.[132] However, the rule of five should be taken as a rough 
guide and not as an absolute necessity. Furthermore, these ‘rules’ are more appropriate when 
designing drugs from scratch and not when optimising drugs already shown to be effective, 
as in the compounds above. The polar surface areas of all 6 drugs are below the ‘upper’ limit 
of 140 Å, which is a good predictor for the permeation of compounds through 
membranes.[133, 134] The ratio between ABL and SRC inhibition is also listed in table 7.3. 
This highlights the excellent selectivity between the two kinases, something that was 
unprecedented to date. 
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8. Pre-clinical Testing of Lead Compounds 
8.1 Introduction & Aims 
 
Pre-clinical testing of a drug involves determining whether a compound has the potential, 
and safety aspect, required for use in humans, using biological techniques. Drug metabolism 
and pharmacokinetics (DMPK) is commonly used to describe such studies. Here the 
absorption, distribution, metabolism, excretion and toxicology (ADMET) of a compound is 
assessed to predict its safety and usefulness as a drug. It is important to assess these 
properties of a drug prior to clinical testing. Contrary to the lab, drugs in vivo may act 
differently and the best compound in the lab may simply be too poorly absorbed or 
metabolised too quickly, to be useful as a drug. It is at this point that properties other than 
efficacy are more important. Perhaps a less potent drug has the better ADMET properties 
and is the best choice for clinical evaluation. Dosing schemes can also be predicted or 
determined by looking at the metabolism and clearance of a drug vs. its bioavailability –
absorption and distribution. These studies are not only undertaken pre-clinically but remain 
important when the drug is finally dosed in human. 
Firstly, it is important to assess a drug’s toxicity, in particular, any potential cardiotoxicity. 
QT (the time taken from the start of the Q to the end of the T wave in the heart's electrical 
cycle) prolongation is a potentially fatal condition in which the QT interval is elongated 
during the heart’s electric cycle. These cardiac arrhythmias can be brought on by inhibition 
of one of the potassium channels in the heart known as human ether-a-go-go or hERG, 
which a surprising number of drugs are able to inhibit. Inhibition of the hERG channel has 
become a major obstacle for drug development, particularly in industry, due to its connection 
with QT interval prolongation.[135, 136] For this reason, it is important to assess the effect 
of any new drugs in development against hERG in order to modify, or rule out, any potential 
compounds likely to cause future complications.[137] Compounds which possess a basic 
amine with aromatic/lipophilic groups surrounding are prone to hERG inhibition and 
common pharmacophores have been identified to try and predict hERG liabilities.[138-140] 
Figure 8.1 shows some drugs that are known to clinically induce QT prolongation. Here the 
common pharmacophores can be identified: all compounds possess substituted piperidines 





Figure 8.1: Three drugs known to clinically induce QT prolongation via inhibition of hERG. 
Substituted piperidines and lipophilic aromatic groups are common to all three structures, 
highlighting a pharmacophore model for hERG inhibition.[141] 
 
Whether drugs are administered orally or intravenously, or otherwise, they must enter the 
blood stream (unless topical medicines) to enable transport around the body and reach the 
site of action. Firstly, this requires soluble and permeable compounds stable to the acidic 
conditions of the stomach, if taken orally. Secondly, an important factor to consider is a 
drug’s stability and binding properties in the blood itself. Proteins are able to bind to drugs in 
the blood, appropriately called plasma protein binding (PPB). Too highly bound could mean 
drugs are unable to reach their targets, thus, limiting their effectiveness, and too weakly 
bound could mean the drugs are cleared from the body quickly, thus, limiting their half-life. 
Further, some drugs may be unstable in blood plasma alone. There are an abundance of 
enzymes in the blood, including many esterases, capable of metabolising drugs. For this 
purpose, plasma stability assays are carried out to determine a drug’s stability over a time 
period in blood plasma. 
The main site of metabolism in the body is the liver. Although essential for the proper 
clearance of toxic substances from the body, fast metabolism of drugs limits their 
effectiveness and lowers convenience for the patient as higher or more frequent doses are 
required to maintain a steady concentration of active drug. Most metabolisms in the liver 
occur from cytochrome P450 (CYPs) enzymes found in the endoplasmic reticulum (ER). In 
the lab, these CYPs can be concentrated into small vesicles known as microsomes by cell 
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centrifugation. The microsomes, containing parts of the ER with CYPs, are then incubated 
alongside drugs to assess their stability in a given time period. Similarly, stability can be 
assessed by incubation with whole liver hepatocyctes over a time period. This is, arguably, 
more representative of natural bodily functions than CYPs or microsomes in isolation. 
Along with CYPs conducting essential (and sometimes troublesome) metabolism of drugs, 
they also conduct the metabolism of some endogenous hormones and are even involved in 
the synthesis of cholesterol.[142] Therefore, CYPs play an important role in the body. Some 
drugs are capable of inhibiting CYPs, rather than acting as substrates. This causes problems 
for the metabolism of other compounds/drugs so potentially dangerous overdoses may occur 
when more than one drug is taken. This is known as drug-drug interactions. To test for this, 
compounds can be incubated with various CYPs, in isolation, to determine if they inhibit or 
induce the enzymes. CYPs 1A2, 2A6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 are the isoforms 
generally used to determine drug-drug interactions.[143] 
Although in vitro testing gives some insights into the more important issues of pre-clinical 
testing, it is often hard to predict how a drug will actually behave in a whole organism. For 
this purpose, pharmacokinetic (PK) studies can be carried out in mice or rats to determine 
oral bioavailability and the half-life of a compound. 
The excretion of a drug is less commonly studied as it generally requires radio labelled 
compounds and the collection of urine and faeces from an organism. It is difficult to assess a 
drug’s excretion in vitro and so experiments are generally more expensive. As long as the 
drug, or its metabolites, do not accumulate in the body, excretion is generally not a problem. 
Although the chemistry around the lead structures could go on indefinitely, the 6 
compounds, described in section 6.3, possessed the properties of leads suitable for pre-
clinical evaluation. The considerations discussed above highlight some of the most common 




8. Pre-clinical Testing of Lead Compounds 
8.2 Results 
 
8.2.1 hERG Liability Study 
The 6 lead compounds all possess a basic amine (2, in fact) and an aromatic (though not 
lipophilic, except 66) group commonly associated with hERG inhibition so it was essential 
to test their activity against the hERG channel before advancing any further. Compounds 
were added to mammalian cells expressing the hERG channel in a 384-well plate across a 
concentration range (8nM to 25 µM). The percentage change in hERG tail-current was then 
calculated by whole-cell voltage-clamping and IC50 values calculated from the data. The 
study was performed by Cyprotex, see section 10.7.8 for methods.  











Highly Potent - <0.1 µM
Potent - 0.1<1 µM
Moderately Potent - 1<10 µM







Figure 8.1: IC50 values against hERG inhibition plotted as a bar graph for 6 lead compounds. 
Replicates ranged from n=11 to n=18. Error bars denote standard error. Compound 84 
showed 25 % inhibition of hERG at the top concentration of 25 µM so an accurate IC50 could 
not be calculated. Curve fit estimates suggest ~140 µM. 
 
The study revealed that all compounds inhibit hERG above 1 µM. Only one compound, 66, 
was considered a moderately potent hERG inhibitor with the other 5 being weak or non-
inhibitors, in the case of 84. This correlates well with the pharmacophore model which 
suggests more lipophilic aromatic groups inhibit hERG to a greater extent. This excellent 
result allowed the progressing of compounds towards assessing their stability and other 
ADME properties. With 86 being less potent than the other compounds in the viability 
assays, and the cost of screening taken into consideration, it was disregarded going forward 
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and only the other 5 compounds were tested for CYP inhibition. Although 66 was a 
moderately potent hERG inhibitor, and was less potent, both against SRC and MDA-MB-
231 cell proliferation, it was included in the next study due to its structural difference over 
the other 5 inhibitors. 
 
8.2.2 Cytochrome P450 Enzyme Inhibition Assay 
As discussed above, inhibition of the cytochrome P450 enzymes can result in a potentially 
dangerous drug overdose due to the reduced metabolism of another drug. To test for this, 
compounds 52, 55, 56, 66 and 84 were screened at 10 µM in duplicate against 5 of the most 
commons CYPs to cause drug-drug interactions – CYPs 1A2, 3A4, 2C9, 2D6 and 2C19 – 
table 8.1. This work was undertaken by Dr Scott Webster, The University of Edinburgh, see 
section 10.7.9 for methods. 
 
Compound CYP1A2 CYP3A4 CYP2C9 CYP2D6 CYP2C19 
52 24.54 0 0 0 0 
55 6.86 0 0 0 0 
56 0 0 0 0 0 
66 8.25 3.05 0 0 26.80 
84 4.33 5.59 0 0 0 
Naphthoflavone (1A2, 2C19) 99.82    99.29 
Ketaconozole (3A4)  92.62    
Sulphenazole (2C9)   95.57   
Quinidine (2D6)    88.09  
Table 8.1: Inhibition of cytochrome P450 enzymes by compounds 52, 55, 56, 66 and 84. 
Experiments were performed in duplicate and average values calculated. Appropriate 
controls are highlighted towards the bottom of the table. Blank spaces indicate non-tested. 0 
indicates zero or negative values. 
 
The study revealed that the compounds had very little inhibition over the 5 CYPs. CYP1A2 
was the most inhibited enzyme with 24.5% inhibition observed from compound 52 and 
compound 66 caused the most inhibition with 3 CYPs being inhibited from 3-27%. Overall, 
the compounds caused very little CYP inhibition at a moderately high concentration of 10 
µM. This was an excellent result, giving rise to confidence that the drugs should not cause 
significant drug-drug interactions in vivo, although, it would be essential to test against all 
the known isoforms, and get IC50 values, for full reassurance.  
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8.2.3 Plasma Protein Binding Study 
Compounds 52, 55, 56, 66 and 84 were subjected to plasma protein binding (PPB) assays to 
assess to which extent they were likely to remain bound to plasma in the blood. This plays an 
important role on the clearance of a drug from the body and also may determine which dose 
to give to a patient. Compounds were incubated with human or rat plasma at 37 
o
C for 24 
hours then the percentage unbound determined by LC-MS/MS. Compounds were tested in 
duplicate with Warfarin (99-100% bound) and Quinidin (81-87% bound) as controls.[144] 
This work was undertaken by Dr Scott Webster, The University of Edinburgh, see section 
10.7.10 for methods. 















Figure 8.2: Average bound fraction of compounds 52, 55, 56, 66 and 84 plotted as a 
percentage of starting concentration in human and rat plasma. All compounds were between 
80 and 90% bound to plasma proteins which are widely accepted values. Warf = warfarin; 
Quin = quinidine. Error bars denote standard deviation, n = 2.  
 
All compounds were between 80 and 90 % bound to plasma proteins in both the human and 
rat plasma. The ideal value of bound drug is widely disputed, however, even though > 90% 
bound is considered to be high, 30% of drugs approved between 2003 and 2013 had > 95% 






8.2.4 Human Liver Microsome Stability Assay 
The bioavailability of a compound is dependent on many factors with one of them being the 
first-pass metabolism by the liver. To get an idea for metabolism by CYPs, human liver 
microsomes (HLM) were incubated alongside the 5 compounds for 30 minutes, at 37 
o
C, and 
the percentage remaining compound determined, relative to the parent compound at the start 
of the assay. The results, figure 8.3, show generally excellent stability across all compounds. 
Unfortunately, the data for compound 56 was inconsistent due to problems with the MS so it 
has been excluded from the study. This work was undertaken by Dr Scott Webster, The 
University of Edinburgh, see section 10.7.11 for methods. 


























Figure 8.3: Percentage compound remaining after 30 min incubation with human liver 
microsomes relative to time 0. All compounds showed values >75 % remaining, thus, 
indicating they are highly stable in the presence of liver microsomes. Error bars denote 
standard deviation, n = 2. 
 
Given that compound 84 is an ester, rather than a carbamate, it is understandable that is 
should be less stable in the presence of microsomes containing CYPs. Nonetheless, 79% of 
the parent compound was still detectable after 30 minutes incubation. Further, the most 
likely metabolite of 84 is the carboxylic acid derivative, compound 86, which is completely 
non-active against the SFK or cells. That means the primary metabolite of 84 is likely to be 
non-active and non-toxic in the body, and cleared very quickly due to its charged nature. 
Predictable metabolisation pathways aid the anticipation of the formation of toxic 




8.2.5 Stability in Human, Mouse and Rat Plasma 
Compounds 52, 55 and 84, which excelled in the hERG, CYP, PPB and HLM study, had 
their stability in human, mouse and rat plasma tested. Due to costs, compound 56 and 66 
were excluded as they had shown greater potency towards hERG, and were generally less 
potent than the other compounds. As the blood is the main transport system for carrying 
drugs around the body, their stability in plasma is critical to their effectiveness as a 
treatment. Compounds 52, 55 and 84 were incubated at 1 µM with plasma from either 
human, mouse or rat for 2 hours at 37 
o
C. The percentage of compound remaining after 15, 
30, 60 and 120 minutes was determined by LC-MS/MS and reported relative to time 0. 
Studies were performed by Cyprotex, see section 10.7.12 for methods. 
Compounds were stable in all 3 plasmas with > 90% recovery after 2 hours incubation, 
figure 7.4. Compound 84, which contains an ester rather than a carbamate, was also stable in 
all 3 plasmas. This is an excellent result given that esters are generally less stable than 
carbamates, more so, in plasma, which contains a cocktail of enzymes including esterases. 
 
Figure 8.4: Compound stability in a) human, b) mouse or c) rat plasma over 2 hours. All 




8.2.6 Hepatocyte Stability of Compounds 52 and 84 
Compounds 52, 55 and 84 were stable in human, mouse and rat plasma, however, most 
metabolism occurs in the liver and, although the compounds were previously tested with 
human liver microsomes, more robust assessment of their stability was required before 
proceeding to in vivo studies. Compounds, 52 and 84 were incubated with mouse and human 
hepatocytes, which contain the CYP enzymes necessary for metabolism, to assess their 
stability. 
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 cells) SE CLint t1/2 (min) 
52 - Human 1.84 0.989 751 
52 - Mouse 12.5 0.447 110 
84 - Human 6.82 0.853 203 
84 - Mouse 67.9 3.08 20.4 
 
Figure 8.5: Compound stability in human and mouse hepatocytes over 60 minute incubation. 
Calculated factors from hepatocyte study - intrinsic clearance (CLint) with standard error (SE) 
and half-life (t1/2). 
 
Compounds 52 and 84, at 3 µM, were incubated with hepatocytes over 60 minutes and 
samples taken at 0, 5, 10, 20, 40 and 60 mins and analysed by LCMS/MS. Data is presented 
relative to compound concentration at time 0 and intrinsic clearance and half-life calculated 
from the values obtained. Verapamil and umbelliferone are used as control compounds. 
Studies were performed by Cyprotex, see section 10.7.13 for methods. 
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As expected, and in correlation with the human liver microsome study, 8.2.4, compound 84 
was less stable than 52, figure 8.5. This can be attributed to the less stable ester in 84 
compared to the carbamate in 52. Compound 84 is rather unstable in mouse hepatocyctes 
with a half-life of only 20.4 minutes. However, incubation with human heptocytes gave a t1/2 
value of 203 minutes, 10x longer than in mouse. Importantly, the same trend was observed 
for compound 52 in human and mouse hepatocytes (7.5x difference in half-life). This 
emphasises the importance of cross species testing, more importantly, it highlights that data 
obtained from mice experiments cannot translate similarly in humans but consistent 
differences between values in different species from structurally related compounds can help 
to estimate the expected human half-life after corroboration of in vivo PK. 
Compound 52 showed significantly to be more stable in human hepatocytes than mouse, and 
gave a t1/2 of 751 minutes and intrinsic clearance value of 1.84 µL/min/10
6
 cells. These 
represent very encouraging values indicating that the compounds are stable enough for 
therapeutic dosing.  
 
8.2.7 Pharmacokinetic Data of Compounds 52 and 84 
Given that compound 52 is the superior compound in terms of SFK inhibition, and against 
cell viability, it was chosen to undergo mouse PK studies to determine its oral bioavailability 
and half-life, in vivo. Both compounds 55 and 84 showed similar potencies regarding kinase 
inhibition and cell proliferation, however, compound 84 was superior in the hERG assay 
meaning that a higher dose could be accepted in the clinic without causing toxicity, at least 
due to hERG inhibition. 84 is also of lower molecular weight (509.64 vs 539.67) than 55 
which makes it the more efficient ligand and more compliant to Lipinski’s rules. The 
presence of an ester, rather than a carbamate, does make 84 less stable than 55, as 
demonstrated by the HLM study, however, it would result in a nice comparison in PK values 
with 52 in vivo. Further, compound 52 and 84 both showed excellent-to-good stability when 
incubated with human hepatocytes. This work was performed by Cyprotex, see section 
10.7.14 for methods. 
Female CD1 mice were given 10 mg/kg (0.25 mg/25 g mouse) of compound 52 or 84 orally 
(as a solution in nanopure water) or via IV injection (as a saline solution) and compound 
concentration measured over 8 hours. Shown in figure 8.6 are the concentration curves over 
8 hours of both compounds after oral and IV administration, respectively. The consequent 




Compound T1/2 (hrs) Bioavailability 
52 2.94 25.3 % 
84 2.14 52.1 % 
 
Table 8.1: In vivo half-life and bioavailability based on the PK data for compounds 52 and 
84.  
 
The half-life values of 2.94 and 2.14 hours for compounds 52 and 84, respectively, are 
moderate and acceptable values as is, however, the hepatocyte studies strongly suggest that 
the compounds would be more stable in humans than in mice. The bioavailability values of 
25.3 and 52.1 % for 52 and 84, respectively, are reasonable values, again suggesting that 
both compounds could be suitable as orally available drugs. 
 





















































Figure 8.6: In vivo pharmacokinetic data of compounds 52 and 84. Average compound 




8. Pre-clinical Testing of Lead Compounds 
8.3 Conclusion 
 
Compounds 52, 55, 56, 66, 84 and 86, optimised via a mechanism informed phenotypic drug 
discovery route, previously presented properties suggestive of a preclinical candidate. As 
such, they were progressed through assays designed to test hERG inhibition, cytochrome 
P450 enzyme inhibition, plasma protein binding, human liver microsome stability and 
stability in human, mouse and rat plasma. Compounds 52 and 84, which excelled in all the 
assays described, had their pharmacokinetic properties in mice tested leading to a prediction 
of bioavailability and compound half-life. 
Compounds 52 and 84 represent suitable candidates for further investigation and studies are 






Cancer survival rates have undoubtedly improved over the last 40 years.[146] In the 1970s, 
only 25 % of patients diagnosed with cancer survived over ten years and, nowadays, this 
figure has risen to 50 %. This can be attributed to both the development of better therapies 
and increased knowledge and detection of cancers. These numbers are highly generalised, 
however, and survival depends implicitly on the type of cancer. For example, men with 
cancer of the testis show a 98 % survival rate over ten years, whereas, a mere 1% of patients 
with pancreatic cancer can expect to live over ten years. 
Breast cancer remains the most common cancer in females, accounting for 30 % of cases; 
however, survival is generally quite high (78 %) due to the ease of detection and consequent 
surgical removal of the breast.[146, 147] Nonetheless, due to its high incidence, breast 
cancer still remains one of the most lethal cancers, accounting for 7% of cancer deaths in 
2012 in the UK. In particular, triple negative breast cancer, which accounts for around 15-
20% of all breast cancers, is aggressive and still poorly treated.[148] Evidently, even with 
the increase in survival over the last 40 years, a lot more research is required to improve the 
treatment options for cancer, particularly to improve efficacy and response duration across 
multiple patient subgroups, and particularly, those cancer sub-types which are poorly served 
by current therapies such as triple negative breast cancer.  
Using an agile ligand based, mechanism informed, phenotypic approach to drug discovery, 
the identification of a series of potent and selective inhibitors towards targets strongly 
implicated in cancer has been discovered, and is discussed in this thesis.  
Using PP1 and ATP as models, the generation and evaluation of an initial 10-membered 
library led to the design of a further two compounds with interesting anti-proliferative effects 
(EC50 values of 12 µM). Probing into the compounds' mechanisms of action led to the 
conclusion that the early 'hit' compounds 17 and 18 were affecting cell viability by the 
induction of apoptosis. 
Further optimisation by pseudo-rational ligand-based design, and careful examination of the 
literature, led to the discovery of compounds 19 and 29, which were found to affect cell 
viability differently, by two distinct mechanisms. Compound 19, which was halting the 
growth of the cells without causing death, was revealed to be a moderately potent mTOR 
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inhibitor with an IC50 of 328 nM. Compound 29, on the other hand, which was inducing 
apoptosis and causing cell death, was a potent SRC family kinase inhibitor. This enabled the 
classification of compounds into two different categories for exploration of selective mTOR 
and SRC family inhibitors, respectively.  
Through optimisation of compound 19, a series of extremely potent and selective mTOR 
inhibitors were produced. The most selective of which, 41, was screened against 342 kinases 
- a significant portion of the kinome - and had selectivity for mTOR greater than current 
competitors. Its properties were thoroughly examined in vitro and to date, 41 represents the 
most selective mTOR inhibitor discovered, to the best of my knowledge. Due to its structure 
bearing strong similarities with INK-128, however, intellectual property for this compound, 
and the series, would never be granted, and such is the sad reality of the world we live in 
today, without intellectual property, and proper investment, a compound cannot be 
progressed to clinical stage. As such, the optimisation of the mTOR inhibitors has 
temporarily stopped until novel chemical space with freedom-to-operate is found. 
Optimisation of the early SRC inhibitor, compound 29, led to the discovery of lead 
compound 52. 52 demonstrated excellent phenotypic properties in in vitro experiments 
against cell proliferation (40 and 10 nM EC50 against MCF7 and MDA-MB-231, 
respectively) and cell migration (8.6 nM EC50, MDA-MB-231 cells) and was, importantly, 
non-toxic during incubation with zebrafish embryos. Most importantly, 52 inhibited SRC 
with an IC50 of <0.5 nM and did not potently inhibit ABL, unlike all other clinical SRC 
inhibitors reported. Simultaneous inhibition of ABL with an allosteric inhibitor was shown to 
be non-beneficial and drastically reduced the effectiveness of SRC inhibition against triple 
negative breast cancer cell proliferation. Further, 52 was shown to be extremely selective to 
the SRC family kinase branch of kinases, even at the high concentration of 1 µM. This level 
of selectivity allows for more predictive results in the clinic and enables the selection of 
patients by SRC driven biomarkers. Combination treatment involving compounds with this 
level of selectivity also allows for a more fine-tuned treatment while reducing the 
susceptibility to acquired drug resistance and adverse effects. 
The development of a further 5 lead compounds was mediated by the synthesis and testing of 
26 compounds, all designed to challenge the structural requirements of compound 52. These 
6 lead compounds had their properties compared in cell viability and kinase assays and 
possessed the characteristics suitable for pre-clinical testing. 
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Due to the strong attrition rate of drugs in the clinic, it is of upmost importance to thoroughly 
test drugs pre-clinically, to the best of one's ability. Of course, biological assays will never 
match the complexity and unpredictability of the human body but, nonetheless, a 
comprehensive investigation of their properties is sought after.  
Since 1996, when the biological impact of the hERG channel was beginning to be explored, 
there have been 8 drugs withdrawn from the market due to observed QT prolongation.[141] 
However, only 1 of these drugs, propoxyphene, was removed after 2005 with the other 7 
occurring before. Increasing knowledge of the hERG channel has led to robust testing of 
drugs, pre-clinically, to ensure that they are not later rejected in the clinic. As such, it has 
become paramount to test drugs for hERG inhibition prior to progression. Failure to do so 
could result in a costly withdrawal later on.  
All 6 lead compounds were tested for hERG inhibition and were found to be non-inhibitors, 
in general, with only 1, compound 66, containing an unsubstituted benzylamino group, 
giving an IC50 of 2.55 µM - a value relating to a moderately potent hERG inhibitor. It is 
important to note, however, that the difference between the on-target (SRC) IC50 and hERG's 
is around 1,000 fold. This large gap makes the hERG liability less of a concern. Compound 
84 excelled with an estimated IC50 of 140 µM - completely non-active.  
Compounds 52 and 85 showed little cytochrome P450 inhibition, were bound to human and 
rat plasma proteins between 80 and 90 %, were relatively stable during incubation with 
human liver microsomes, and were stable in human, mouse and rat plasma over 120 minutes. 
As such, they were taken forward to have their pharmacokinetic properties assessed in mice. 
Compound 52 had a plasma half-life of 2.94 hours and an oral bioavailability of 25.3 %. 84 
had a plasma half-life of 2.14 hours and oral bioavailability of 52.1 %. Initially, these figures 
seemed far from optimum, however, when comparing with the clinical SRC inhibitor 
Dasatinib, which has a half-life of only 0.79 hours, in mice, and oral bioavailability between 
14-34%, compounds 52 and 84 possess sufficient pharmacokinetic properties to allow 
progression.[149] Importantly, the difference in stability between mouse and human 
hepatocytes (>7.5x) also supports the hypothesis that the compounds would have longer half-
lives in patients. 
The pre-clinical testing of compounds 52 and 84 are on-going. Owing to the previously 
discussed properties of the two compounds, in vivo pharmacodynamic and efficacy models 
are being organised and the development of the series of compounds is in continuation.  
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To summarise, this thesis describes the development of a series of novel mTOR and SRC 
family kinase inhibitors using a ligand-based phenotypic drug discovery approach. In the 
relatively short time of 3 years, and low cost of approximately £100k (materials, labour and 
outsourcing costs), a series of compounds have been discovered possessing properties 
suitable for clinical evaluation. These compounds inhibit targets strongly shown to correlate 
with cancer progression and as such, are valuable assets to the fight against cancer. 
Comparing with industrial standards, the work described in this thesis is at a tiny fraction of 
the cost expected to produce such a potent and promising series of compounds. It is evident 
that, despite the identification of a plethora of new drug targets in the post-genomic era, 
productivity within the pharmaceutical industry is slowing, and perhaps the 'classical model' 
of targeted drug discovery should be thoughtfully examined and new approaches considered.  
Not only does the work described in this thesis challenge the way that industry conducts its 
research but it also highlights that, although multi-target inhibitors may circumvent problems 
associated with drug acquired resistance, their off-target inhibition may present counter 
intuitive solutions to cancer therapy. Such is the case with ABL inhibition. The majority of 
SRC inhibitors, and indeed all of the clinically approved SRC inhibitors, inhibit ABL to the 
same or greater degree than their 'primary' target. The work described in section 6.2.2 
suggests that inhibition of ABL is detrimental to cancer treatment and there is increasing 
evidence in the literature to support this premise, particularly regarding cardiotoxicity. [114, 
115, 126, 127, 129] 
Compounds 52, 55, 56, 66, 84 and 86, to the best of my knowledge, represent the first and 
only sub-nano molar SRC inhibitors that do not inhibit ABL, with selectivity ranging from 
344x (66) to 2950x (86), assuming a SRC inhibition value of 0.5 nM (actual value is <0.5 
nM). These compounds possess properties as good as, or better than, competitors, which 
represent approved drugs, or clinical candidates undergoing clinical development, and could 
represent the basis of a valid therapy for cancer treatment, providing further investigation. 
The speed and cost of the discovery of these compounds represent a perfect example of the 
advantages of phenotypic drug discovery over traditional targeted discovery. The 
development of these compounds is on-going and they will, hopefully, one day represent the 
gold standard in SRC targeted cancer treatment. 
From a critical point of view, however, it is likely that one or more of the 78 novel 
compounds generated and tested during this thesis could possess interesting potency and/or 
selectivity over targets that did not play a role on the highly proliferative nature of the cancer 
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cell lines used in the phenotypic screens. On the other hand, some compounds might have 
shown poor phenotypic effect due to low cell penetrability. These "false negatives" are 
indeed the main weakness of this approach. With this last comment, I would like to 
emphasise that the strategy proposed herein is far from perfect. Consequently, all drug 
discovery approaches have their place, and their validity, in the fight against cancer, and 
many complement each other. This modest contribution describes just another possible 





10.1 General Information 
 
All experiments were performed in a Biotage Initiator microwave synthesiser or conventially 
under an inert atmosphere of nitrogen using commercially available anhydrous solvents. 
 
10.1.1 Chemicals 
All commercially available chemicals were obtained from Fisher Scientific, Matrix 
Scientific, Sigma-Aldrich or VWR International Ltd and were used without purification. 
 
10.1.2 Chromatography 
Thin layer chromatography was run on Merck TLC Silica gel 60 F254 plates; typically 5 cm 
x 10 cm. Detection was achieved using a 254 nm UV source or permanganate stain. 
Purification of compounds was achieved through manual column chromatography using 
commercially available silica gel (220 – 440 mesh, Sigma-Aldrich) and solvents.  
 
 
10.1.3 Nuclear Magnetic Resonance 
All NMR spectra were recorded at ambient temperature on a 500 MHz Bruker Avance III 
spectrometer at the School of Chemistry, The University of Edinburgh. Samples were 
dissolved in deuterated solvents commercially available from Sigma-Aldrich.  
 
1
H NMR spectra: chemical shifts are reported in parts per million (ppm) relative to 
tetramethylsilane. The data is presented as follows: chemical shift, integration, multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (in Hertz, 
Hz) and interpretation. 
13
C NMR spectra were referenced to the solvent carbon peak. The 
data is presented as follows: chemical shift and assignment; and were confirmed by 





10.1.4 Mass Spectrometry 
Low Resolution Mass Spectra (LRMS) were obtained using a Microsaic Systems 4000 MiD 
system under electron spray ionisation (ESI) conditions. High Resolution Mass Spectra 
(HRMS) were obtained using a Bruker 3.0 T Apex II Spectrometer at the School of 





10.2 Experimental for Chapter 2 
 
10.2.1 Synthesis of Compounds 2-6 
Synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amine (2): 
 
5-amino-1H-pyrazole-4-carbonitrile (3 g, 27.77 mmol) and formamide (15 ml) were added to 
a 20 ml microwave vial and the mixture heated at 180 
o
C for 2 hours using microwave 
radiation. The precipitate formed on cooling was filtered off and washed with water (50 ml) 
and allowed to dry giving the product as a cream solid (3.5 g, 25.92 mmol, 93 %). 
1
H NMR 
(500 MHz, DMSO) δ 13.34 (s, 1H), 8.13 (s, 1H), 8.07 (s, 1H), 7.69 (br. m, 2H); 
13
C NMR 
(126 MHz, DMSO) δ 158.19 (CH), 156.03 (C), 154.98 (C), 132.79 (CH),99.83 (C); MS (ES 
+ve) [M+H]
+




Synthesis of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3):  
 
1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.5 g, 11.11 mmol) was suspended in 15 ml of DMF 
and N-iodosuccinimide (1.2 eq., 3.0 g, 13.34 mmol) added. The mixture was heated at 180 
o
C in the microwave for an hour. EtOH (80 ml) was added to the reaction and a precipitate 
began to form, which was aided by sonication. The precipitate was filtered and washed with 
EtOH (x3, 20 ml) and allowed to dry in an oven at 40
o
C overnight to give a sand coloured 
solid (2.115 g, 8.105 mmol, 73.0 %). 
1
H NMR (500 MHz, DMSO) δ 13.80 (s, 1H), 8.16 (s, 
1H), 7.79 - 6.44 (m, 2H); 
13
C NMR (126 MHz, DMSO) δ 157.60 (C), 156.08 (CH), 155.04 
(C), 102.50 (C), 89.82 (C); MS (ES +ve) [M+H]
+








Synthesis of 1-(2,2-diethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (4): 
 
To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (500 mg, 1.92 mmol) in DMF 
(15 ml) was added sodium hydride (1.5 eq., 2.88 mmol, 60 % dispersion in mineral oil, 115.2 
mg) and the solution allowed to stir for 30 mins until the gas evolution had subsided. 
Bromoacetaldehyde diethyl acetal (1.5 eq. 2.88 mmol, 0.435 ml) was then added dropwise 
and the mixture heated at 150 
o
C in the microwave for 40 mins. EtOAc and water (50 ml) 
were added to the mixture and the organics separated. The aqueous layer was washed with 
EtOAc (50 ml, x3) and the organics combined and washed with water (x3, 30 ml), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography MeOH/DCM (0-5 %) to give a light orange solid (461 mg, 1.22 mmol, 63.7 
%). 
1
H NMR (500 MHz, DMSO) δ 8.21 (s, 1H), 7.90 - 6.30 (m, 2H), 4.93 (t, J = 5.7, 1H), 
4.33 (d, J = 5.8, 2H), 3.62 (dq, J = 9.4, 6.9, 2H), 3.40 (dq, J = 9.6, 7.0, 2H), 0.98 (t, J = 7.0, 
6H); 
13
C NMR (126 MHz, DMSO) δ 157.86 (C), 156.30 (CH), 154.03 (C), 103.18 (CH), 
99.50 (C), 89.51 (C), 61.39 (CH2), 48.76 (CH2), 15.39 (CH3); MS (ES +ve) [M+H]
+
: 377.8, 




Synthesis of 1-(2,2-diethoxyethyl)-3-(p-tolyl)pyrazolo[3,4-d]pyrimidin-4-amine (5): 
 
To a solution of 1-(2,2-diethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (1.135 g, 
3.01 mmol) in dioxane/water (10 ml/1 ml) was added p-tolylboronic acid (1.5 eq., 614 mg, 
4.52 mmol), potassium carbonate (1.5 eq., 624.7 mg, 4.52 mmol) followed by palladium 
acetate (5 mol %, 33.8 mg) and the mixture heated in the microwave at 120 
o
C for an hour. 
EtOAc and water (50 ml) were added to the mixture and the organic layer separated, dried 
146 
 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography, MeOH/DCM (0-5 %) to give a light brown solid (902 mg, 2.64 mmol, 87.8 
%). 
1
H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 7.58 (d, J = 8.0, 2H), 7.34 (d, J = 7.8, 2H), 
5.12 (t, J = 5.8, 1H), 4.58 (d, J = 5.8, 2H), 3.78 (dq, J = 9.4, 7.0, 2H), 3.52 (dq, J = 9.4, 7.0, 
2H), 2.44 (s, 3H), 1.12 (t, J = 7.0, 6H); 
13
C NMR (126 MHz, CDCl3) δ 158.28 (C), 156.43 
(C), 155.55 (CH), 145.25 (C), 139.76 (C), 131.90 (CH), 128.93 (CH), 100.49 (CH), 62.46 
(CH2), 49.53 (CH2), 21.09 (CH3), 15.78 (CH3); MS (ES +ve) [M+1]
+





Synthesis of 2-[4-amino-3-(p-tolyl)pyrazolo[3,4-d]pyrimidin-1-yl]acetaldehyde (6): 
 
To a suspension of 1-(2,2-diethoxyethyl)-3-(p-tolyl)pyrazolo[3,4-d]pyrimidin-4-amine (400 
mg, 1.17 mmol) in 5 ml of water was added 5 ml of TFA and the mixture heated to 100 
o
C 
for 30 mins in the microwave. The mixture was transferred to a RBF, washed with DCM and 
concentrated in vacuo. The product was washed with DCM and Et2O and dried in vacuo to 
give a light brown solid (assuming quantitative yield). NMR spectra were not obtained for 
this compound as different salts of the product led to messy spectra. 
 
10.2.2 Synthesis of Compounds 7-18 
To a suspension of 2-[4-amino-3-(p-tolyl)pyrazolo[3,4-d]pyrimidin-1-yl]acetaldehyde (40 
mg, 0.105 mmol) in DCM (1 ml) was added either morpholine, 1-methylpiperazine, 2-
piperazin-1-ylethanol, N,N-dimethyl-2-piperazin-1-yl-ethanamine, piperidin-4-ol, 4-
piperidylmethanol, 2-(4-piperidyl)ethanol, N,N-dimethylpiperidin-4-amine, 4-
methylpiperidine, or piperidine (7-16, 1 eq., 0.105 mmol), respectively, and a drop of AcOH 
and the mixture allowed to stir for 10 mins. Sodium triacetoxyborohydride (22.2 mg, 0.105 
mmol) was then added and the mixture stirred until complete (~ 1hr). The reaction mixture 
was concentrated in vacuo and purified without any further work up due to the high 






Purified by column chromatography (MeOH/DCM 0-5 %) to give a pale yellow solid (17 
mg, 0.05 mmol, 47.9 %). 
1
H NMR (500 MHz, MeOD) δ 8.27 (s, 1H), 7.60 (d, J = 8.1, 2H), 
7.42 (d, J = 7.8, 2H), 4.58 (t, J = 6.5, 2H), 3.67 – 3.61 (m, 4H), 2.97 (t, J = 6.5, 2H), 2.61 (s, 
4H), 2.47 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 158.60 (C), 156.29 (CH), 155.24 (C), 
145.23 (C), 138.81 (C), 130.95 (C), 130.35 (CH), 129.05 (CH), 99.05 (C), 67.59 (2x CH2), 
58.02 (CH2), 54.16 (CH3), 44.93 (CH2), 22.12 (2x CH2); MS (ES +ve) [M+1]
+
: 339.1, 361.0 
(+Na), (ES -ve) [M-1]
-
: 377.0; HRMS (ES +ve), C18H22N6O [M+H]
+





Purified by column chromatography (MeOH/DCM 0-10% - 10% MeOH with 3 drops of 
NH3 aq. per 20 ml) to give a pale orange solid (20 mg, 0.057 mmol, 54.2 %) 
1
H NMR (500 
MHz, MeOD) δ 8.27 (s, 1H), 7.60 (d, J = 8.1, 2H), 7.41 (d, J = 7.8, 2H), 4.57 (t, J = 6.5, 
2H), 2.97 (t, J = 6.5, 2H), 2.53 (m, 8H), 2.47 (s, 3H), 2.37 (s, 3H).; 
13
C NMR (126 MHz, 
CDCl3) δ 158.02 (C), 155.87 (CH), 154.77 (C), 144.58 (C), 139.25 (C), 130.45 (C), 130.14 
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(CH), 128.50 (CH), 98.59 (C), 56.89 (CH2), 54.91 (CH2), 52.50 (CH2), 45.59 (CH3), 44.60 
(CH2), 21.47 (CH3); MS (ES +ve) [M+1]
+
: 352.0, 374.2 (+Na), (ES -ve) [M-1]
-
: 350.2; 
HRMS (ES +ve), C19H26N7 [M+H]
+




Purified by column chromatography (MeOH/DCM 5-10% - 10% MeOH with 10-30 drops of 
NH3 aq. per 100 ml) to give a pale orange solid (15 mg, 0.039 mmol, 37.5 %). 
1
H NMR (500 
MHz, MeOD) δ 8.27 (s, 1H), 7.60 (d, J = 8.0, 2H), 7.41 (d, J = 7.9, 2H), 4.57 (t, J = 6.4, 
2H), 3.73 (t, J = 5.7, 2H), 2.99 (t, J = 6.4, 2H), 2.74 (m, 10H), 2.46 (s, 3H); 
13
C NMR (126 
MHz, CDCl3) δ 157.70 (C), 155.50 (CH), 154.57 (C), 144.39 (C), 139.07 (C), 130.26 (C), 
129.93 (CH), 128.24 (CH), 98.28 (C), 59.13 (CH2), 57.16 (CH2), 56.58 (CH2), 52.80 (CH2), 
52.04 (CH2), 44.34 (CH2), 21.23 (CH3); MS (ES +ve) [M+1]
+
: 382.0, 404.2 (+Na), (ES -ve) 
[M-1]
-
: 379.9; HRMS (ES +ve), C20H28N7O [M+H]
+
















Purified by column chromatography (MeOH/DCM 5-10 % - 10 % MeOH with 25 drops of 
NH3 aq. per 100 ml) to give a pale orange solid (5 mg, 0.0312 mmol, 11.7 %). 
1
H NMR (500 
MHz, MeOD) δ 8.27 (s, 1H), 7.59 (d, J = 8.0, 2H), 7.41 (d, J = 8.0, 2H), 4.56 (t, J = 6.6, 
2H), 2.96 (t, J = 6.6, 2H), 2.89 (t, J = 6.6, 2H), 2.76 – 2.60 (m, 6H), 2.60 (s, 6H), 2.51 (m, 
4H), 2.46 (s, 3H); 
13
C NMR (126 MHz, MeOD) δ 158.50 (C), 155.39 (CH), 154.14 (C), 
145.16 (C), 139.21 (C), 129.83 (C), 129.60 (CH), 128.10 (CH), 97.76 (C), 56.40 (CH2), 
54.64 (CH2), 53.51 (CH2), 52.56 (CH2), 52.24 (CH2), 43.79 (CH2), 43.36 (CH3), 19.97 
(CH3); MS (ES +ve) [M+1]
+
: 409.3, 431.2 (+Na); HRMS (ES +ve), C22H33N8 [M+H]
+
: 






Purified by column chromatography (MeOH/DCM 5-10 % - 10 % MeOH with 10 drops of 
NH3 aq. per 50 ml) to give a light brown solid (8 mg, 0.023 mmol, 21.6 %). 
1
H NMR (500 
MHz, MeOD) δ 8.33 (s, 1H), 7.63 (d, J = 8.1, 2H), 7.43 (d, J = 7.8, 2H), 4.82 (t, J = 5.9, 
2H), 3.96 (s, 1H), 3.66 (s, 2H), 3.53 (s, 2H), 3.32 – 3.16 (m, 2H), 2.47 (s, 3H), 2.03 (s, 2H), 
1.82 (s, 2H); 
13
C NMR (126 MHz, CDCl3) δ 157.59 (C), 154.87 (CH), 154.55 (C), 145.87 
(C), 139.77 (C), 130.28 (CH), 129.74 (C), 128.37 (CH), 98.57 (C), 55.54 (CH2), 53.57 
(CH2), 48.95 (CH2), 42.60 (CH2), 31.59 (CH2), 21.45 (CH3); MS (ES +ve) [M+1]
+
: 353.2, 
375.1 (+Na); HRMS (ES +ve), C19H25N6O [M+H]
+





Purified by column chromatography (MeOH/DCM 5-10 % - 10 % MeOH with 10 drops of 
NH3 aq. per 100 ml) to give a light brown solid (7 mg, 0.019 mmol, 18.2 %). 
1
H NMR (400 
MHz, MeOD) δ 8.28 (s, 1H), 7.61 (d, J = 8.1, 2H), 7.42 (d, J = 7.8, 2H), 4.61 (t, J = 6.7, 
2H), 3.42 – 3.36 (m, 4H), 3.16 (s, 2H), 3.03 (s, 2H), 2.47 (s, 3H), 2.23 (s, 2H), 1.77 (d, J = 
11.9, 2H), 1.56 – 1.49 (m, 1H), 1.26 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 157.69 (C), 
155.74 (CH), 154.38 (C), 144.35 (C), 139.05 (C), 130.27 (C), 129.99 (CH), 128.30 (CH), 
98.40 (C), 67.76 (CH2), 57.10 (CH2), 53.31 (CH2), 44.67 (CH2), 38.26 (CH), 28.56 (CH2), 
21.29 (CH3); MS (ES +ve) [M+1]
+
: 367.3, 338.9 (+Na); HRMS (ES +ve), C20H27N6O 
[M+H]
+









Purified by column chromatography (MeOH/DCM 5-10 % - 10 % MeOH with 2 drops of 
NH3 aq. per 10 ml) to give a light orange solid (13 mg, 0.034 mmol, 32.6 %). 
1
H NMR (500 
MHz, CDCl3) δ 8.36 (s, 1H), 7.58 (d, J = 8.1, 2H), 7.37 (d, J = 7.8, 2H), 5.94 (br. s, 2H), 4.79 
(t, J = 6.4, 2H), 3.74 - 3.67 (m, 2H), 3.49 (m, 4H), 2.56 (br. s, 2H), 2.46 (s, 3H), 1.85 (d, J = 
11.0, 2H), 1.58 (m, 5H); 
13
C NMR (126 MHz, CDCl3) δ 158.02 (C), 155.80 (CH), 154.96 
(C), 145.91 (C), 139.94 (C), 130.55 (CH), 130.13 (C), 128.65 (CH), 118.15 (C), 115.83 (C), 
98.92 (CH), 60.29 (CH2), 51.28 (CH2), 42.73 (CH2), 38.56 (CH2), 31.34 (CH2), 30.08 (CH2), 
21.76 (CH3); MS (ES +ve) (M+1)
+
: 381.1, (ES -ve) [M-1]
-
: 378.7; HRMS (ES +ve), 
C21H29N6O [M+H]
+







Purified by column chromatography (MeOH/DCM 10 % - 10 % MeOH with 20 drops of 
NH3 aq. per 50 ml) to give a light brown solid (13 mg, 0.034 mmol, 32.7 %). 
1
H NMR (500 
MHz, CDCl3) δ 8.35 (s, 1H), 7.56 (d, J = 8.0, 2H), 7.33 (d, J = 7.8, 2H), 5.68 (s, 2H), 4.54 (t, 
J = 7.0, 2H), 3.08 (d, J = 11.8, 2H), 2.93 (t, J = 7.0, 2H), 2.43 (s, 3H), 2.41 (m, 1H), 2.40 (s, 
6H), 2.10 (dd, J = 11.8, 9.9, 2H), 1.84 (d, J = 12.3, 2H), 1.52 (qd, J = 12.1, 3.7, 2H); 
13
C 
NMR (126 MHz, CDCl3) δ 158.16 (C), 156.04 (CH), 154.87 (C), 144.69 (C), 139.38 (C), 
130.60 (C), 130.32 (CH), 128.57 (CH), 98.70 (C), 62.72 (CH), 56.96 (CH2), 52.86 (2x CH2), 
45.13 (CH2), 41.01 (2x CH3), 27.71 (CH2), 21.61 (CH3); MS (ES +ve) [M+1]
+
: 380.2, 402.1 
(+Na); HRMS (ES +ve), C21H30N7 [M+H]
+




Purified by column chromatography (MeOH/DCM 0-8 %) to give a light brown solid (16 
mg, 0.046 mmol, 43.5 %). 
1
H NMR (500 MHz, CDCl3) δ 8.35 (s, 1H), 7.57 (d, J = 8.0, 2H), 
7.37 (d, J = 7.8, 2H), 4.85 (t, J = 6.3, 2H), 3.64 (m, 2H), 3.40 (d, J = 12.7, 2H), 2.87 (dd, J = 
12.8, 10.2, 2H), 2.46 (s, 3H), 1.83 (d, J = 13.2, 2H), 1.64 (m, 1H), 1.52 (td, J = 14.6, 3.9, 
2H), 1.02 (d, J = 6.5, 3H); 
13
C NMR (126 MHz, CDCl3) δ 157.55 (C), 155.04 (CH), 154.44 
(C), 145.98 (C), 139.71 (C), 130.20 (2x CH), 129.48 (C), 128.27 (2x CH), 98.51 (C), 53.44 
(CH2), 43.99 (2x CH2), 41.68 (CH2), 30.36 (2x CH2), 29.13 (CH), 21.37 (CH3), 21.28 (CH3); 
MS (ES +ve) [M+1]
+
: 351.1; HRMS (ES +ve), C20H27N6 [M+H]
+











Purified by column chromatography (MeOH/DCM 0-10 %) to give a light brown solid (20 
mg, 0.059 mmol, 56.7 %). 
1
H NMR (601 MHz, MeOH) δ 8.31 (s, 1H), 7.61 (d, J = 8.0, 2H), 
7.42 (d, J = 7.8, 2H), 4.75 (t, J = 6.3, 2H), 3.45 (m, 2H), 3.18 – 3.14 (m, 2H), 2.47 (s, 3H), 
1.83 – 1.70 (m, 6H), 1.63 (s, 2H). 
13
C NMR (151 MHz, MeOH) δ 177.66 (C), 155.72 (CH), 
145.87 (C), 139.30 (C), 129.64 (2x CH), 128.04 (2x CH), 109.85 (C), 97.95 (C), 56.01 
(CH2), 53.55 (CH2), 44.34 (CH2), 23.69 (CH2), 22.38 (CH2), 21.64 (2x CH2), 19.95 (CH3).; 
MS (ES +ve) [M+1]
+
: 337.0; HRMS (ES +ve), C19H24N6 [M+H]
+






To a suspension of 2-[4-amino-3-(p-tolyl)pyrazolo[3,4-d]pyrimidin-1-yl]acealdehyde (100 
mg, 0.374 mmol) in DCM (2 ml) was added N,N-Dimethyl-1-piperidin-4-ylmethanamine (1 
eq. 53.2 mg, 0.374 mmol) and a drop of AcOH and the mixture allowed to stir for 10 mins. 
Sodium triacetoxyborohydride (79.3 mg, 0.374 mmol) was then added and the mixture 
154 
 
allowed to stir for 18 hours. The mixture was reduced in vacuo and purified, without a work 
up, by column chromatography MeOH/DCM (0-10 % - 10 % with 10 drops NH3 aq. per 100 
ml) to give a light orange solid (48 mg, 0.122 mmol, 32.6 %). 
1
H NMR (500 MHz, CDCl3) δ 
8.30 (s, 1H), 7.55 (d, J = 8.1, 2H), 7.32 (d, J = 7.8, 2H), 4.54 (t, J = 6.8, 2H), 3.04 (d, J = 
11.6, 2H), 2.95 (t, J = 6.8, 2H), 2.57 (s, 6H), 2.41 (s, 3H), 2.11 (t, J = 10.9, 2H), 1.74 (d, J = 
12.6, 2H), 1.63 (s, 2H), 1.26 (m, 3H); 
13
C NMR (126 MHz, CDCl3) δ 158.06 (C), 155.40 
(CH), 154.56 (C), 144.79 (C), 139.23 (C), 130.36 (C), 130.16 (CH), 128.40 (CH), 98.53 (C), 
64.32 (CH2), 56.97 (CH2), 53.15 (CH2), 44.52 (CH2), 44.42 (CH3), 32.62 (CH), 30.14 (CH2), 
21.44 (CH3); MS (ES +ve) [M+1]
+
: 394.3, 416.2 (+Na); HRMS (ES +ve), C22H32N7 
[M+H]
+





To a suspension of 2-[4-amino-3-(p-tolyl)pyrazolo[3,4-d]pyrimidin-1-yl]acealdehyde (100 
mg, 0.374 mmol) in DCM (2 ml) was added dimethyl-(2-piperidin-4-yl-ethyl)-amine (1 eq. 
58.4 mg, 0.374 mmol) and a drop of AcOH and the mixture allowed to stir for 10 mins. 
Sodium triacetoxyborohydride (79.3 mg, 0.374 mmol) was then added and the mixture 
allowed to stir for 18 hours. The mixture was reduced in vacuo and purified, without a work 
up, by column chromatography MeOH/DCM (0-10 % - 10 % with 0-10 drops NH3 aq per 
100 ml) to give a light yellow solid (69.8 mg, 0.171 mmol, 45.8 %).
 1
H NMR (500 MHz, 
MeOD) δ 8.25 (s, 1H), 7.59 – 7.55 (m, 2H), 7.38 (d, J = 7.8, 2H), 4.58 (t, J = 6.6, 2H), 3.14 
(d, J = 11.8, 2H), 3.09 – 2.99 (m, 4H), 2.79 (s, 6H), 2.43 (s, 3H), 2.23 (t, J = 11.0, 2H), 1.74 
(d, J = 12.9, 2H), 1.65 – 1.57 (m, 2H), 1.44 – 1.36 (m, 1H), 1.27 (dd, J = 21.1, 11.8, 2H); 
13
C 
NMR (126 MHz, MeOD) δ 158.50 (C). 155.45 (CH), 154.14 (C), 145.30 (C), 139.23 (C), 
155 
 
129.79 (C), 129.60 (CH), 128.09 (CH), 97.83 (C), 56.50 (CH2), 55.70 (CH2), 52.99 (2x 
CH2), 43.45 (CH2), 42.14 (2x CH3), 32.84 (CH), 30.88 (2x CH2), 30.64 (CH2), 19.97 (CH3); 
MS (ES +ve) [M+1]
+
: 408.1; HRMS (ES +ve), C23H34N7 [M+H]
+










10.3 Experimental for Chapter 3 
 
10.3.1 Synthesis of Compounds 19-27 
To a solution of 1-(2,2-diethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine, 4, (100 mg, 
0.265 mmol) in dioxane/water (4.5 ml/0.5 ml) was added either 1H-pyrrolo[2,3-b]pyridine-
5-boronic acid pinicol ester, 6-indolylboronicacid,  5-isoquinolineboronicacid, 3,4-
dimethoxyphenylboronicacid, 3-hydroxyphenylboronicacid, furan-3-boronicacid, 3-(N-Boc-
amino)phenylboronic, 3-aminocarbonylphenylboronicacid or 4-aminocarbonylphenylboronic 
acid  (1.5 eq., 0.397 mmol), potassium carbonate (1.5 eq., 54.8 mg, 0.397 mmol), 
triphenylphosphine (20 mol %, 20.8 mg) and palladium acetate (5 mol %, 4.5 mg)  and the 
mixture heated in the microwave at 120 
o
C for an hour. EtOAc (50 ml) and water (50 ml) 
were added to the mixture and the organic layer separated, washed with brine (50 ml), dried 





Purified by column chromatography, MeOH/DCM (0-6 %) to give a white solid (93 mg, 
0.253 mmol, 95.6 %). 
1
H NMR (500 MHz, CDCl3) δ 9.53 (s, 1H), 8.62 (d, J = 1.9, 1H), 
8.41 (s, 1H), 8.24 (d, J = 2.0, 1H), 7.45 (d, J = 3.4, 1H), 6.62 (d, J = 3.5, 1H), 6.29 – 5.86 (br. 
s, 2H), 5.14 (t, J = 5.7, 1H), 4.62 (d, J = 5.7, 2H), 3.79 (dq, J = 9.4, 7.0, 2H), 3.55 (dq, J = 
9.4, 7.0, 2H), 1.14 (t, J = 7.0, 6H); 
13
C NMR (126 MHz, CDCl3) δ 156.75 (C), 154.58 (C), 
153.42 (CH), 148.87 (C), 143.78 (C), 142.83 (CH), 128.83 (CH), 126.85 (CH), 121.30 (C), 
120.46 (C), 101.80 (CH), 99.93 (CH), 98.47 (C), 62.17 (2x CH2), 49.33 (CH2), 15.34 (2x 
CH3); MS (ES +ve) [M+H]
+
: 368.2, 390.2 (+Na), (ES –ve) [M-H]
-
: 366.2; HRMS (ES +ve), 
C18H22N7O2 (M+H)
+





Purified by column chromatography, MeOH/DCM (0-4 %) to give a deep red solid (86 mg, 
0.253 mmol, 95.6 %). 
1
H NMR (500 MHz, CDCl3) δ 8.51 (s, 1H), 8.40 (s, 1H), 7.79 (d, J = 
8.1, 1H), 7.72 (s, 1H), 7.41 (dd, J = 8.1, 1.4, 1H), 7.35 – 7.29 (m, 1H), 6.63 (t, J = 2.1, 1H), 
5.62 (s, 2H), 5.15 (t, J = 5.8, 1H), 4.59 (d, J = 5.8, 2H), 3.78 (dq, J = 9.4, 7.0, 2H), 3.53 (dq, J 
= 9.4, 7.0, 2H), 1.12 (t, J = 7.0, 6H); 
13
C NMR (126 MHz, CDCl3) δ 157.68 (C), 155.02 
(CH), 146.56 (C), 136.51 (C), 129.02 (C), 126.69 (C), 126.35 (CH), 122.17 (CH), 120.38 
(CH), 111.69 (CH), 103.20 (CH), 100.35 (C), 98.73 (CH), 62.39 (2x CH2), 49.44 (CH2), 




Purified by column chromatography, MeOH/DCM (0-5 %) to give a pale orange solid (86 
mg, 0.227 mmol, 85.8 %). 
1
H NMR (400 MHz, CDCl3) δ 9.39 (s, 1H), 8.59 (d, J = 6.0, 1H), 
8.47 (s, 1H), 8.16 (d, J = 8.2, 1H), 7.93 (dd, J = 7.1, 1.2, 1H), 7.84 (d, J = 6.0, 1H), 7.79 (dd, 
J = 8.2, 7.2, 1H), 5.18 (t, J = 5.7, 1H), 4.68 (d, J = 5.8, 2H), 3.83 (dq, J = 9.4, 7.0, 2H), 3.58 
(dq, J = 9.4, 7.0, 2H), 1.21 – 1.13 (m, 6H); 
13
C NMR (126 MHz, CDCl3) δ 157.36 (C), 
155.87 (CH), 154.77 (C), 152.99 (CH), 144.34 (CH), 141.21 (C), 134.32 (C), 132.29 (CH), 
129.43 (CH), 129.32 (C), 128.98 (C), 127.01 (CH), 118.25 (CH), 99.92 (C), 99.80 (CH), 
61.94 (2x CH2), 49.18 (CH2), 15.23 (2x CH3); MS (ES +ve) [M+H]
+





: 377.2; HRMS (ES +ve), C20H23N6O2 (M+H)
+





Purified by column chromatography, MeOH/DCM (0-2%) to give a pale yellow solid (97 
mg, 0.251 mmol, 94.5%). 
1
H NMR (500 MHz, CDCl3) δ 8.38 (s, 1H), 7.23 – 7.19 (m, 2H), 
7.02 (d, J = 8.7, 1H), 5.94 (s, 2H), 5.12 (t, J = 5.7, 1H), 4.57 (d, J = 5.8, 2H), 3.97 (d, J = 9.8, 
6H), 3.78 (dq, J = 9.4, 7.0, 2H), 3.53 (dq, J = 9.4, 7.0, 2H), 1.13 (t, J = 7.0, 6H); 
13
C NMR 
(126 MHz, CDCl3) δ 157.59 (C), 155.28 (CH), 154.78 (C), 149.94 (C), 149.69 (C), 144.70 
(C), 125.68 (C), 120.81 (CH), 111.61 (CH), 111.56 (CH), 99.82 (CH), 98.32 (C), 61.81 (2x 
CH2), 56.06 (2x CH3), 48.88 (CH2), 15.19 (2x CH3); MS (ES +ve) [M+H]
+
: 388.2, (ES –ve) 
[M-H]
-
: 368.2; HRMS (ES +ve), C19H26N5O4 (M+H)
+





Purified by column chromatography, MeOH/DCM (0-3%) to give a cream solid (80 mg, 
0.233 mmol, 88.0 %). 
1
H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 7.38 (t, J = 7.9, 1H), 7.20 
(d, J = 7.5, 1H), 7.12 (s, 1H), 6.95 (d, J = 8.1, 1H), 5.89 (s, 2H), 5.10 (t, J = 5.7, 1H), 4.57 (d, 
J = 5.7, 2H), 3.76 (tt, J = 14.1, 7.0, 2H), 3.52 (tt, J = 14.1, 7.0, 2H), 1.11 (t, J = 7.0, 6H); 
13
C 
NMR (126 MHz, CDCl3) δ 157.10 (C), 155.85 (CH), 153.86 (C), 152.23 (C), 145.53 (C), 
159 
 
133.41 (C), 131.04 (CH), 120.31 (CH), 117.10 (CH), 115.15 (CH), 99.75 (CH), 97.78 (C), 
62.16 (2x CH2), 49.22 (CH2), 15.17 (2x CH3); MS (ES +ve) [M+H]
+
: 344.2, 366.2 (+Na), 
(ES –ve) [M-H]
-
: 342.2; HRMS (ES +ve), C17H22N5O3 (M+H)
+





Purified by column chromatography, MeOH/DCM (0-2 %) to give a cream coloured solid, 
(66.8 mg, 0.211 mmol, 79.5 %). 
1
H NMR (500 MHz, CDCl3) δ 8.38 (s, 1H), 7.83 (dd, J = 
1.4, 0.9, 1H), 7.61 (t, J = 1.7, 1H), 6.77 (dd, J = 1.8, 0.8, 1H), 5.82 (s, 2H), 5.09 (t, J = 5.8, 
1H), 4.55 (d, J = 5.8, 2H), 3.76 (dq, J = 9.4, 7.0, 2H), 3.52 (dq, J = 9.4, 7.0, 2H), 1.11 (t, J = 
7.0, 6H); 
13
C NMR (126 MHz, CDCl3) δ 156.93 (C), 154.38 (C), 154.12 (CH), 144.66 
(CH), 141.11 (CH), 136.98 (C), 118.52 (C), 110.29 (CH), 99.73 (CH), 98.61 (C), 61.92 (2x 
CH2), 49.04 (CH2), 15.17 (2x CH3); MS (ES +ve) [M+H]
+
: 318.2, 340.2(+Na), 657.2 
(2M+Na), (ES –ve) [M-H]
-
: 317.2; HRMS (ES +ve), C15H20N5O3 (M+H)
+
: calculated 





Purified by column chromatography, MeOH/DCM (0-2%) to give a light brown sold (118 
mg, 0.268 mmol, 100 %). 
1
H NMR (500 MHz, CDCl3) δ 8.40 (s, 1H), 7.85 (s, 1H), 7.52 – 
7.45 (m, 2H), 6.66 (s, 1H), 6.42 (s, 2H), 5.14 (t, J = 5.7, 1H), 4.61 (d, J = 5.8, 2H), 3.80 (dq, 
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J = 9.4, 7.0, 2H), 3.55 (dq, J = 9.4, 7.0, 2H), 1.56 (s, 9H), 1.15 (t, J = 7.0, 6H); 
13
C NMR 
(126 MHz, CDCl3) δ 156.33 (C), 154.37 (C), 153.16 (C), 152.61 (CH), 145.15 (C), 139.02 
(C), 133.26 (C), 130.27 (CH), 123.17 (CH), 119.83 (CH), 119.30 (CH), 99.83 (CH), 97.91 
(C), 81.30 (C), 62.09 (2x CH2), 49.25 (CH2), 28.32 (3x CH3), 15.20 (2x CH3); MS (ES 
+ve) [M+H]
+
: 443.2, 465.2 (+Na), (ES –ve) [M-H]
-
: 441.2; HRMS (ES +ve), C22H31N6O4 
(M+H)
+




Purified by column chromatography, MeOH/DCM (0-8 %) to give a cream/light rose 
coloured solid (71 mg, 0.192 mmol, 72.4 %). 
1
H NMR (500 MHz, MeOD) δ 8.34 (s, 1H), 
8.24 (t, J = 1.6, 1H), 8.03 (d, J = 8.3, 1H), 7.93 – 7.89 (m, 1H), 7.69 (t, J = 7.7, 1H), 5.09 (t, J 
= 5.7, 1H), 4.55 (d, J = 5.7, 2H), 3.76 (dq, J = 9.5, 7.1, 2H), 3.52 (dq, J = 9.5, 7.0, 2H), 1.10 
(t, J = 7.0, 6H); 
13
C NMR (126 MHz, MeOD) δ 170.18 (C), 153.90 (C), 152.52 (C), 152.85 
(CH), 145.20 (C), 134.81 (C), 132.54 (C), 131.37 (CH), 129.26 (CH), 128.06 (CH), 127.51 
(CH), 100.11 (CH), 97.34 (C), 62.42 (2x CH2), 49.09 (CH2), 14.11 (2x CH3); MS (ES +ve) 
[M+H]
+
: 371.2, 393.2 (+Na), (ES –ve) [M-H]
-
: 369.2; HRMS (ES +ve), C18H23N6O3 
(M+H)
+






Purified by column chromatography, MeOH/DCM (0-6 %) to give a cream solid (90 mg, 
0.243 mmol, 91.7 %). 
1
H NMR (500 MHz, MeOD) δ 8.33 (s, 1H), 8.10 – 8.05 (m, 2H), 7.85 
– 7.80 (m, 2H), 5.09 (t, J = 5.7, 1H), 4.55 (d, J = 5.7, 2H), 3.76 (dq, J = 9.5, 7.0, 2H), 3.52 
(dq, J = 9.5, 7.0, 2H), 1.09 (t, J = 7.0, 6H); 
13
C NMR (126 MHz, MeOD) δ 170.27 (C), 
157.12 (C), 154.16 (C), 153.44 (CH), 144.76 (C), 135.58 (C), 134.35 (C), 128.30 (4x CH), 
100.11 (CH), 97.50 (C), 62.39 (2x CH2), 49.05 (CH2), 14.10 (2x CH3); MS (ES +ve) 
[M+H]
+
: 371.2, 393.2 (+Na), (ES –ve) [M-H]
-
: 369.2; HRMS (ES +ve), C18H23N6O3 
(M+H)
+
: calculated 371.18262, found 371.17970. 
 
10.3.2 Synthesis of Compound 28 
1-(2,2-diethoxyethyl)-3-(2-phenylethynyl)pyrazolo[3,4-d]pyrimidin-4-amine (28): 
 
To a solution of 1-(2,2-diethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (100 mg, 
0.265 mmol) in THF (5 ml) was added phenylacetylene (1.5 eq., 0.397mmol, 40.5 mg, 37.7 
µl),  triethylamine (1.5 eq., 0.397 mmol, 29.1 µl), palladium acetate (5 mol %, 4.5 mg), 
triphenylphosphine (20 mol %, 20.8 mg) and copper iodide (5 mol%, 2.5 mg). The mixture 
was heated conventially at 70
o
C for 2 hours. EtOAc and water were added to the mixture and 
the organic layer separated, dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography, MeOH/DCM (0-2%) to give a light yellow solid 
(52 mg, 0.148 mmol, 55.9 %). 
1
H NMR (500 MHz, CDCl3) δ 8.90 – 8.35 (m, 1H), 7.59 (dd, 
J = 7.7, 1.7, 2H), 7.45 – 7.36 (m, 3H), 6.20 (s, 2H), 5.09 (t, J = 5.6, 1H), 4.53 (d, J = 5.7, 
2H), 3.74 (dq, J = 9.3, 7.0, 2H), 3.50 (dq, J = 14.4, 7.2, 2H), 1.10 (t, J = 7.0, 6H); 
13
C NMR 
(126 MHz, CDCl3) δ 153.88 (CH), 131.82 (2x CH), 129.58 (CH), 128.67 (2x CH), 121.45 
(C), 99.81 (CH), 94.33 (C), 80.63 (C), 62.07 (2x CH2), 49.41 (CH2), 15.16 (2x CH3);  MS 
(ES +ve) [M+H]
+
: 352.2, 725.2 (2M +Na), (ES –ve) [M-H]
-
: 350.2; HRMS (ES +ve), 
C19H22N5O2 (M+H)
+








60 mg, 0.163 mmol, of 1-(2,2-diethoxyethyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-
d]pyrimidin-4-amine was added to a 20 ml microwave vial. 5 ml of water was added 
followed by 5 ml of TFA and the mixture heated conventially at 100
o
C for an hour.  The 
mixture was concentrated in vacuo to leave a light brown oil which was used without further 
purification 0.163 mmol of 2-[4-amino-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-
d]pyrimidin-1-yl]acetaldehyde was dissolved in 2 ml of DCM. N,N-dimethyl-1-(4-
piperidyl)methanamine (1.5 eq., 0.245 mmol, 34.8 mg) was added followed by a drop of 
acetic acid. The mixture was allowed to stir for 10 mins then sodium triacetoxyborohydride 
(1.5 eq., 0.245 mmol, 51.9 mg) added and the mixture allowed to stir for 2 hours. The 
mixture was concentrated in vacuo and the product purified by column chromatography, 
MeOH/DCM (5-10% then 10% with 5-20 drops of NH3 aq. Per 100 ml) to give a light 
orange solid, (15.3 mg, 0.0365 mmol, 14.9 %). 
1
H NMR (500 MHz, MeOD) δ 8.52 (s, 1H), 
8.29 (d, J = 2.0, 1H), 8.28 (s, 1H), 7.52 (d, J = 3.5, 1H), 6.62 (d, J = 3.5, 1H), 4.64 (t, J = 6.4, 
2H), 3.25 (d, J = 11.7, 2H), 3.13 (t, J = 6.3, 2H), 2.96 (d, J = 7.2, 2H), 2.84 (s, 6H), 2.37 (t, J 
= 11.4, 2H), 1.88 (m, 1H), 1.80 (d, J = 13.1, 2H), 1.36 – 1.31 (m, 2H); 
13
C NMR (126 MHz, 
MeOD) δ 161.79 (C), 158.65 (C), 155.54 (CH), 154.33 (C), 148.16 (C), 143.72 (C), 141.84 
(CH), 128.67 (CH), 127.12 (CH), 120.73 (C), 100.63 (CH), 98.19 (C), 62.67 (CH2), 56.31 
(CH2), 52.22 (2x CH2), 43.41 (CH2), 42.72 (2x CH3), 30.93 (CH), 28.39 (2x CH2); MS (ES 
+ve) [M+H]
+
: 420.2; HRMS (ES +ve), C22H29N9 [M+H]
+







60 mg, 0.159 mmol of 1-(2,2-diethoxyethyl)-3-(6-quinolyl)pyrazolo[3,4-d]pyrimidin-4-
amine was added to a 20 ml microwave vial. 5 ml of water was added followed by 5 ml of 
TFA and the mixture heated conventially at 100
o
C for an hour. The mixture was 
concentrated in vacuo to give a brown oil which was used without further purification. 0.159 
mmol of 2-[4-amino-3-(6-quinolyl)pyrazolo[3,4-d]pyrimidin-1-yl]acetaldehyde was 
dissolved in 2 ml of DCM. N,N-dimethyl-1-(4-piperidyl)methanamine (1.5 eq., 0.238 mmol, 
33.9 mg) was added followed by a drop of acetic acid and the mixture allowed to stir for 10 
mins. Sodium triacetoxyborohydride (1.5 eq., 0.238 mmol, 50.4 mg) was added and the 
mixture allowed to stir for 17 hours. The mixture was concentrated in vacuo and purified by 
column chromatography, MeOH/DCM (5-10% then 20 drops NH3 aq per 100 ml) to give a 
fluorescent yellow coloured solid, 48.9 mg, 0.122 mmol, 70.6 %. 
1
H NMR (500 MHz, 
MeOD) δ 9.37 (s, 1H), 8.47 (d, J = 6.0, 1H), 8.31 (m, 2H), 7.99 (dd, J = 7.1, 1.2, 1H), 7.90 – 
7.84 (m, 2H), 4.65 (t, J = 6.7, 2H), 3.09 (d, J = 11.7, 2H), 2.99 (t, J = 6.7, 2H), 2.28 (s, 6H), 
2.27 (m, 2H), 2.18 – 2.11 (m, 2H), 1.75 (d, J = 12.4, 2H), 1.57 (ddd, J = 11.3, 7.4, 3.9, 1H), 
1.24 – 1.12 (m, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.26 (C), 155.67 (CH), 154.06 (C), 
152.47 (CH), 142.47 (CH), 141.58 (C), 134.67 (C), 132.89 (CH), 129.35 (CH), 129.21 (c), 
129.11 (C), 127.33 (CH), 118.82 (CH), 99.55 (C), 65.35 (CH2), 56.79 (CH2), 53.22 (2x 
CH2), 44.34 (2x CH3), 44.05 (CH2), 33.06 (CH), 30.04 (2x CH2); MS (ES +ve) [M+H]
+
: 
431.2; HRMS (ES +ve), C24H30N9 [M+H]
+







70 mg, 0.181 mmol of 1-(2,2-diethoxyethyl)-3-(3,4-dimethoxyphenyl)pyrazolo[3,4-
d]pyrimidin-4-amine was added to a 20 ml microwave vial. 5 ml of water was added 
followed by 5 ml of TFA and the mixture heated conventially at 100
o
C for an hour. The 
mixture was concentrated in vacuo to leave a light brown oil which was used without further 
purification. 0.181 mmol of 2-[4-amino-3-(3,4-dimethoxyphenyl)pyrazolo[3,4-d]pyrimidin-
1-yl]acetaldehyde was dissolved in 4 ml of DCM. N,N-dimethyl-1-(4-
piperidyl)methanamine (1.5 eq., 0.271 mmol, 38.5 mg) was added followed by a drop of 
acetic acid and the mixture allowed to stir for 10 mins. Sodium triacetoxyborohydride (1.5 
eq., 0.271 mmol, 57.4 mg) was added and the mixture allowed to stir for 17 hours. The 
mixture was concentrated in vacuo and the product purified by column chromatography, 
MeOH/DCM (5-10 % then 10 drops of NH3 aq per 100 ml) to give a light yellow solid (14.5 
mg, 0.033 mmol, 20.8 %). 
1
H NMR (500 MHz, MeOD) δ 8.26 (s, 1H), 7.27 (s, 1H), 7.25 (d, 
J = 8.2, 1H), 7.14 (d, J = 8.2, 1H), 4.63 (t, J = 6.3, 2H), 3.91 (s, 6H), 3.18 (s, 2H), 2.98 (d, J = 
7.2, 2H), 2.85 (s, 6H), 2.45 (m, 2H), 1.92 (m, 1H), 1.83 (d, J = 13.2, 2H), 1.35 (dd, J = 22.2, 
11.5, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.58 (C), 155.51 (CH), 154.22 (C), 150.22 (C), 
149.67 (C), 145.44 (C), 125.19 (C), 120.91 (CH), 111.94 (CH), 111.73 (CH), 97.82 (C), 
62.49 (CH2), 56.18 (CH2), 55.13 (2x CH3), 52.16 (2x CH2), 43.08 (CH2), 42.69 (2x CH3), 
30.70 (CH), 28.13 (2x CH2); MS (ES +ve) [M+H]
+
: 440.2; HRMS (ES +ve), C23H33N7O2 
[M+H]
+




Synthesis of  3-[4-amino-1-[2-[4-(dimethylaminomethyl)-1-piperidyl]ethyl]pyrazolo[3,4-
d]pyrimidin-3-yl]phenol (32): 
 
60 mg, 0.175 mmol of 3-[4-amino-1-(2,2-diethoxyethyl)pyrazolo[3,4-d]pyrimidin-3-
yl]phenol was added to a 20 ml microwave vial. 5 ml of water was added followed by 5 ml 
of TFA and the mixture heated conventially at 100
o
C for an hour. The mixture was 
concentrated in vacuo to leave a light brown oil which was used without further purification. 
0.175 mmol of 2-[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]acetaldehyde 
was dissolved in 4 ml of DCM. N,N-dimethyl-1-(4-piperidyl)methanamine (1.5 eq., 0.262 
mmol, 37.2 mg) was added followed by a drop of acetic acid and the mixture allowed to stir 
for 10 mins. Sodium triacetoxyborohydride (1.5 eq., 0.262 mmol, 55.5 mg) was added and 
the mixture allowed to stir for 20 hours. The mixture was concentrated in vacuo and the 
product purified by column chromatography, MeOH/DCM (10 % then 0-20 drops of NH3 aq 
per 100 ml) to give a dark orange solid (5.5 mg, 0.0139 mmol, 8.0 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.26 (s, 1H), 7.39 (t, J = 7.9, 1H), 7.17 – 7.09 (m, 2H), 6.95 (dd, J = 7.8, 2.1, 1H), 
4.57 (t, J = 6.7, 2H), 3.08 (d, J = 11.7, 2H), 2.96 (t, J = 6.7, 2H), 2.47 (m, 8H), 2.16 (t, J = 
11.0, 2H), 1.74 (d, J = 12.9, 2H), 1.64 (m, 1H), 1.21 (dd, J = 21.1, 12.0, 2H); 
13
C NMR (126 
MHz, MeOD) δ 158.44 (C), 158.06 (C), 155.42 (CH), 154.06 (C), 145.17 (C), 133.97 (C), 
130.16 (CH), 119.09 (CH), 115.96 (CH), 114.92 (CH), 97.73 (C), 64.57 (CH2), 56.66 (CH2), 
52.78 (2x CH2), 43.83 (2x CH3), 43.77 (CH2), 32.46 (CH), 29.58 (2x CH2). MS (ES +ve) 
[M+H]
+
: 396.4; HRMS (ES +ve), C21H29N7O [M+H]
+









52 mg, 0.164 mmol of 1-(2,2-diethoxyethyl)-3-(3-furyl)pyrazolo[3,4-d]pyrimidin-4-amine 
was added to a 20 ml microwave vial. 5 ml of water was added followed by 5 ml of TFA and 
the mixture heated conventially at 100
o
C for an hour. The mixture was concentrated in vacuo 
to leave a light brown oil which was used without further purification. 0.164 mmol of 2-[4-
amino-3-(3-furyl)pyrazolo[3,4-d]pyrimidin-1-yl]acetaldehyde was dissolved in 4 ml of 
DCM. N,N-dimethyl-1-(4-piperidyl)methanamine (1.5 eq., 0.246 mmol, 35.0 mg) was added 
followed by a drop of acetic acid and the mixture allowed to stir for 10 mins. Sodium 
triacetoxyborohydride (1.5 eq., 0.246 mmol, 52.1 mg) was added and the mixture allowed to 
stir over the weekend. The mixture was concentrated in vacuo and the product purified by 
column chromatography, MeOH/DCM (5-10 % then 10-20 drops of NH3 aq per 100 ml) to 
give a dark golden brown solid (45.7 mg, 0.124 mmol, 75.5 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.23 (s, 1H), 7.96 (dd, J = 1.4, 0.9, 1H), 7.71 (t, J = 1.7, 1H), 6.82 (dd, J = 1.8, 0.8, 
1H), 4.53 (t, J = 6.7, 2H), 3.08 (d, J = 11.7, 2H), 2.94 (t, J = 6.7, 2H), 2.62 (d, J = 6.6, 2H), 
2.57 (s, 6H), 2.16 (dd, J = 11.8, 10.0, 2H), 1.72 (d, J = 12.9, 2H), 1.68 (m, 1H), 1.26 – 1.18 
(m, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.57 (C), 155.45 (CH), 153.98 (C), 144.34 (CH), 
141.47 (CH), 137.22 (C), 118.30 (C), 109.73 (CH), 98.17 (C), 63.97 (CH2), 56.59 (CH2), 
52.62 (2x CH2), 43.73 (CH2), 43.43 (2x CH3), 32.02 (CH), 29.27 (2x CH2); MS (ES +ve) 
[M+H]
+
: 370.2; HRMS (ES +ve), C19H27N7O [M+H]
+









50 mg, 0.142 mmol of 1-(2,2-diethoxyethyl)-3-(2-phenylethynyl)pyrazolo[3,4-d]pyrimidin-
4-amine was added to a 20 ml microwave vial. 5 ml of water was added followed by 5 ml of 
TFA and the mixture heated conventially at 100
o
C for an hour. The mixture was 
concentrated in vacuo to leave a dark brown oil which was used without further purification. 
0.142 mmol of 2-[4-amino-3-(2-phenylethynyl)pyrazolo[3,4-d]pyrimidin-1-yl]acetaldehyde 
was suspended in 4 ml of DCM. N,N-dimethyl-1-(4-piperidyl)methanamine (1.5 eq., 0.213 
mmol, 30.3 mg) was added followed by a drop of acetic acid and the mixture allowed to stir 
for 10 mins. Sodium triacetoxyborohydride (1.5 eq., 0.213 mmol, 45.1 mg) was added and 
the mixture allowed to stir for an hour. The mixture was concentrated in vacuo and the 
product purified by column chromatography, MeOH/DCM (5-10 % then 5-10 drops of NH3 
aq per 100 ml) to give a dark orange solid, (23.4 mg, 0.058 mmol, 40.7 %). 
1
H NMR (500 
MHz, MeOD) δ 8.23 (s, 1H), 7.69 – 7.61 (m, 2H), 7.46 – 7.40 (m, 3H), 4.51 (t, J = 6.7, 2H), 
3.02 (d, J = 11.7, 2H), 2.90 (t, J = 6.7, 2H), 2.29 (s, 6H), 2.28 – 2.25 (m, 2H), 2.10 (td, J = 
11.8, 2.3, 2H), 1.71 (d, J = 12.8, 2H), 1.54 (dtd, J = 14.6, 7.5, 3.7, 1H), 1.15 (qd, J = 12.5, 
3.7, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.22 (C), 156.07 (CH), 153.13 (C), 131.48 (CH 
x2), 129.25 (CH), 128.38 (CH x2), 126.72 (C), 121.47 (C), 100.98 (C), 93.76 (C), 79.88 (C), 
65.21 (CH2), 56.68 (CH2), 52.96 (CH2 x2), 44.27 (CH3 x2), 44.22 (CH2), 32.94 (CH), 29.92 
(CH2 x2); MS (ES +ve) [M+H]
+
: 404.3; HRMS (ES +ve), C23H29N7 [M+H]
+
: calculated 







75 mg, 0.199 mmol of 1-(2,2-diethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine was 
added to a 10 ml microwave tube. 2.5 ml of water and 2.5 ml of TFA were added and the 
mixture heated to 100
o
C for an hour. The mixture was concentrated in vacuo to give a white 
solid which was used without further purification. 0.199 mmol of 2-(4-amino-3-iodo-
pyrazolo[3,4-d]pyrimidin-1-yl)acetaldehyde was suspended in 3 ml of DCM. N,N-dimethyl-
1-(4-piperidyl)methanamine (1.5 eq., 0.299 mmol, 42.2 mg) was added followed by a drop 
of acetic acid and the mixture allowed to stir for 10 mins. Sodium triacetoxyborohydride (1.5 
eq., 0.299 mmol, 63.4 mg) was added and the mixture allowed to stir for 17 hours. The 
mixture was concentrated in vacuo and purified by column chromatography, MeOH/DCM 
(0-10 % then 5-15 drops of NH3 aq. per 100 ml) to give a light yellow coloured solid (63.6 
mg, 0.148 mmol, 74.5 %). 
1
H NMR (500 MHz, MeOD) δ 8.20 (s, 1H), 4.49 (t, J = 6.7, 2H), 
3.01 (d, J = 11.7, 2H), 2.87 (t, J = 6.7, 2H), 2.28 (s, 6H), 2.27 (d, 2H), 2.10 (td, J = 11.8, 2.3, 
2H), 1.72 (d, J = 13.0, 2H), 1.55 (ddt, J = 15.0, 7.6, 3.8, 1H), 1.15 (qd, J = 12.3, 3.7, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.05 (C), 155.63 (CH), 153.58 (C), 103.66 (C), 86.95 (C), 
65.27 (CH2), 56.73 (CH2), 52.96 (2x CH2), 44.30 (2x CH3), 44.15 (CH2), 32.97 (CH), 30.09 











10.4 Experimental for Chapter 4 
 
10.4.1 Synthesis of Compounds 36-43 
Synthesis of 1-(1,3-dioxolan-2-ylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (36): 
 
To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1 g, 3.83 mmol) in DMF (15 
ml) was added sodium hydride (1 eq., 3.83 mmol, 60% dispersion in mineral oil, 153.5 mg) 
and the suspension allowed to stir for 30 mins until gas evolution had subsided. 2-
Bromomethyl-1,3-dioxolane (1 eq. 3.83 mmol, 635.6 g, 0.39 ml) was then added dropwise 
and the mixture heated to 150 
o
C in the microwave for an hour. EtOAc and water (50 ml) 
were added to the mixture and the organics separated. The aqueous layer was washed with 
EtOAc (x5, 50 ml) and organics combined. The combined organics were then washed with 
water (x3, 30 ml) to remove any residual DMF and the organics combined, dried over 
MgSO4 and concentrated in vacuo. The product was purified by column chromatography, 
MeOH/DCM (0-5 %) to give a light yellow solid (695.6 mg, 2.005 mmol, 52.3 %). 
1
H NMR 
(500 MHz, CDCl3) δ 8.33 (s, 1H), 6.07 (s, 2H), 5.36 (t, J = 4.5, 1H), 4.52 (d, J = 4.5, 2H), 
4.00 – 3.92 (m, 2H), 3.90 – 3.83 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 157.01 (C), 
155.66 (CH), 154.45 (C), 103.95 (C), 101.51 (CH), 87.00 (C), 65.27 (2x CH2) , 49.97 (CH2); 










Synthesis of 1-(1,3-dioxolan-2-ylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (37): 
 
To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (750 mg, 2.87 mmol) in DMF 
(10 ml) was added sodium hydride (1.5 eq., 4.31 mmol, 60% dispersion in mineral oil, 172.4 
mg) and the suspension allowed to stir for 30 mins until the gas evolution had subsided. 
Bromoacetaldehyde dimethyl acetal (1.5 eq. 4.31 mmol, 724.0 mg, 0.506 ml) was then added 
dropwise and the mixture heated in the microwave for 30 mins at 150 
o
C. EtOAc and water 
(50 ml) were added to the mixture and the organic layer separated. The aqueous layer was 
washed with EtOAc (x3, 20 ml) and the organic layers combined, dried over MgSO4 and 
concentrated in vacuo. The product was purified by column chromatography, MeOH/DCM 
(0-3 %) to give a light cream coloured solid (638.9 mg, 1.83 mmol, 63.8 %). 
1
H NMR (500 
MHz, CDCl3) δ 8.35 (s, 1H), 6.11 (s, 2H), 4.94 (t, J = 5.7, 1H), 4.50 (d, J = 5.7, 2H), 3.38 (s, 
6H); 
13
C NMR (126 MHz, CDCl3) δ 156.94(c), 155.42 (CH), 154.20 (C), 103.87 (C), 




Synthesis of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzoxazol-2-amine (38): 
 
To a solution of 5-bromo-1,3-benzoxazol-2-amine  (500 mg, 2.359 mmol) in dioxane/water 
(9 ml/1 ml) was added bis(pinacolato)diboron (1.5 eq., 899 mg, 3.538 mmol), potassium 
carbonate (1.5 eq., 489 mg, 3.538 mmol) and triphenylphosphine (20 mol %, 185.6 mg) 
followed by palladium acetate (5 mol %, 39.7 mg)  and the mixture heated in the microwave 
at 120 
o
C for 30 mins. EtOAc and water (50 ml) were added to the mixture and the organics 
separated. The aqueous layer was washed with EtOAc (x2, 50 ml) and the organics 
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combined. The combined organics were then washed with brine, dried over MgSO4 and 
concentrated in vacuo. The product was purified by column chromatography, MeOH/DCM 
(0-3 %) to give a red/orange solid (556.1 mg, 2.137 mmol, 90.6 %). 
1
H NMR (500 MHz, 
MeOD) δ 7.63 (s, 1H), 7.49 (dd, J = 8.0, 1.1, 1H), 7.29 (d, J = 8.0, 1H), 1.37 (s, 12H); 
13
C 
NMR (126 MHz, MeOD) δ 163.38 (C), 150.64 (C), 142.08 (C), 127.70 (CH), 121.07 (CH), 





d]pyrimidin-4-amine (39):  
 
To a solution of 1-(1,3-dioxolan-2-ylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (100 
mg, 0.288 mmol) in dioxane/water (4.5 ml/0.5 ml) was added 1H-pyrrolo[2,3-b]pyridine-5-
boronic acid pinicol ester (1.5 eq., 70.3 mg, 0.576 mmol), potassium carbonate (1.5 eq., 59.7 
mg, 0.576 mmol) and triphenylphosphine (20 mol %, 22.6 mg) followed by palladium 
acetate (5 mol %, 4.2 mg)  and the mixture heated in the microwave at 120 
o
C for an hour. 
EtOAc (50 ml) and water (50 ml) were added to the mixture and the organic layer separated. 
The aqueous layer was washed with EtOAc (20 ml, x2) and the organics combined dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography, MeOH/DCM (0-10 %) to give a white solid (65.6 mg, 0.195 mmol, 67.6 
%). 
1
H NMR (500 MHz, DMSO) δ 11.81 (s, 1H), 8.45 (d, J = 2.0, 1H), 8.24 (s, 1H), 8.17 (d, 
J = 1.7, 1H), 7.56 – 7.52 (m, 1H), 6.55 (dd, J = 3.4, 1.9, 1H), 5.34 (t, J = 4.8, 1H), 4.44 (d, J 
= 4.8, 2H), 3.96 – 3.86 (m, 2H), 3.86 – 3.75 (m, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.69 
(C), 155.72 (CH), 154.66 (C), 148.21 (C), 143.81 (C), 141.90 (CH), 128.77 (CH), 127.06 
(CH), 120.73 (C), 120.63 (C), 101.42 (CH), 100.66 (CH), 98.16 (C), 64.80 (2x CH2), 49.19 
(CH2); MS (ES +ve) [M+H]
+
: 338.9; HRMS (ES +ve), C16H16N7O2 (M+H)
+
: calculated 






To a solution of 1-(1,3-dioxolan-2-ylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (100 
mg, 0.287 mmol) in dioxane/water (4.5 ml/0.5 ml) was added 1H-pyrrolo[2,3-b]pyridine-5-
boronic acid pinicol ester (1.5 eq., 70.3 mg, 0.430 mmol), potassium carbonate (1.5 eq., 59.7 
mg, 0.430 mmol) and triphenylphosphine (20 mol %, 22.6 mg) followed by palladium 
acetate (5 mol %, 4.2 mg)  and the mixture heated in the microwave at 120 
o
C for an hour. 
EtOAc (50 ml) and water (50 ml) were added to the mixture and the organic layer separated. 
The aqueous layer was washed with EtOAc (20 ml, x2) and the organics combined, dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography, MeOH/DCM (0-5 %) to give a white solid (67.5 mg, 0.199 mmol, 69.3 %). 
1
H NMR (500 MHz, CDCl3) δ 9.22 (s, 1H), 8.68 (s, 1H), 8.46 (s, 1H), 8.29 (d, J = 1.8, 1H), 
7.49 (d, J = 10.6, 1H), 6.66 (s, 1H), 5.71 (s, 2H), 5.09 (t, J = 5.7, 1H), 4.64 (d, J = 5.7, 2H), 
3.46 (s, 6H); 
13
C NMR (126 MHz, CDCl3) δ 157.21 (C), 154.80 (CH), 148.64 (C), 143.34 
(C), 143.18 (C), 143.08 (CH), 128.76 (CH), 126.40 (CH), 121.56 (C), 120.19 (C), 101.81 
(CH), 101.31 (CH), 98.63 (C), 53.44 (2x CH3), 48.11 (CH2); MS (ES +ve) [M+H]
+
: 340.2, 
379.2 (+K), (ES –ve) [M-H]
-
: 338.2; HRMS (ES +ve), C16H18N7O2 (M+H)
+
: calculated 











To a solution of 1-(2,2-diethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (50 mg, 
0.133 mmol) in dioxane/water (4.5 ml/0.5 ml) was added 5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1,3-benzoxazol-2-amine (1.5 eq., 51.8 mg, 0.199 mmol), potassium 
carbonate (1.5 eq., 27.2 mg, 0.199 mmol) and triphenylphosphine (20 mol %, 10.4 mg) 
followed by palladium acetate (5 mol %, 2.25 mg)  and the mixture heated in the microwave 
at 120 
o
C for 30 mins. The reaction was repeated to double the product. EtOAc (50 ml) and 
water (50 ml) were added to the mixture and the organic layer separated. The aqueous layer 
was washed with EtOAc (20 ml) and the organics combined, dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column chromatography, 
MeOH/DCM (0-8 %) to give a pale orange/red solid (54.6 mg, 0.142 mmol, 53.7 %). 
1
H 
NMR (500 MHz, MeOD) δ 8.25 (s, 1H), 7.51 (d, J = 1.4, 1H), 7.46 (d, J = 8.2, 1H), 7.35 
(dd, J = 8.2, 1.7, 1H), 5.06 (t, J = 5.7, 1H), 4.49 (d, J = 5.7, 2H), 3.75 (dq, J = 9.5, 7.1, 2H), 
3.49 (dq, J = 9.5, 7.0, 2H), 1.08 (t, J = 7.0, 6H); 
13
C NMR (126 MHz, MeOD) δ 164.34 (C), 
158.52 (C), 155.52 (CH), 154.38 (C), 149.00 (C), 145.43 (C), 143.61 (C), 128.63 (C), 121.13 
(CH), 114.96 (CH), 109.00 (CH), 100.27 (CH), 97.73 (C), 62.43 (2x CH2), 48.85 (CH2), 
14.12 (2x CH3); MS (ES +ve) [M+H]
+
: 384.8; HRMS (ES +ve), C18H22N7O3 (M+H)
+
: 










To a solution of 1-(1,3-dioxolan-2-ylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (100 
mg, 0.288 mmol) in dioxane/water (4.5 ml/0.5 ml) was added  5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1,3-benzoxazol-2-amine (1.5 eq., 111.4 mg, 0.432 mmol), potassium 
carbonate (1.5 eq., 59.7 mg, 0.432 mmol) and triphenylphosphine (20 mol %, 22.6 mg) 
followed by palladium acetate (5 mol %, 4.2 mg)  and the mixture heated in the microwave 
at 120 
o
C for an hour. EtOAc (50 ml) and water (50 ml) were added to the mixture and the 
organic layer separated. The aqueous layer was washed with EtOAc (20 ml, x2) and the 
organics combined dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography, MeOH/DCM (0-10 %) to give a peach coloured solid 
(43.36 mg, 0.123 mmol, 42.6 %). 
1
H NMR (500 MHz, DMSO) δ 8.24 (s, 1H), 7.53 (s, 2H), 
7.47 (d, J = 8.1, 1H), 7.40 (d, J = 1.5, 1H), 7.23 (dd, J = 8.1, 1.7, 1H), 5.34 (t, J = 4.8, 1H), 
4.43 (d, J = 4.8, 2H), 3.97 – 3.90 (m, 2H), 3.85 – 3.78 (m, 2H); 
13
C NMR (126 MHz, 
DMSO) δ 163.92 (C), 158.62 (C), 156.32 (CH), 155.19 (C), 148.84 (C), 145.03 (C), 144.89 
(C), 128.84 (C), 120.91 (CH), 115.45 (CH), 109.37 (CH), 101.49 (CH), 97.76 (C), 64.86 (2x 
CH2), 49.28 (CH2); MS (ES +ve) [M+H]
+
: 354.9; HRMS (ES +ve), C16H16N7O3 (M+H)
+
: 










To a solution of 1-(1,3-dioxolan-2-ylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (100 
mg, 0.287 mmol) in dioxane/water (4.5 ml/0.5 ml) was added  5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1,3-benzoxazol-2-amine (1.5 eq., 112.1 mg, 0.431 mmol), potassium 
carbonate (1.5 eq., 59.7 mg, 0.431 mmol) and triphenylphosphine (20 mol %, 22.6 mg) 
followed by palladium acetate (5 mol %, 4.2 mg)  and the mixture heated in the microwave 
at 120 
o
C for an hour. EtOAc (50 ml) and water (50 ml) were added to the mixture and the 
organic layer separated. The aqueous layer was washed with EtOAc (20 ml, x2) and the 
organics combined dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography, MeOH/DCM (0-10 %) to give a peach coloured solid 
(60.22 mg, 0.169 mmol, 59.1 %). 
1
H NMR (500 MHz, MeOD) δ 8.28 (s, 1H), 7.55 (d, J = 
1.3, 1H), 7.48 (d, J = 8.2, 1H), 7.38 (dd, J = 8.2, 1.7, 1H), 4.98 (t, J = 5.7, 1H), 4.53 (d, J = 
5.7, 2H), 3.41 (s, 6H); 
13
C NMR (126 MHz, MeOD) δ 164.33 (C), 158.53 (C), 155.53 (CH), 
154.33 (C), 149.00 (C), 145.49 (C), 143.60 (C), 128.63 (C), 121.04 (CH), 114.98 (CH), 
108.98 (CH), 101.82 (CH), 97.72 (C), 52.94 (2x CH3), 47.79 (CH2); MS (ES +ve) (M+H)
+
: 
356.7; HRMS (ES +ve), C16H18N7O3 (M+H)
+














43, (9.0 mg, 25.3 umol) was added to a 2ml microwave tube. 1 ml of water and 1 ml of TFA 
were added and the mixture heated to 100
o
C in the microwave for 30 mins. The product was 
transferred to a flask and concentrated in vacuo giving the product without further 
purification in quantitative yield. 
 
10.4.3 Synthesis of Compounds 45-48 
Synthesis of 1-(cyclopentylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (45): 
 
To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (200 mg, 0.766 mmol) in 
DMF (2 ml) was added sodium hydride (1.5 eq., 1.149 mmol, 60% dispersion in mineral oil, 
45.9 mg) and the suspension allowed to stir for 30 mins until gas evolution had subsided. 
(iodomethyl)cyclopentane (1.5 eq. 1.149 mmol, 312.9 mg, 0.195 ml) was then added 
dropwise and the mixture heated at 150 
o
C in the microwave for an hour. EtOAc and water 
(50 ml) were added to the mixture and the organic layer separated. The aqueous layer was 
washed with EtOAc (x1, 50 ml) and organics combined. The combined organics were then 
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washed with brine (30 ml) to remove any residual DMF and the organics dried over MgSO4 
and concentrated in vacuo. The product was purified by column chromatography, 
MeOH/DCM (0-1.5 %) to give a white solid (190.44 mg, 0.555 mmol, 72.5 %). 
1
H NMR 
(500 MHz, MeOD) δ 8.21 (s, 1H), 4.28 (d, J = 7.6, 2H), 2.55 (dt, J = 14.8, 7.4, 1H), 1.76 – 
1.64 (m, 4H), 1.63 – 1.54 (m, 2H), 1.34 (dd, J = 12.9, 5.7, 2H); 
13
C NMR (126 MHz, 
MeOD) δ 158.11 (C), 155.61 (CH), 153.23 (C), 103.43 (C), 86.40 (C), 51.63 (CH2), 40.09 




Synthesis of 3-iodo-1-(tetrahydrofuran-2-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine (46): 
 
To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (200 mg, 0.766 mmol) in 
DMF (2 ml) was added sodium hydride (1.5 eq., 1.149 mmol, 60% dispersion in mineral oil, 
45.9 mg) and the suspension allowed to stir for 30 mins until gas evolution had subsided. 2-
(bromomethyl)tetrahydrofuran  (1.5 eq. 1.149 mmol, 188.4 mg) was then added dropwise 
and the mixture heated at 150 
o
C in the microwave for 30 mins. EtOAc and water (50 ml) 
were added to the mixture and the organic layer separated. The aqueous layer was washed 
with EtOAc (x2, 50 ml) and organics combined. The combined organics were then washed 
with brine (30 ml) to remove any residual DMF and the organics dried over MgSO4 and 
concentrated in vacuo. The product was purified by column chromatography, MeOH/DCM 
(0-2 %) to give a white solid (177.05 mg, 0.564 mmol, 73.6 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.22 (s, 1H), 4.47 – 4.36 (m, 2H), 4.33 (dd, J = 12.9, 3.9, 1H), 3.91 – 3.83 (m, 1H), 
3.78 – 3.69 (m, 1H), 2.05 (dt, J = 12.4, 6.7, 1H), 1.98 – 1.86 (m, 2H), 1.83 – 1.74 (m, 1H); 
13
C NMR (126 MHz, MeOD) δ 158.10 (C), 155.70 (CH), 153.70 (C), 103.55 (C), 87.00 (C), 











To a solution of 1-(cyclopentylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine (100 mg, 
0.292 mmol) in dioxane/water (4.5 ml/0.5 ml) was added  5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1,3-benzoxazol-2-amine (1.5 eq., 113.9 mg, 0.438 mmol), potassium 
carbonate (1.5 eq., 60.5 mg, 0.438 mmol) and triphenylphosphine (20 mol %, 15.3 mg) 
followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 120 
o
C 
for an hour. EtOAc (50 ml) and water (50 ml) were added to the mixture and the organic 
layer separated. The aqueous layer was washed with EtOAc (20 ml) and the organics 
combined dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography, MeOH/DCM (0-6 %) to give a light cream solid (48.91 mg, 0.140 
mmol, 48.0 %). 
1
H NMR (500 MHz, MeOD) δ 8.26 (s, 1H), 7.54 (d, J = 1.4, 1H), 7.48 (d, J 
= 8.2, 1H), 7.37 (dd, J = 8.2, 1.7, 1H), 4.35 (d, J = 7.6, 2H), 2.63 (dt, J = 14.9, 7.5, 1H), 1.84 
– 1.66 (m, 4H), 1.61 (m, 2H), 1.43 (m, 2H); 
13
C NMR (126 MHz, MeOD) δ 164.32 (C), 
158.56 (C), 155.37 (CH), 153.70 (C), 148.96 (C), 144.95 (C), 143.59 (C), 128.74 (C), 121.17 
(CH), 114.99 (CH), 108.94 (CH), 97.59 (C), 51.23 (CH2), 40.14 (CH), 29.69 (2x CH2), 24.61 
(2x CH2); MS (ES +ve) [M+H]
+
: 350.2, 721.4 (2M+Na), (ES -ve) [M-H]
-
: 348.2; HRMS 
(ES +ve), C18H20N7O1 (M+H)
+










To a solution of 3-iodo-1-(tetrahydrofuran-2-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine 
(100 mg, 0.299 mmol) in dioxane/water (4.5 ml/0.5 ml) was added  5-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-1,3-benzoxazol-2-amine (1.5 eq., 113.9 mg, 0.438 mmol), 
potassium carbonate (1.5 eq., 60.5 mg, 0.438 mmol) and triphenylphosphine (20 mol %, 15.3 
mg) followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 
120 
o
C for an hour. EtOAc (50 ml) and water (50 ml) were added to the mixture and the 
organic layer separated. The aqueous layer was washed with EtOAc (20 ml) and the organics 
combined dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography, MeOH/DCM (0-10 %) to give a light rose coloured solid (50.09 
mg, 0.143 mmol, 47.7 %). 
1
H NMR (500 MHz, MeOD) δ 8.27 (s, 1H), 7.55 (d, J = 1.5, 1H), 
7.48 (d, J = 8.2, 1H), 7.38 (dd, J = 8.2, 1.7, 1H), 4.50 (dq, J = 13.1, 7.0, 2H), 4.40 (dd, J = 
13.0, 3.9, 1H), 3.91 (dd, J = 14.7, 6.8, 1H), 3.76 (dd, J = 14.1, 7.6, 1H), 2.08 (dt, J = 12.3, 
6.6, 1H), 2.02 – 1.89 (m, 2H), 1.89 – 1.79 (m, 1H); 
13
C NMR (126 MHz, MeOD) δ 164.32 
(C), 158.52 (C), 155.46 (CH), 154.21 (C), 148.97 (C), 145.32 (C), 143.56 (C), 128.69 (C), 
121.19 (CH), 115.02 (CH), 108.97 (CH), 97.75 (C), 77.22 (CH), 67.76 (CH2), 50.41 (CH2), 
28.54 (CH2), 24.94 (CH2); MS (ES +ve) [M+H]
+
: 352.2, 725.3 (2M+Na); HRMS (ES +ve), 
C17H18N7O2 (M+H)
+








10.5 Experimental for Chapter 5 
 




40 mg, 0.109 mmol of 1-(2,2-diethoxyethyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-
d]pyrimidin-4-amine was added to a 10 ml microwave tube. 2.5 ml of water and 2.5 ml of 
TFA were then added and the mixture heated to 100 
o
C for 30 mins in the microwave. The 
solvents were removed in vacuo to give a dark brown oil which was used without further 
purification. 0.109 mmol of 2-[4-amino-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-
d]pyrimidin-1-yl]acetaldehyde was dissolved in 3 ml of THF. N,N-dimethylpiperidine-4-
amine (1.5 eq., 0.1635 mmol, 20.9 mg) was added and the mixture was allowed to stir for 5 
mins. Sodium triacetoxyborohydride (1.5 eq., 0.1635 mmol, 34.7 mg) was then added and 
the mixture allowed to stir for an hour. The reaction mixture was concentrated in vacuo and 
purified by column chromatography, MeOH/DCM (10 % then 5-40 drops of NH3 aq. per 50 
ml) to give a light yellow solid (26.9 mg, 0.0664 mmol, 60.9 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.50 (d, J = 1.9, 1H), 8.28 (d, J = 2.0, 1H), 8.27 (s, 1H), 7.51 (d, J = 3.5, 1H), 6.62 
(d, J = 3.5, 1H), 4.56 (t, J = 6.4, 2H), 3.19 (d, J = 12.1, 2H), 3.06 (tt, J = 12.0, 3.9, 1H), 2.97 
(t, J = 6.4, 2H), 2.77 (s, 6H), 2.18 (t, J = 11.1, 2H), 2.00 (d, J = 12.4, 2H), 1.58 (qd, J = 12.3, 
3.9, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.64 (C), 155.49 (CH), 154.32 (C), 148.16 (C), 
143.50 (C), 141.84 (CH), 128.66 (CH), 127.12 (CH), 120.78 (C), 120.73 (C), 100.63 (CH), 
181 
 
98.08 (C), 63.37 (CH), 55.82 (CH2), 51.54 (2xCH2), 44.11 (CH2), 39.16 (2xCH3), 26.18 
(2xCH2); MS (ES +ve) (M+H)
+
: 406.6; HRMS (ES +ve), C21H28N9 (M+H)
+
: calculated 
406.24622, found 406.24490. 
 




150 mg, 0.398 mmol, of 1-(2,2-diethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine 
was added to a 10 ml microwave tube. 2.5 ml of water and 2.5 ml of TFA were added and 
the mixture heated to 100
o
C for an hour. The mixture was concentrated in vacuo to give a 
white solid which was used without further purification. 0.398 mmol of 2-(4-amino-3-iodo-
pyrazolo[3,4-d]pyrimidin-1-yl)acetaldehyde was suspended in 3 ml of DCM. N,N-
dimethylpiperidine-4-amine (1.5 eq., 0.598 mmol, 76.6 mg) was added followed by a drop of 
acetic acid and the mixture allowed to stir for 10 mins. Sodium triacetoxyborohydride (1.5 
eq., 0.598 mmol, 126.8 mg) was added and the mixture allowed to stir for 17 hours 
overnight. The mixture was concentrated in vacuo and the product purified by column 
chromatography, MeOH/DCM (0-10 % then 5-20 drops of NH3 aq. per 100 ml) to give a 
light orange/brown solid (163.8 mg, 0.405 mmol, 99.1 %). 
1
H NMR (500 MHz, MeOD) δ 
8.22 (s, 1H), 4.49 (t, J = 6.4, 2H), 3.32 (s, 3H), 3.15 (d, J = 12.1, 2H), 2.96 (ddd, J = 16.0, 
8.0, 4.0, 1H), 2.91 (t, J = 6.4, 2H), 2.72 (s, 6H), 2.15 (td, J = 12.0, 2.0, 2H), 2.04 – 1.96 (m, 
2H), 1.54 (qd, J = 12.2, 3.9, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.07 (C), 155.67 (CH), 
153.70 (C), 103.59 (C), 86.97 (C), 63.18 (CH), 55.86 (CH2), 51.38 (2x CH2), 44.37 (CH2), 






Synthesis of tert-butyl N-[4-[4-amino-1-[2-[4-(dimethylaminomethyl)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxy-phenyl]carbamate (51): 
 
To a solution of 1-[2-[4-(dimethylaminomethyl)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine (50 mg, 0.1165 mmol) in dioxane/water (4.5 ml/0.5 ml) was added [4-
(tert-butoxycarbonylamino)-3-methoxy-phenyl]boronic acid (1.5 eq., 46.7 mg, 0.175 mmol), 
potassium carbonate (1.5 eq., 24.2 mg, 0.175 mmol) and triphenylphosphine (20 mol %, 9.2 
mg) followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 
120 
o
C for 45 mins. EtOAc (50 ml) and water (50 ml) were added to the mixture and the 
organic layer separated. The aqueous layer was washed with EtOAc (20 ml, x3) and the 
organics combined dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography, MeOH/DCM (0-10 % then 5-20 drops of NH3 aq. per 
100 ml) to give a dark brown solid (36.5 mg, 0.0696 mmol, 59.7 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.27 (s, 1H), 8.08 (d, J = 8.2, 1H), 7.30 (d, J = 1.8, 1H), 7.26 (dd, J = 8.2, 1.8, 1H), 
4.58 (t, J = 6.8, 2H), 3.98 (s, 3H), 3.08 (d, J = 11.7, 2H), 2.96 (t, J = 6.8, 2H), 2.34 (s, 6H), 
2.32 (d, J = 7.2, 2H), 2.16 (dd, J = 11.8, 9.6, 2H), 1.76 (d, J = 12.3, 2H), 1.63 – 1.58 (m, 1H), 
1.57 (s, 9H), 1.24 – 1.16 (m, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.52 (C), 155.40 (CH), 
154.07 (C), 153.46 (C), 149.24 (C), 145.04 (C), 128.77 (C), 127.39 (C), 120.43 (CH), 119.56 
(CH), 110.29 (CH), 97.78 (C), 80.18 (C), 65.19 (CH2), 56.76 (CH2), 55.08 (CH3), 52.96 (2x 
CH2), 44.24 (2x CH3), 43.79 (CH2), 32.92 (CH), 29.89 (2x CH2), 27.22 (3x CH3); MS (ES 
+ve) [M+H]
+
: 525.4, (ES –ve) [M-H]
-
: 523.3; HRMS (ES +ve), C27H41N8O3 (M+H)
+
: 




Synthesis of tert-butyl N-[4-[4-amino-1-[2-[4-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxy-phenyl]carbamate (52): 
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5 ml/0.5 ml) was added [4-
(tert-butoxycarbonylamino)-3-methoxy-phenyl]boronic acid (1.5 eq., 48.3 mg, 0.181 mmol), 
potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 
mg) followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 
120 
o
C for an hour. EtOAc (50 ml) and water (50 ml) were added to the mixture and the 
organic layer separated. The aqueous layer was washed with EtOAc (20 ml, x2) and the 
organics combined dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography, MeOH/DCM (0-10 % then 5-20 drops of NH3 aq. per 
100 ml) to give a light brown solid (23.1 mg, 0.0453 mmol, 37.6 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.27 (s, 1H), 8.08 (d, J = 8.2, 1H), 7.30 (d, J = 1.8, 1H), 7.26 (dd, J = 8.2, 1.9, 1H), 
4.56 (t, J = 6.7, 2H), 3.98 (s, 3H), 3.14 (d, J = 11.9, 2H), 2.94 (t, J = 6.7, 2H), 2.39 (m, 7H), 
2.14 (dd, J = 12.0, 10.0, 2H), 1.90 (d, J = 12.5, 2H), 1.57 (s, 9H), 1.49 (qd, J = 12.1, 3.6, 
2H); 
13
C NMR (126 MHz, MeOD) δ 158.53 (C), 155.40 (CH), 154.12 (C), 153.46 (C), 
149.24 (C), 145.02 (C), 128.78 (C), 127.38 (C), 120.43 (CH), 119.56 (CH), 110.28 (CH), 
97.73 (C), 80.18 (C), 62.29 (CH), 56.22 (CH2), 55.07 (CH3), 52.20 (2x CH2), 44.00 (CH2), 
40.06 (2x CH3), 27.24 (2x CH2), 27.21 (3x CH3); MS (ES +ve) [M+H]
+
: 511.3; HRMS (ES 
+ve), C26H38N8O3 [M+H]
+






10.6 Experimental for Chapter 6 
 
 




300 mg, 0.8646 mmol of 1-(1,3-dioxolan-2-ylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-
amine was added to a 10 ml microwave tube. 2.5 ml of water and 2.5 ml of TFA were added 
and the mixture heated to 100
o
C for 3 hours. The product was concentrated in vacuo and 
used without further purification. 0.432 mmol of 2-(4-amino-3-iodo-pyrazolo[3,4-
d]pyrimidin-1-yl)acetaldehyde was suspended in 3 ml of DCM. 4-(1-pyrrolidinyl)piperidine 
(1.5 eq., 0.648 mmol, 99.9 mg) was added followed by a drop of acetic acid and the mixture 
allowed to stir for 10 mins. Sodium triacetoxyborohydride (1.5 eq., 0.648 mmol, 137.3 mg) 
was added and the mixture allowed to stir for 17 hours. The mixture was concentrated in 
vacuo and purified by column chromatography, MeOH/DCM (0-10 %) to give a 
green/brown solid, (183.1 mg, 0.415 mmol, 96.1 %). 
1
H NMR (500 MHz, MeOD) δ 8.22 (s, 
1H), 4.50 (t, J = 6.3, 2H), 3.34 (m, 4H), 3.12 (d, J = 12.0, 2H), 3.06 (dd, J = 13.9, 9.7, 1H), 











300 mg, 0.8646 mmol of 1-(1,3-dioxolan-2-ylmethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-
amine was added to a 10 ml microwave tube. 2.5 ml of water and 2.5 ml of TFA were added 
and the mixture heated to 100
o
C for 3 hours. The product was concentrated in vacuo and 
used without further purification. 0.432 mmol of 2-(4-amino-3-iodo-pyrazolo[3,4-
d]pyrimidin-1-yl)acetaldehyde was suspended in 3 ml of DCM. 1,4-bipiperidine (1.5 eq., 
0.648 mmol, 108.9 mg) was added followed by a drop of acetic acid and the mixture allowed 
to stir for 10 mins. Sodium triacetoxyborohydride (1.5 eq., 0.648 mmol, 137.3 mg) was 
added and the mixture allowed to stir for 17 hours. The mixture was concentrated in vacuo 
and purified by column chromatography, MeOH/DCM (0-10 %) to give a dark green/brown 
thick oil, (191.6 mg, 0.421 mmol, 97.5%). 
1
H NMR (601 MHz, DMSO) δ 8.21 (s, 1H), 4.38 













Synthesis of tert-butyl N-[4-[4-amino-1-[2-(4-pyrrolidin-1-yl-1-
piperidyl)ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxy-phenyl]carbamate (55): 
 
To a solution of 3-iodo-1-[2-(4-pyrrolidin-1-yl-1-piperidyl)ethyl]pyrazolo[3,4-d]pyrimidin-
4-amine (50 mg, 0.113 mmol) in dioxane/water (4.5 ml/0.5 ml) was added [4-(tert-
butoxycarbonylamino)-3-methoxy-phenyl]boronic acid (1.5 eq., 45.4 mg, 0.170 mmol), 
potassium carbonate (1.5 eq., 23.5 mg, 0.170 mmol) and triphenylphosphine (20 mol %, 8.9 
mg) followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 
120 
o
C for an hour. EtOAc (50 ml) and water (50 ml) were added to the mixture and the 
organic layer separated. The aqueous layer was washed with EtOAc (20 ml, x2) and the 
organics combined and washed with brine then dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by column chromatography, MeOH/DCM (0-10 % then 5-25 
drops of NH3 aq. per 100 ml) to give a light orange solid (16.69 mg, 31.12 µmol, 27.5 %). 
1
H NMR (500 MHz, MeOD) δ 8.27 (s, 1H), 8.08 (d, J = 8.2, 1H), 7.30 (d, J = 1.8, 1H), 7.25 
(dd, J = 8.2, 1.8, 1H), 4.56 (t, J = 6.6, 2H), 3.98 (s, 3H), 3.12 (d, J = 12.0, 2H), 2.94 (m, 6H), 
2.53 (m, 1H), 2.15 (t, J = 11.1, 2H), 2.01 (d, J = 12.2, 2H), 1.93 (dd, J = 8.3, 5.0, 4H), 1.57 
(s, 9H), 1.55 – 1.48 (m, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.52 (C), 155.40 (CH), 
154.15 (C), 153.45 (C), 149.24 (C), 145.00 (C), 128.80 (C), 127.36 (C), 120.43 (CH), 119.55 
(CH), 110.27 (CH), 97.69 (C), 80.19 (C), 62.00 (CH), 56.16 (CH2), 55.08 (CH3), 51.62 (2x 
CH2), 51.22 (2x CH2), 44.01 (CH2), 29.65 (2x CH2), 27.22 (3x CH3), 22.49 (2x CH2); MS 
(ES +ve) [M+H]
+
: 537.4, (ES -ve) [M-H]
-
: 535.3; HRMS (ES +ve), C28H40N8O3 [M+H]
+
: 




Synthesis of tert-butyl N-[4-[4-amino-1-[2-[4-(1-piperidyl)-1-piperidyl]ethyl]pyrazolo[3,4-
d]pyrimidin-3-yl]-2-methoxy-phenyl]carbamate (56): 
 
To a solution of 3-iodo-1-[2-[4-(1-piperidyl)-1-piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-4-
amine (50 mg, 0.110 mmol) in dioxane/water (4.5 ml/0.5 ml) was added [4-(tert-
butoxycarbonylamino)-3-methoxy-phenyl]boronic acid (1.5 eq., 44.0 mg, 0.165 mmol), 
potassium carbonate (1.5 eq., 22.8 mg, 0.165 mmol) and triphenylphosphine (20 mol %, 5.8 
mg) followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 
120 
o
C for an hour. EtOAc (50 ml) and water (50 ml) were added to the mixture and the 
organic layer separated. The aqueous layer was washed with EtOAc (20 ml, x2) and the 
organics combined, dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography, MeOH/DCM (0-10 % then 5-15 drops of NH3 aq. per 
100 ml) to give a light brown solid (12.3 mg, 22.35 µmol, 20.3 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.27 (s, 1H), 8.08 (d, J = 8.2, 1H), 7.30 (d, J = 1.7, 1H), 7.26 (dd, J = 8.2, 1.8, 1H), 
4.55 (t, J = 6.6, 2H), 3.96 (s, 3H), 3.15 (d, J = 11.8, 2H), 2.93 (t, J = 6.6, 2H), 2.74 (br. s, 
4H), 2.51 (br. s, 1H), 2.13 (t, J = 11.1, 2H), 1.91 (d, J = 12.0, 2H), 1.72 – 1.62 (m, 4H), 1.55 
(m, 13H); 
13
C NMR (126 MHz, MeOD) δ 158.52 (C), 155.40 (CH), 154.13 (C), 153.45 (C), 
149.24 (C), 145.02 (C), 128.79 (C), 127.37 (C), 120.43 (CH), 119.56 (CH), 110.28 (CH), 
97.73 (C), 80.19 (C), 62.69 (CH), 56.21 (CH2), 55.08 (CH3), 52.43 (2x CH2), 49.83 (2x 
CH2), 44.00 (CH2), 27.22 (3x CH3), 26.78 (2x CH2), 24.68 (2x CH2), 23.34 (CH2); MS (ES 
+ve) [M+H]
+
: 551.2; HRMS (ES +ve), C29H42N8O3 [M+H]
+









To a solution of 4-Amino-3-methoxybenzeneboronic acid, pinacol ester (150 mg, 0.602 
mmol) in DCM (2 ml) was added triethylamine (1.2 eq., 0.722 mmol, 73.1 mg, 100.76 µl) 
followed by t-butylacetal chloride (1.2 eq., 0.722 mmol, 96.8 mg, 99.9 µl) and the mixture 
allowed to stir for 20 hours. Water was added to the mixture and the organic layer separated, 
dried over MgSO4 and concentrated in vacuo. The product was purified by column 
chromatography, MeOH/DCM (0-3%) to give a brown solid (195.7 mg, 0.564 mmol, 93.6 
%). 
1
H NMR (500 MHz, CDCl3) δ 8.44 (d, J = 8.0, 1H), 7.83 (s, 1H), 7.47 (dd, J = 8.0, 1.0, 
1H), 7.32 – 7.29 (m, 1H), 3.95 (s, 3H), 2.31 – 2.27 (m, 2H), 1.36 (s, 12H), 1.13 (s, 9H); 
13
C 
NMR (126 MHz, CDCl3) δ 170.06 (C), 169.99 (C), 146.89 (C), 130.52 (C), 128.54 (CH), 
118.61 (CH), 115.22 (CH), 83.75 (2x C), 55.86 (CH3), 52.08 (CH2), 31.22 (C), 29.81 (3x 
CH3), 24.86 (4x CH3); MS (ES +ve) [M+H]
+
: 348.6, 370.6 (+Na). 
 
Synthesis of 1-tert-butyl-3-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-




To a solution of 4-Amino-3-methoxybenzeneboronic acid, pinacol ester (150 mg, 0.602 
mmol) in DCM (3 ml) was added t-butylisocyanate (20 eq., 12.04 mmol, 1.19 g) and the 
mixture left to stir at for 72 hours. DCM and water were added to the mixture and the 
organic layer separated, dried over MgSO4 and concentrated in vacuo. The product was 
purified by column chromatography, MeOH/DCM (0-2%) to give a dark brown solid, (40.9 
mg, 0.117 mmol, 19.5 %). 
1
H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 8.0, 1H), 7.44 (dd, J = 
8.0, 1.2, 1H), 7.27 (d, J = 1.0, 1H), 6.88 (s, 1H), 3.92 (s, 3H), 1.42 (s, 9H), 1.37 (d, J = 3.9, 
12H); 
13
C NMR (126 MHz, CDCl3) δ 153.97 (C), 146.81 (C), 131.78 (C), 128.70 (CH), 
117.77 (CH), 115.36 (CH), 83.65 (CH), 55.74 (C), 50.97 (CH3), 29.36 (C), 29.09 (3x CH3), 
24.87 (4x CH3); MS (ES +ve) [M+H]
+
: 349.7, 371.6 (+Na) 
 
Synthesis of Phenyl N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]carbamate (59): 
 
To a solution of 4-Amino-3-methoxybenzeneboronic acid, pinacol ester (150 mg, 0.602 
mmol) in DCM (2 ml) was added triethylamine (1.2 eq., 0.722 mmol, 73.1 mg, 100.76 µl) 
followed by phenyl chloroformate (1.2 eq., 0.722 mmol, 112.6 mg, 90.25 µl) and the mixture 
allowed to stir for 20 hours. Water was added to the mixture and the organic layer separated, 
dried over MgSO4 and concentrated in vacuo. The product was purified by column 
chromatography, (100% DCM) to give a clear white solid (190.8 mg, 0.517 mmol, 85.9 %). 
1
H NMR (500 MHz, CDCl3) δ 8.16 (d, J = 7.6, 1H), 7.74 (s, 1H), 7.49 (dd, J = 8.0, 1.1, 1H), 
7.46 – 7.40 (m, 2H), 7.33 (d, J = 1.0, 1H), 7.29 – 7.20 (m, 3H), 3.99 (s, 3H), 1.38 (s, 12H); 
13
C NMR (126 MHz, CDCl3) δ 151.36 (C), 150.61 (C), 146.98 (C), 129.97 (C), 129.41 (2x 
CH), 128.61 (CH), 125.68 (CH), 125.05 (C), 121.74 (2x CH), 117.30 (CH), 115.41 (CH), 
83.80 (2x C), 55.96 (CH3), 24.92 (4x CH3); MS (ES +ve) [M+H]
+




Synthesis of N-benzyl-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
(60*): 
 
To a solution of 4-Amino-3-methoxybenzeneboronic acid, pinacol ester (150 mg, 0.602 
mmol) in DCM (2 ml) was added triethylamine (1.2 eq., 0.722 mmol, 73.1 mg, 100.76 µl) 
followed by benzyl chloroformate (1.2 eq., 0.722 mmol, 123.2 mg, 103.07 µl) and the 
mixture allowed to stir for 18 hours. The product was concentrated in vacuo and purified by 
column chromatography (100% DCM), to give a light brown thick oil, (65.9 mg, 0.172 
mmol, 28.6 %). Only after characterisation was it discovered that the alkylated product 
(shown) had been produced instead. 
1
H NMR (600 MHz, CDCl3) δ 7.43 – 7.26 (m, 8H), 
6.68 (d, J = 7.6, 1H), 4.41 (s, 2H), 3.91 (s, 3H), 1.35 (s, 12H); 
13
C NMR (126 MHz, MeOD) 
δ 158.39 (C), 146.09 (C), 141.18 (C), 139.78 (C), 128.82 (CH), 128.08 (CH), 126.76 (CH), 
126.52 (CH), 114.34 (CH), 108.93 (CH), 83.13 (CH2), 54.55 (CH3), 46.58 (C), 23.73 (4x 







To a solution of 4-Amino-3-methoxybenzeneboronic acid, pinacol ester (150 mg, 0.602 
mmol) in DCM (2 ml) was added triethylamine (1.2 eq., 0.722 mmol, 73.1 mg, 100.76 µl) 
followed by phenylacetyl chloride (1.2 eq., 0.722 mmol, 111.2 mg, 95.1 µl) and the mixture 
allowed to stir for 18 hours. The mixture was concentrated in vacuo and purified by column 
191 
 
chromatography, MeOH/DCM (0-1.5 %) to give a cream solid, (200.9 mg, 0.547 mmol, 90.9 
%). 
1
H NMR (500 MHz, CDCl3) δ 8.40 (d, J = 8.0, 1H), 7.95 (s, 1H), 7.43 (ddd, J = 11.3, 
6.6, 1.6, 3H), 7.39 – 7.33 (m, 3H), 7.22 (d, J = 1.0, 1H), 3.78 (s, 5H), 1.35 (s, 12H); 
13
C 
NMR (126 MHz, CDCl3) δ 168.92 (C), 168.84 (C), 147.04 (C), 134.50 (C), 130.31 (C), 
129.61 (2x CH), 129.05 (2x CH), 128.51 (CH), 127.47 (CH), 118.43 (CH), 115.31 (CH), 
83.76 (C), 55.88 (CH3), 45.24 (CH2), 24.86 (4x CH3); MS (ES +ve) [M+H]
+






To a solution of 4-Amino-3-methoxybenzeneboronic acid, pinacol ester (150 mg, 0.602 
mmol) in DCM (2 ml) was added triethylamine (1.2 eq., 0.722 mmol, 73.1 mg, 100.76 µl) 
followed by hydrocinnamoyl chloride (1.2 eq., 0.722 mmol, 121.3 mg, 106.9 µl) and the 
mixture allowed to stir for 23 hours. The mixture was concentrated in vacuo and purified by 
column chromatography, MeOH/DCM (0-2 %) to give a brown solid, (240.0 mg, 0.629 
mmol, 100 %). 
1
H NMR (500 MHz, CDCl3) δ 8.44 (d, J = 8.0, 1H), 7.83 (s, 1H), 7.47 (d, J 
= 8.0, 1H), 7.35 – 7.30 (m, 2H), 7.28 – 7.21 (m, 4H), 3.90 (s, 3H), 3.14 – 3.04 (m, 2H), 2.79 
– 2.72 (m, 2H), 1.37 (s, 12H); 
13
C NMR (126 MHz, CDCl3) δ 170.25 (C), 170.17 (C), 
146.82 (C), 140.70 (C), 130.40 (C), 128.56 (CH), 128.52 (CH), 128.40 (CH), 126.34 (CH), 
118.68 (CH), 115.21 (CH), 83.78 (2x C), 55.84 (CH3), 39.72 (CH2), 31.42 (CH2), 24.87 (4x 
CH3); MS (ES +ve) [M+H]
+









To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5 ml/0.5 ml) was added N-
[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3,3-dimethyl-
butanamide (1.5 eq., 63.1 mg, 0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 
mmol) and triphenylphosphine (20 mol %, 9.5 mg) followed by palladium acetate (5 mol %)  
and the mixture heated in the microwave at 120 
o
C for 30 mins. The product was 
concentrated in vacuo and purified by column chromatography, MeOH/DCM (5-10% then 0-
30 drops of triethylamine per 100 ml) to give a sand coloured solid, (34.3 mg, 0.0675 mmol, 
56.0 %). 
1
H NMR (500 MHz, MeOD) δ 8.28 (s, 1H), 8.10 (d, J = 8.1, 1H), 7.35 (d, J = 1.8, 
1H), 7.28 (dd, J = 8.1, 1.8, 1H), 4.57 (t, J = 6.7, 2H), 3.99 (s, 3H), 3.15 (m, 2H), 2.95 (t, J = 
6.7, 2H), 2.39 (m, 9H), 2.15 (t, J = 11.0, 2H), 1.91 (d, J = 16.8, 2H), 1.49 (m, 2H), 1.14 (s, 
9H); 
13
C NMR (126 MHz, MeOD) δ 172.20 (C), 158.53 (C), 155.44 (CH), 154.22 (C), 
151.00 (C), 144.89 (C), 129.52 (C), 127.69 (C), 123.12 (CH), 120.22 (CH), 110.74 (CH), 
97.79 (C), 62.24 (CH), 56.24 (CH2), 55.08 (CH3), 52.23 (2x CH2), 49.79 (CH2), 44.04 (CH2), 
40.11 (2x CH3), 30.67 (C), 28.81 (3x CH3), 27.31 (2x CH2); MS (ES +ve) [M+H]
+
: 509.6; 
HRMS (ES +ve), C27H41N8O2 [M+H]
+









To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added 1-tert-
butyl-3-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea (1.5 eq., 
62.9 mg, 0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and 
triphenylphosphine (20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. The mixture was concentrated in 
vacuo and purified by column chromatography, MeOH/DCM (10% then 0-30 drops of NEt3 
per 100 ml) to give a light brown solid, (30.4 mg, 0.0597 mmol, 49.5 %). 
1
H NMR (500 
MHz, MeOD) δ 8.24 (s, 1H), 8.16 (d, J = 8.3, 1H), 7.25 (d, J = 1.8, 1H), 7.19 (dd, J = 8.3, 
1.9, 1H), 4.53 (t, J = 6.7, 2H), 3.96 (s, 3H), 3.12 (d, J = 11.9, 2H), 2.92 (t, J = 6.7, 2H), 2.36 
(m, 7H), 2.12 (t, J = 11.1, 2H), 1.87 (d, J = 12.5, 2H), 1.51 – 1.42 (m, 2H), 1.38 (s, 9H); 
13
C 
NMR (126 MHz, MeOD) δ 155.74 (C), 155.40 (CH), 154.09 (C), 148.52 (C), 145.33 (C), 
130.34 (C), 125.66 (C), 120.49 (CH), 118.66 (CH), 110.02 (CH), 97.73 (C), 62.27 (CH), 
56.23 (CH2), 55.02 (CH3), 52.22 (2x CH2), 49.71 (C), 43.97 (CH2), 40.07 (2x CH3), 28.15 
(3x CH3), 27.20 (2x CH2); MS (ES +ve) [M+H]
+
: 510.8; HRMS (ES +ve), C26H40N9O2 
(M+H)
+









To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5 ml/0.5 ml) was added 
phenyl N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (1.5 
eq., 66.8 mg, 0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and 
triphenylphosphine (20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. The mixture was concentrated in 
vacuo and the product purified by column chromatography, MeOH/DCM (10% then 0-30 
drops of NEt3 per 100 ml) to give a brown solid, (19.4 mg, 0.0473 mmol, 39.2 %). 
1
H NMR 
(600 MHz, MeOD) δ 8.25 (s, 1H), 7.16 (d, J = 1.8, 1H), 7.09 (dd, J = 7.9, 1.8, 1H), 6.91 (d, J 
= 7.9, 1H), 4.54 (t, J = 6.7, 2H), 3.95 (s, 3H), 3.14 (d, J = 12.0, 2H), 2.93 (t, J = 6.7, 2H), 
2.40 (m, 7H), 2.14 (t, J = 11.0, 2H), 1.90 (d, J = 12.3, 2H), 1.49 (d, J = 12.1, 2H); 
13
C NMR 
(126 MHz, MeOD) δ 158.62 (C), 155.35 (CH), 153.98 (C), 147.74 (C), 146.01 (C), 138.32 
(C), 121.70 (CH), 121.07 (C), 114.69 (CH), 110.25 (CH), 109.97 (C), 62.19 (CH2), 56.24 
(CH3), 54.74 (2x CH2), 52.29 (CH), 43.91 (CH2), 40.14 (2x CH3), 27.35 (2x CH2); MS (ES 
+ve) (M+H)
+
: 411.6; HRMS (ES +ve), C21H31N8O1 (M+H)
+











To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5 ml/0.5 ml) was added N-
benzyl-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.5 eq., 61.4 mg, 
0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and triphenylphosphine 
(20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the mixture heated in the 
microwave at 120 
o
C for 30 mins. The mixture was concentrated in vacuo without and 
purified by column chromatography, MeOH/DCM (10% then 5-20 drops of NEt3 per 100 
ml) to give a light brown coloured solid, (31.8 mg, 0.0584, 48.5 %). 
1
H NMR (400 MHz, 
MeOD) δ 8.24 (s, 1H), 7.40 (d, J = 7.5, 2H), 7.33 (t, J = 7.5, 2H), 7.24 (t, J = 7.3, 1H), 7.15 
(d, J = 1.8, 1H), 7.08 (dd, J = 8.1, 1.8, 1H), 6.67 (d, J = 8.1, 1H), 4.52 (t, J = 6.7, 2H), 4.47 
(s, 2H), 3.98 (s, 3H), 3.13 (d, J = 11.9, 2H), 2.92 (t, J = 6.7, 2H), 2.37 (s, 7H), 2.13 (t, J = 
11.0, 2H), 1.88 (d, J = 12.3, 2H), 1.47 (d, J = 8.5, 2H); 
13
C NMR (126 MHz, MeOD) δ 
166.23 (C), 158.62 (C), 155.34 (CH), 153.97 (C), 147.34 (C), 139.75 (C), 139.27 (C), 128.13 
(2x CH), 126.78 (2x CH), 126.58 (CH), 121.15 (CH), 119.94 (C), 109.78 (CH), 109.27 
(CH), 97.66 (C), 62.17 (CH), 56.20 (CH2), 54.81 (CH3), 52.22 (2x CH2), 46.71 (CH2), 43.89 
(CH2), 40.08 (2x CH3), 27.28 (2x CH2); MS (ES +ve) [M+H]
+
: 501.4; HRMS (ES +ve), 
C28H37N8O1 [M+H]
+








To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5 ml/0.5 ml) was added N-
[2-methoxy-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl]-2-phenyl-acetamide (1.5 eq., 
66.5 mg, 0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and 
triphenylphosphine (20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. The product was concentrated in 
vacuo and purified by column chromatography, MeOH/DCM (10% then 0-30 drops of 
triethylamine per 100 ml) to give a light brown solid, (37.9 mg, 0.0717 mmol, 59.5 %). 
1
H 
NMR (600 MHz, MeOD) δ 8.27 (s, 1H), 8.20 (d, J = 8.2, 1H), 7.40 (dt, J = 15.2, 7.5, 4H), 
7.32 (dd, J = 11.0, 4.4, 2H), 7.26 (dd, J = 8.2, 1.8, 1H), 4.56 (t, J = 6.7, 2H), 3.95 (s, 3H), 
3.83 (s, 2H), 3.13 (d, J = 11.8, 2H), 2.93 (t, J = 6.7, 2H), 2.34 (d, J = 13.6, 7H), 2.13 (t, J = 
11.0, 2H), 1.88 (d, J = 12.7, 2H), 1.47 (dt, J = 12.2, 8.6, 2H); 
13
C NMR (126 MHz, MeOD) 
δ 171.20 (C), 158.51 (C), 155.42 (CH), 154.17 (C), 150.35 (C), 144.81 (C), 135.19 (C), 
129.30 (C), 128.98 (2x CH), 128.38 (2x CH), 127.83 (C), 126.78 (CH), 122.00 (CH), 120.30 
(CH), 110.62 (CH), 97.77 (C), 62.25 (CH), 56.21 (CH2), 55.12 (CH3), 52.24 (2x CH2), 44.05 
(CH2), 43.30 (CH2), 40.09 (2x CH3), 27.29 (2x CH2); MS (ES +ve) [M+H]
+
: 529.6; HRMS 
(ES +ve), C29H37N8O2 [M+H]
+







To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5 ml/0.5 ml) was added N-
[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-phenyl-propanamide 
(1.5 eq., 69.0 mg, 0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and 
triphenylphosphine (20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. The product was concentrated in 
vacuo and purified by column chromatography, MeOH/DCM (10% then 0-30 drops of 
triethylamine per 100 ml) to give a light brown solid, (36.0 mg, 0.0664 mmol, 55.1 %). 
1
H 
NMR (600 MHz, MeOD) δ 8.27 (s, 1H), 8.13 (d, J = 8.1, 1H), 7.27 (d, J = 1.7, 5H), 7.26 
(dd, J = 8.2, 1.8, 1H), 7.21 (dd, J = 8.6, 4.4, 1H), 4.57 (t, J = 6.7, 2H), 3.95 (s, 3H), 3.15 (d, J 
= 11.8, 2H), 3.05 (m, 3H), 2.95 (t, J = 6.7, 2H), 2.81 (t, J = 7.7, 2H), 2.41 (s, 6H), 2.14 (t, J = 
11.0, 2H), 1.91 (d, J = 17.2, 3H), 1.49 (d, J = 8.7, 2H); 
13
C NMR (126 MHz, MeOD) δ 
172.65 (C), 158.53 (CH), 155.44 (C), 154.18 (C), 150.64 (C), 144.88 (C), 140.73 (C), 129.32 
(C), 128.15 (CH), 127.76 (C), 125.85 (CH), 122.70 (CH), 120.20 (CH), 110.65 (CH), 97.77 
(CH), 62.38 (C), 56.18 (CH2), 55.06 (CH3), 52.14 (2x CH2), 46.33 (CH2), 44.04 (CH2), 39.99 
(2x CH3), 38.18 (CH2), 31.38 (CH2), 27.17 (2x CH2); MS (ES +ve) [M+H]
+
: 543.6; HRMS 
(ES +ve), C30H39N8O2 [M+H]
+










To a solution of 4-Amino-3-methoxybenzeneboronic acid, pinacol ester (150 mg, 0.602 
mmol) in DCM (5 ml) was added triethylamine (3 eq., 1.806 mmol, 182.7 mg, 251.9 µl) 
followed by 2-(bromomethyl)pyridine hydrobromide (2.4 eq., 1.44 mmol, 362.2 mg) and the 
mixture allowed to stir for 72 hours. Water and DCM were added and the organic layer 
separated, dried over MgSO4 and concentrated in vacuo.  The product was purified by 
column chromatography, EtOAc/Hexane (20 %), to give a dark brown solid, (86.2 mg, 0.253 
mmol, 42.1 %). 
1
H NMR (500 MHz, CDCl3) δ 8.59 (d, J = 4.2, 1H), 7.68 (d, J = 7.6, 1H), 
7.37 (d, J = 7.9, 1H), 7.31 (dd, J = 7.8, 1.2, 1H), 7.23 (d, J = 6.8, 1H), 7.18 (d, J = 1.1, 1H), 
6.79 (d, J = 8.0, 1H), 6.50 (d, J = 7.8, 1H), 4.60 (s, 2H), 3.92 (s, 3H), 1.31 (s, 12H); 
13
C 
NMR (126 MHz, CDCl3) δ 158.33 (C), 148.11 (CH), 147.04 (C), 146.18 (C), 140.29 (C), 
137.81 (CH), 129.23 (CH), 122.39 (CH), 121.24 (CH), 114.68 (CH), 109.22 (CH), 83.30 







To a solution of 4-Amino-3-methoxybenzeneboronic acid, pinacol ester (150 mg, 0.602 
mmol) in THF (5 ml) was added triethylamine (6 eq., 3.612 mmol, 365.4.7 mg, 503.8 µl) 
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followed by 3-(bromomethyl)pyridine hydrobromide (2.4 eq., 1.444 mmol, 362.2 mg) and 
the mixture heated to 180
o
C in the microwave for 4 hours. Water and DCM were added and 
the organic layer separated, dried over MgSO4 and concentrated in vacuo. The product was 
purified by column chromatography, EtOAc/Hexane (20-50 %) to give a dark brown solid, 
(80.9 mg, 0.238 mmol, 39.5 %). 
1
H NMR (500 MHz, CDCl3) δ 8.63 (d, J = 1.6, 1H), 8.53 
(dd, J = 4.9, 1.5, 1H), 7.75 (d, J = 8.2, 1H), 7.36 – 7.29 (m, 2H), 7.19 (d, J = 1.1, 1H), 6.51 
(d, J = 7.8, 1H), 4.93 (s, 1H), 4.43 (d, J = 11.7, 2H), 3.90 (s, 3H), 1.33 (s, 12H); 
13
C NMR 
(126 MHz, CDCl3) δ 148.03 (CH), 147.60 (CH), 146.06 (C), 140.12 (C), 136.07 (CH), 
135.46 (C), 129.22 (CH), 123.90 (CH), 114.76 (CH), 109.13 (CH), 83.36 (C), 55.59 (CH3), 
44.96 (CH2), 29.71 (), 24.84 (4x CH3); MS (ES +ve) (M+H)
+





To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was 2-methoxy-
N-(2-pyridylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1 eq., 41 mg, 
0.1205 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and triphenylphosphine 
(20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the mixture heated in the 
microwave at 120 
o
C for 30 mins. The mixture was concentrated in vacuo and purified by 
column chromatography, MeOH/DCM (10 % then 10-30 drops of NEt3 per 100 ml) to give a 
sand coloured solid, (37 mg, 0.0738 mmol, 61.3 %). 
1
H NMR (500 MHz, MeOD) δ 8.50 (d, 
J = 4.2, 1H), 8.21 (s, 1H), 7.77 (dd, J = 7.7, 6.0, 1H), 7.46 (d, J = 7.9, 1H), 7.29 (d, J = 5.3, 
1H), 7.14 (d, J = 1.8, 1H), 7.05 (dd, J = 8.1, 1.9, 1H), 6.58 (d, J = 8.1, 1H), 4.55 (s, 2H), 4.49 
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(t, J = 6.6, 2H), 3.96 (s, 3H), 3.12 (d, J = 12.5, 2H), 2.90 (t, J = 6.6, 2H), 2.64 – 2.58 (m, 
1H), 2.50 (s, 6H), 2.12 (t, J = 11.0, 2H), 1.90 (s, 2H), 1.49 (d, J = 8.4, 2H); 
13
C NMR (126 
MHz, MeOD) δ 159.35 (C), 158.62 (C), 155.36 (CH), 154.03 (C), 148.39 (CH), 147.49 (C), 
146.03 (C), 138.91 (C), 137.40 (CH), 122.27 (CH), 121.57 (CH), 121.15 (CH), 120.38 (C), 
109.62 (CH), 109.42 (CH), 97.64 (C), 62.72 (CH), 56.04 (CH2), 54.85 (CH3), 51.85 (2x 
CH2), 47.48 (CH2), 43.92 (CH2), 39.73 (2x CH3), 26.86 (2x CH2); MS (ES +ve) [M+H]
+
: 
502.2; HRMS (ES +ve), C27H36N9O1 [M+H]
+





To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was 2-methoxy-
N-(3-pyridylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.5 eq., 61.6 
mg, 0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and 
triphenylphosphine (20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. The mixture was concentrated in 
vacuo and purified by column chromatography, MeOH/DCM (10 % then 0-25 drops of NEt3 
per 100 ml), to give a light brown solid, (41.6 mg, 0.083 mmol, 68.9 %). 
1
H NMR (500 
MHz, MeOD) δ 8.57 (s, 1H), 8.42 (d, J = 3.4, 1H), 8.23 (s, 1H), 7.87 (d, J = 7.9, 1H), 7.41 
(dd, J = 7.9, 4.9, 1H), 7.16 (d, J = 1.8, 1H), 7.08 (dd, J = 8.1, 1.9, 1H), 6.65 (d, J = 8.1, 1H), 
4.55 (s, 2H), 4.51 (t, J = 6.6, 2H), 3.97 (s, 3H), 3.13 (d, J = 7.3, 2H), 2.92 (t, J = 6.6, 2H), 
2.59 (s, 1H), 2.50 (s, 6H), 2.14 (t, J = 11.0, 2H), 1.91 (d, J = 9.2, 2H), 1.50 (d, J = 8.5, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.61 (C), 155.36 (CH), 154.02 (C), 147.77 (CH), 147.48 
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(C), 147.18 (CH), 146.00 (C), 138.73 (C), 136.44 (C), 135.79 (CH), 123.80 (CH), 121.13 
(CH), 120.43 (C), 109.71 (CH), 109.45 (CH), 97.64 (C), 62.71 (CH), 55.96 (CH2), 54.84 
(CH3), 51.85 (2x CH2), 43.95 (CH2), 43.92 (CH2), 39.71 (2x CH3), 26.84 (2x CH2); MS (ES 
+ve) [M+H]
+
: 502.4; HRMS (ES +ve), C27H36N9O1 [M+H]
+
: calculated 502.30373, found 
502.30140. 
 
10.6.4 Synthesis of Compounds 73-95 
Synthesis of tert-butyl N-(4-bromo-2-hydroxy-phenyl)carbamate (73): 
 
2-amino-5-bromophenol (250 mg, 1.34 mmol) was suspended in DCM (5 ml). Di-
tertbutyldicarbonate (1 eq., 1.34 mmol, 292.2 mg) was added followed by a small spatula of 
DMAP and the reaction allowed to stir for 18 hours. Water was added and the organic layer 
separated, dried over MgSO4 and concentrated in vacuo. The product was purified by 
column chromatography, EtOAc/Hexane (0-20 %) to give a cream solid, (177.3 mg, 0.618 
mmol, 46.1 %). 
1
H NMR (500 MHz, MeOD) δ 7.63 (d, J = 8.4, 1H), 6.97 (d, J = 2.2, 1H), 
6.93 (dd, J = 8.6, 2.2, 1H), 1.54 (s, 9H); 
13
C NMR (126 MHz, MeOD) δ 153.72 (C), 147.85 
(C), 126.01 (C), 121.88 (CH), 120.93 (CH), 117.43 (CH), 84.51 (C), 80.08 (C), 27.19 (3x 











Synthesis of tert-butyl N-[2-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]carbamate (74): 
 
To a solution of tert-butyl N-(4-bromo-2-hydroxy-phenyl)carbamate (50 mg, 0.174 mmol) in 
dioxane/water (4.5/0.5 ml) was added bis(pinacolato)diboron (1.5 eq., 66.4 mg, 0.261 
mmol), potassium carbonate (1.5 eq., 36.1 mg, 0.261 mmol) and triphenylphosphine (20 mol 
%, 13.7 mg) followed by palladium acetate (5 mol %) and the mixture heated in the 
microwave at 120 
o
C for 30 mins. EtOAc and water were added to the mixture and the 
organic layer separated, dried over MgSO4 and concentrated in vacuo. The product was 
purified by column chromatography, EtOAc/Hexane (0-20%) to give a white solid (26.4 mg, 
0.0788 mmol, 22.6 %). The reaction was repeated to give a second batch of product. 
1
H 
NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 7.33 – 7.28 (m, 2H), 6.78 (s, 1H), 1.52 (s, 9H), 
1.34 (d, J = 10.2, 12H); 
13
C NMR (126 MHz, CDCl3) δ 154.27 (C), 145.75 (C), 128.66 (C), 
127.70 (CH), 124.11 (CH), 119.94 (CH), 119.84 (C), 83.76 (C), 81.86 (C), 28.27 (3x CH3), 











Synthesis of tert-butyl N-[4-[4-amino-1-[2-[4-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-hydroxy-phenyl]carbamate (75):  
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (42.7 mg, 0.103 mmol) in dioxane/water (4.5/0.5 ml) was added tert-
butyl N-[2-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (1 eq., 
34.4 mg, 0.103 mmol, limiting reagent), potassium carbonate (1.5 eq., 21.3 mg, 0.154 mmol) 
and triphenylphosphine (20 mol %, 8.1 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. MS showed the reaction was 
complete. The product was purified by column chromatography, MeOH/DCM (10 % then 
10-40 drops of NEt3 per 100 ml) to give a light brown/grey solid, (27.1 mg, 0.0546 mmol, 
53.0 %). 
1
H NMR (500 MHz, MeOD) δ 8.26 (s, 1H), 7.95 (d, J = 8.1, 1H), 7.17 (d, J = 1.9, 
1H), 7.14 (dd, J = 8.2, 1.9, 1H), 4.60 – 4.52 (m, 2H), 3.14 (m, 2H), 3.01 – 2.90 (m, 2H), 2.36 
(m, 7H), 2.14 (t, J = 12.0, 2H), 1.88 (m, 2H), 1.57 (s, 9H), 1.47 (m, 2H); 
13
C NMR (126 
MHz, MeOD) δ 158.53 (C), 155.40 (CH), 147.42 (C), 145.04 (C), 144.84 (C), 144.67 (C), 
141.18 (C), 127.83 (C), 126.66 (C), 120.09 (CH), 119.29 (CH), 114.47 (CH), 110.24 (C), 
97.09 (C), 62.20 (CH), 56.22 (CH2), 52.27 (2x CH2), 44.00 (CH2), 40.14 (2x CH3), 27.37 (2x 
CH2), 27.22 (3x CH3); MS (ES +ve) (M+H)
+
: 497.4; HRMS (ES +ve), C25H37N8O3 (M+H)
+
: 






Synthesis of tert-butyl N-[4-[4-amino-1-[2-[4-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]carbamate (76): 
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added 3-
(boc-amino)benzeneboronic acid (1.5 eq., 42.9 mg, 0.181 mmol), potassium carbonate (1.5 
eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 mg) followed by 
palladium acetate (5 mol %) and the mixture heated in the microwave at 120 
o
C for 30 mins. 
The mixture was concentrated in vacuo and purified by column chromatography, 
MeOH/DCM (10% then 0-30 drops NEt3 per 100 ml) to give a light brown coloured solid, 
(26.0 mg, 0.0541 mmol, 44.9 %). 
1
H NMR (500 MHz, MeOD) δ 8.24 (s, 1H), 7.65 – 7.57 
(m, 4H), 4.53 (t, J = 6.6, 2H), 3.12 (d, J = 12.0, 2H), 2.92 (t, J = 6.6, 2H), 2.41 (m, 7H), 2.12 
(t, J = 11.0, 2H), 1.88 (d, J = 14.4, 2H), 1.54 (s, 9H), 1.47 (m, 2H); 
13
C NMR (126 MHz, 
MeOD) δ 158.54 (C), 155.40 (CH), 154.15 (C), 153.74 (C), 144.96 (C), 140.47 (C), 128.68 
(2x CH), 126.62 (C), 118.79 (2x CH), 97.74 (C), 79.76 (C), 62.43 (CH), 56.15 (CH2), 52.09 
(2x CH2), 43.99 (CH2), 39.95 (2x CH3), 27.27 (3x CH3), 27.13 (2x CH2); MS (ES +ve) 
[M+H]
+
: 481.6; HRMS (ES +ve), C25H37N8O2 [M+H]
+








Synthesis of tert-butyl N-[3-[4-amino-1-[2-[4-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]carbamate (77): 
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added 3-
(boc-amino)benzeneboronic acid (1.5 eq., 42.9 mg, 0.181 mmol), potassium carbonate (1.5 
eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 mg) followed by 
palladium acetate (5 mol %) and the mixture heated in the microwave at 120 
o
C for 30 mins. 
The mixture was concentrated in vacuo and purified by column chromatography, 
MeOH/DCM (10% then 0-30 drops NEt3 per 100 ml) to give a cream solid, (28.0 mg, 0.0583 
mmol, 48.4 %). 
1
H NMR (500 MHz, MeOD) δ 8.27 (s, 1H), 7.88 (s, 1H), 7.50 – 7.44 (m, 
2H), 7.37 (d, J = 7.0, 1H), 4.57 (t, J = 6.7, 2H), 3.16 – 3.10 (m, 2H), 2.95 (t, J = 6.7, 2H), 
2.35 (m, 7H), 2.14 (t, J = 11.0, 2H), 1.88 (d, J = 12.7, 2H), 1.56 (s, 9H), 1.47 (m, 2H); 
13
C 
NMR (126 MHz, MeOD) δ 158.42 (C), 155.37 (CH), 154.22 (C), 154.00 (C), 144.97 (C), 
140.14 (C), 133.30 (C), 129.46 (CH), 122.27 (CH), 119.16 (CH), 118.54 (CH), 97.74 (C), 
79.72 (C), 62.16 (CH), 56.21 (CH2), 52.29 (2x CH2), 44.06 (CH2), 40.16 (2x CH3), 27.38 (2x 
CH2), 27.28 (3x CH3); MS (ES +ve) [M+H]
+
: 481.4; HRMS (ES +ve), C25H37N8O2 [M+H]
+
: 






Synthesis of tert-butyl N-[5-[4-amino-1-[2-[4-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-pyridyl]carbamate (78): 
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added (6-
((tert-Butoxycarbonyl)amino)pyridin-3-yl)boronic acid (1.5 eq., 43.1 mg, 0.181 mmol), 
potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 
mg) followed by palladium acetate (5 mol %) and the mixture heated in the microwave at 
120 
o
C for 30 mins. The mixture was concentrated in vacuo and purified by column 
chromatography, MeOH/DCM (10 % then 10-30 drops of NEt3 per 100 ml) to give a white 
solid, (23.8 mg, 0.0495 mmol, 41.0 %). 
1
H NMR (500 MHz, MeOD) δ 8.55 – 8.51 (m, 1H), 
8.26 (s, 1H), 8.06 – 8.01 (m, 2H), 4.55 (t, J = 6.5, 2H), 3.14 (d, J = 12.0, 2H), 2.94 (t, J = 
6.5, 2H), 2.68 (m, 1H), 2.55 (s, 6H), 2.14 (t, J = 11.0, 2H), 1.92 (d, J = 12.7, 2H), 1.55 (s, 
9H), 1.53 – 1.46 (m, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.58 (C), 155.47 (CH), 154.40 
(C), 153.05 (C), 152.96 (C), 147.13 (CH), 141.83 (C), 137.78 (CH), 123.46 (C), 112.28 
(CH), 97.92 (C), 80.49 (C), 62.79 (CH), 56.00 (CH2), 51.78 (2x CH2), 44.12 (CH2), 39.64 
(2x CH3), 27.16 (3x CH3), 26.76 (2x CH2); MS (ES +ve) [M+H]
+
: 481.8; HRMS (ES +ve), 
C24H36N9O2 [M+H]
+







Synthesis of tert-butyl 5-[4-amino-1-[2-[4-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]indole-1-carboxylate (79): 
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added 1-Boc-
indole-5-boronic acid pinacol ester (1.5 eq., 62.1 mg, 0.181 mmol), potassium carbonate (1.5 
eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 mg) followed by 
palladium acetate (5 mol %) and the mixture heated in the microwave at 120 
o
C for 30 mins. 
The mixture was concentrated in vacuo and purified by column chromatography, 
MeOH/DCM (10 % then 10-30 drops of NEt3 per 100 ml) to give a light cream solid, (31.2 
mg, 0.0619 mmol, 51.3 %). 
1
H NMR (500 MHz, MeOD) δ 8.35 (d, J = 8.5, 1H), 8.29 (s, 
1H), 7.92 (d, J = 1.3, 1H), 7.76 (d, J = 3.7, 1H), 7.65 (dd, J = 8.5, 1.7, 1H), 6.77 (d, J = 3.5, 
1H), 4.58 (t, J = 6.6, 2H), 3.16 (d, J = 11.9, 2H), 2.97 (t, J = 6.6, 2H), 2.43 (s, 7H), 2.16 (t, J 
= 11.0, 2H), 1.91 (d, J = 12.7, 2H), 1.73 (s, 9H), 1.50 (td, J = 12.1, 8.5, 2H); 
13
C NMR (126 
MHz, MeOD) δ 158.56 (C), 155.44 (CH), 154.16 (C), 149.49 (C), 145.58 (C), 135.55 (C), 
131.29 (C), 127.17 (C), 126.91 (CH), 124.19 (CH), 120.88 (CH), 115.42 (CH), 107.14 (CH), 
97.90 (C), 84.04 (C), 62.38 (CH), 56.19 (CH2), 52.15 (2x CH2), 44.02 (CH2), 40.00 (2x 
CH3), 27.19 (2x CH2), 26.95 (3x CH3); MS (ES +ve) [M+H]
+
: 505.0.0; HRMS (ES +ve), 
C27H37N8O2 [M+H]
+






Synthesis of [3-(tert-butoxycarbonylamino)-4-methoxy-phenyl]boronic acid (80): 
 
(3-Amino-4-methoxyphenyl)boronic acid (150 mg, 0.898 mmol) was suspended in DCM (5 
ml). Di-tertbutyldicarbonate (1.5 eq., 1.347 mmol, 294.0 mg) was added followed by a small 
spatula of DMAP and the reaction allowed to stir for 18 hours. Water was added to the 
mixture and the organic layer separated, dried over MgSO4 and concentrated in vacuo. The 
product was purified by column chromatography, MeOH/DCM (0-4 %) to give a dark brown 
solid (189.9 mg, 0.711 mmol, 79.2 %). 
1
H NMR (500 MHz, MeOD) δ 8.12 (s, 1H), 7.34 
(dd, J = 8.2, 1.5, 1H), 6.98 (d, J = 8.2, 1H), 3.88 (s, J = 4.9, 3H), 1.53 (s, 9H); 
13
C NMR (126 
MHz, MeOD) δ 153.77 (C), 150.52 (C), 129.82 (CH), 129.49 (CH), 126.76 (C), 125.18 (C), 




Synthesis of tert-butyl N-[5-[4-amino-1-[2-[4-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxy-phenyl]carbamate (81): 
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added [3-
(tert-butoxycarbonylamino)-4-methoxy-phenyl]boronic acid (1.5 eq., 48.4 mg, 0.181 mmol), 
potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 





C for 30 mins. The mixture was concentrated in vacuo and purified by column 
chromatography, MeOH/DCM (0-10 % then 0-20 drops of NEt3 per 100 ml) to give a light 
brown solid, (32.9 mg, 0.0645 mmol, 53.5 %). 
1
H NMR (500 MHz, MeOD) δ 8.26 (d, J = 
5.2, 1H), 8.19 (d, J = 2.1, 1H), 7.41 (dd, J = 8.4, 2.2, 1H), 7.19 (d, J = 8.5, 1H), 4.56 (t, J = 
6.6, 2H), 3.99 (d, J = 5.1, 3H), 3.15 (d, J = 12.1, 2H), 2.96 (t, J = 6.6, 2H), 2.54 (m, 1H), 2.48 
(s, 6H), 2.16 (t, J = 10.9, 2H), 1.92 (d, J = 10.5, 2H), 1.56 (d, J = 5.1, 9H), 1.55 – 1.46 (m, 
2H); 
13
C NMR (126 MHz, MeOD) δ 158.48 (C), 155.35 (CH), 154.20 (C), 153.82 (C), 
149.93 (C), 145.03 (C), 128.25 (C), 124.95 (C), 123.27 (CH), 119.69 (CH), 111.00 (CH), 
97.67 (C), 80.15 (C), 62.52 (CH), 56.07 (CH2), 55.11 (CH3), 51.99 (2x CH2), 44.01 (CH2), 
39.86 (2x CH3), 27.22 (3x CH3), 27.03 (2x CH2); MS (ES +ve) [M+H]
+
: 511.4; HRMS (ES 
+ve), C26H39N8O3 [M+H]
+
: calculated 511.31396, found 511.31660. 
 
Synthesis of tert-butyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]acetate (82): 
 
2-(4-Bromo-2-methoxyphenyl)acetic acid (2 g, 8.198 mmol) was dissolved in 20 ml of dry 
THF. Thionyl chloride (1.2 eq., 9.837 mmol, 1.17 g, 0.714 ml) was added followed by a drop 
of DMF and the reaction heated to reflux (80
o
C) for 2 hours. The reaction was cooled to r.t. 
then t-butylalcohol (5 eq., 40.99 mmol, 3.04 g, 3.92 ml) and triethylamine (2.5 eq., 20.49 
mmol, 2.86 ml) added and the mixture left to stir for 20 hours. Water and EtOAc were added 
to the mixture and the organic layer separated, dried over MgSO4 and concentrated in vacuo. 
The product was purified by column chromatography, EtOAC/Hexane (0-4%) to give a light 
orange liquid, (694.8 mg, 2.316 mmol, 28.2 %). 
1
H NMR (500 MHz, MeOD) δ 7.10 (s, 1H), 
7.07 – 7.02 (m, 2H), 3.81 s, 3H), 3.47 (s, 2H), 1.42 (s, 9H); 
13
C NMR (126 MHz, MeOD) δ 
171.39 (C), 158.43 (C), 131.77 (CH), 122.99 (C), 122.98 (CH), 121.02 (C), 113.67 (CH), 







Synthesis of tert-butyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]acetate (83): 
 
To a solution of tert-butyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]acetate (600 mg, 2.0 mmol) in dioxane/water (18/2 ml) was added 
bis(pinacolato)diboron (1.5 eq., 762.6 mg, 3.0 mmol), potassium carbonate (1.5 eq., 414.6 
mg, 3.0 mmol) and triphenylphosphine (20 mol %, 104.9 mg) followed by palladium acetate 
(5 mol %, 22.5 mg) and the mixture heated in the microwave at 120 
o
C for an hour. MS 
showed a little SM so the mixture was heated for another hour. MS and TLC showed the 
reaction was complete. EtOAc and water were added to the mixture and the organic layer 
separated, dried over MgSO4 and concentrated in vacuo. The product was purified by 
column chromatography, EtOAc/Hexane (0-10%) to give a colourless oil, (322.4 mg, 0.926 
mmol, 46.3 %). 
1
H NMR (500 MHz, CDCl3) δ 7.37 (d, J = 8.0, 1H), 7.26 (d, J = 3.0, 1H), 
7.18 (d, J = 7.3, 1H), 3.86 (s, 3H), 3.54 (s, 2H), 1.42 (s, 9H), 1.34 (s, 12H); 
13
C NMR (126 
MHz, CDCl3) δ 170.96 (C), 157.02 (C), 130.25 (CH), 127.29 (C), 127.28 (CH), 115.89 
(CH), 109.97 (C), 83.75 (C), 80.34 (C), 55.46 (CH3), 37.58 (CH2), 28.03 (3x CH3), 24.85 (4x 












Synthesis of tert-butyl 2-[4-[4-amino-1-[2-[4-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxy-phenyl]acetate (84): 
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (34.7 mg, 0.0836 mmol) in dioxane/water (4.5/0.5 ml) was added tert-
butyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate (1 eq., 
29.1 mg, 0.0836 mmol), potassium carbonate (1.5 eq., 17.3 mg, 0.125 mmol) and 
triphenylphosphine (20 mol %, 4.4 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. The mixture was concentrated in 
vacuo and purified by column chromatography, MeOH/DCM (0-10 % then 0-30 drops of 
NEt3 per 100 ml) to give a cream solid, (19 mg, 0.0373 mmol, 44.6 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.26 (s, 1H), 7.35 (d, J = 7.6, 1H), 7.26 (d, J = 1.4, 1H), 7.22 (dd, J = 7.5, 1.6, 1H), 
4.56 (t, J = 6.7, 2H), 3.91 (s, 3H), 3.64 (s, 2H), 3.13 (d, J = 11.9, 2H), 2.94 (t, J = 6.7, 2H), 
2.37 (m, 7H), 2.13 (t, J = 11.0, 2H), 1.91 – 1.85 (m, 2H), 1.48 (m, 11H); 
13
C NMR (126 
MHz, MeOD) δ 172.07 (C), 158.55 (C), 158.18 (C), 155.46 (CH), 154.14 (C), 145.09 (C), 
133.02 (C), 131.48 (CH), 124.76 (C), 120.21 (CH), 110.45 (CH), 97.82 (C), 80.76 (C), 62.26 
(CH), 56.22 (CH2), 54.70 (CH3), 52.24 (2x CH2), 44.04 (CH2), 40.09 (2x CH3), 36.61 (CH2), 
27.28 (2x CH2), 26.90 (3x CH3); MS (ES +ve) [M+H]
+
: 510.2; HRMS (ES +ve), 
C27H40N7O3 [M+H]
+






Synthesis of tert-butyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate 
(85): 
 
4-(Carboxymethyl)phenylboronic acid pinacol ester (150 mg, 0.572 mmol) was dissolved in 
5 ml of dry toluene. Thionyl chloride (1.2 eq., 0.686 mmol, 81.6 mg, 49.8 ul) was added 
followed by a drop of DMF and the reaction heated to reflux (120
o
C) for 2 hours. The 
reaction was cooled to r.t. then t-butylalcohol (5 eq., 2.86 mmol, 211.8 mg, 0.273 ml) and 
triethylamine (2.5 eq., 1.43 mmol, 199.3 ul) added and the mixture allowed to stir for 18 
hours. Water and DCM were added to the mixture and the organic layer separated, dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography, (100 % DCM), to give a light brown oil, (60 mg, 0.189 mmol, 33.0 %). MS 
(ES +ve) (M+H)
+
: 340.8 (+Na) 
 





To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added tert-
butyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate (1.5 eq., 57.6 mg, 
0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and triphenylphosphine 
(20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the mixture heated in the 
microwave at 120 
o
C for 30 mins. The mixture was concentrated in vacuo and purified by 
column chromatography, MeOH/DCM (10 % then 0-30 drops of NEt3 per 100 ml) to give a 
light brown thick oil, (40.5 mg, 0.0845 mmol, 70.1 %). 
1
H NMR (500 MHz, MeOD) δ 8.26 
(s, 1H), 7.68 – 7.63 (m, 2H), 7.47 (d, J = 8.2, 2H), 4.55 (t, J = 6.6, 2H), 3.68 (s, 2H), 3.12 (d, 
J = 11.9, 2H), 2.93 (t, J = 6.6, 2H), 2.43 (m, 7H), 2.13 (t, J = 11.0, 2H), 1.87 (m, 2H), 1.47 
(m, 11H); 
13
C NMR (126 MHz, MeOD) δ 171.52 (C), 158.52 (C), 155.44 (CH), 154.21 (C), 
144.85 (C), 136.00 (C), 131.41 (C), 129.95 (2x  CH), 128.45 (2x CH), 97.81 (C), 81.01 (C), 
62.40 (CH), 56.15 (CH2), 52.10 (2x CH2), 44.04 (CH2), 41.58 (CH2), 39.95 (2x CH3), 27.13 
(2x CH2), 26.88 (3x CH3); MS (ES +ve) [M+H]
+
: 480.0; HRMS (ES +ve), C26H38N7O2 
[M+H]
+
: calculated 480.30815, found 480.31210. 
 
Synthesis of 2-[4-[4-amino-1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]pyrazolo[3,4-
d]pyrimidin-3-yl]phenyl]acetic acid (87): 
 
To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added 4-
(Carboxymethyl)phenylboronic acid pinacol ester (1.5 eq., 47.4 mg, 0.181 mmol), potassium 
carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 mg) 
214 
 
followed by palladium acetate (5 mol %) and the mixture heated in the microwave at 120 
o
C 
for 30 mins. The mixture was concentrated in vacuo and purified by column 
chromatography, MeOH/DCM (10 % then 0-50 drops of NEt3 per 100 ml) to give a cream 
solid, (25.0 mg, 0.0591 mmol, 49.0 %). 
1
H NMR (500 MHz, MeOD) δ 8.26 (s, 1H), 7.59 (d, 
J = 8.2, 2H), 7.49 (d, J = 8.2, 2H), 4.55 (t, J = 6.3, 2H), 3.62 (s, 2H), 3.20 – 3.15 (m, 2H), 
2.98 (t, J = 6.3, 3H), 2.74 (s, 6H), 2.18 (t, J = 11.0, 2H), 2.03 – 1.96 (m, 2H), 1.56 (dd, J = 
12.1, 3.9, 2H); 
13
C NMR (126 MHz, MeOD) δ 177.81 (C), 158.57 (C), 155.42 (CH), 154.16 
(C), 145.31 (C), 139.11 (C), 130.29 (C), 129.88 (2x CH), 128.10 (2x CH), 97.82 (C), 63.29 
(CH2), 55.78 (CH2), 51.37 (2x CH2), 44.08 (CH2), 39.26 (2x CH3), 29.53 (CH), 26.34 (2x 
CH2); MS (ES +ve) [M+H]
+
: 424.4; HRMS (ES +ve), C22H30N7O2 [M+H]
+
: calculated 
424.24555, found 424.2475. 
 
Synthesis of 2-(4-bromo-2-methoxy-phenyl)-1-pyrrolidin-1-yl-ethanone (88): 
 
2-(4-Bromo-2-methoxyphenyl)acetic acid (300 mg, 1.229 mmol) was dissolved in 5 ml of 
dry toluene. Thionyl chloride (1.2 eq., 1.476 mmol, 175.6 mg, 107.0 ul) was added followed 
by a drop of DMF and the reaction heated to reflux (120
o
C) for 1.5 hours. The reaction was 
cooled to r.t. then pyrrolidine (2.5 eq., 3.073 mmol, 218.6 mg, 0.257 ml) and triethylamine 
(2.5 eq., 3.073 mmol, 0.428 ml) added and the reaction left to stir for 18 hours. Water and 
DCM were added to the mixture and the organic layer, separated, dried over MgSO4 and 
concentrated in vacuo. The product was purified by column chromatography, EtOAc/hexane 
(20-60 %), to give a cream coloured solid, (238.7 mg, 0.804 mmol, 65.4 %). 
1
H NMR (500 
MHz, CDCl3) δ 7.10 (d, J = 8.0, 1H), 7.05 (dd, J = 8.0, 1.8, 1H), 6.98 (d, J = 1.8, 1H), 3.81 
(s, 3H), 3.56 (s, 2H), 3.46 (m, 4H), 1.87 (m, 4H); 
13
C NMR (126 MHz, CDCl3) δ 169.26 
(C), 157.78 (C), 131.58 (CH), 123.69 (CH), 123.05 (C), 121.10 (C), 114.00 (CH), 55.76 
(CH3), 46.72 (CH2), 45.91 (CH2), 35.37 (CH2), 26.16 (CH2), 24.39 (CH2); MS (ES +ve) 
(M+H)
+







To a solution of 2-(4-bromo-2-methoxy-phenyl)-1-pyrrolidin-1-yl-ethanone (150 mg, 0.505 
mmol) in dioxane/water (4.5/0.5 ml) was added bis(pinacolato)diboron (1.5 eq., 192.5 mg, 
0.758 mmol), potassium carbonate (1.5 eq., 104.8 mg, 0.758 mmol) and triphenylphosphine 
(20 mol %, 26.5 mg) followed by palladium acetate (5 mol %) and the mixture heated in the 
microwave at 120 
o
C for an hour. Water and DCM were added to the mixture and the organic 
layer, separated, dried over MgSO4 and concentrated in vacuo. The product was purified by 
column chromatography, EtOAc/hexane (20-80 %) to give a pale yellow oil, (85.6 mg, 0.248 
mmol, 49.1 %). 
1
H NMR (500 MHz, CDCl3) δ 7.40 (dd, J = 7.4, 0.9, 1H), 7.31 – 7.27 (m, 
2H), 3.88 (s, 3H), 3.69 (d, J = 5.0, 2H), 3.53 – 3.39 (m, 4H), 1.92 – 1.84 (m, 4H), 1.36 (s, 
12H); 
13
C NMR (126 MHz, CDCl3) δ 169.83 (C), 156.58 (C), 132.95 (C), 129.61 (CH), 
127.54 (CH), 127.19 (C), 115.86 (CH), 83.77 (C), 55.52 (CH3), 46.71 (CH2), 45.87 (CH2), 
















To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added 2-[2-
methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-pyrrolidin-1-yl-ethanone 
(1.5 eq., 62.5 mg, 0.181 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and 
triphenylphosphine (20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. The mixture was concentrated in 
vacuo and purified by column chromatography, MeOH/DCM (10 % then 0-30 drops of NEt3 
per 100 ml) to give a white solid, (34.6 mg, 0.0683 mmol, 56.7 %). 
1
H NMR (500 MHz, 
MeOD) δ 8.25 (s, 1H), 7.33 (d, J = 7.6, 1H), 7.23 (s, 1H), 7.21 (dd, J = 7.5, 1.6, 1H), 4.54 (t, 
J = 6.7, 2H), 3.89 (s, 3H), 3.74 (s, 2H), 3.64 (t, J = 6.8, 2H), 3.46 (t, J = 6.9, 2H), 3.11 (d, J = 
11.9, 2H), 2.92 (t, J = 6.7, 2H), 2.34 (m, 7H), 2.12 (t, J = 10.9, 2H), 2.02 (dd, J = 13.3, 6.7, 
2H), 1.96 – 1.90 (m, 2H), 1.86 (d, J = 12.7, 2H), 1.46 (m, 2H); 
13
C NMR (126 MHz, MeOD) 
δ 170.77 (C), 158.57 (C), 158.03 (C), 155.45 (CH), 154.13 (C), 145.18 (C), 132.80 (C), 
131.39 (CH), 125.01 (C), 120.32 (CH), 110.50 (CH), 97.84 (C), 62.22 (CH), 56.23 (CH2), 
54.76 (CH3), 52.27 (2x CH2), 46.79 (CH2), 45.71 (CH2), 44.05 (CH2), 40.11 (2x CH3), 35.42 
(CH2), 27.32 (2x CH2), 25.63 (CH2), 24.02 (CH2); MS (ES +ve) [M+H]
+
: 507.6; HRMS (ES 
+ve), C27H39N8O2 [M+H]
+






Synthesis of 2-(4-bromo-2-methoxy-phenyl)-N-prop-2-ynyl-acetamide (91): 
 
2-(4-Bromo-2-methoxyphenyl)acetic acid (500 mg, 2.049 mmol) was dissolved in 5 ml of 
dry toluene. Thionyl chloride (1.2 eq., 2.46 mmol, 292.7 mg, 178.3 ul) was added followed 
by a drop of DMF and the reaction heated to reflux (120
o
C) for 3 hours. The reaction was 
cooled to r.t. then propargylamine (2.5 eq., 5.12 mmol, 282.2 mg, 0.328 ml) and 
triethylamine (2.5 eq., 5.12 mmol, 0.714 ml) added and the reaction left to stir for 20 hours. 
DCM and water were added to the mixture and the organic layer separated, dried over 
MgSO4 and concentrated in vacuo. The product was purified by column chromatography, 
MeOH/DCM (0-3 %) to give a cream coloured solid, (458.2 mg, 1.631 mmol, 79.6 %). 
1
H 
NMR (500 MHz, CDCl3) δ 7.13 – 7.07 (m, 2H), 7.04 (s, 1H), 5.78 (s, 1H), 3.99 (dd, J = 5.2, 
2.6, 2H), 3.86 (s, 3H), 3.51 (s, 2H), 2.21 – 2.16 (m, 1H); 
13
C NMR (126 MHz, CDCl3) δ 
170.11 (C), 157.79 (C), 132.32 (CH), 124.16 (CH), 122.35 (C), 122.07 (C), 114.50 (CH), 
79.53 (C), 71.45 (CH), 55.85 (CH3), 38.02 (CH2), 29.23 (CH2); MS (ES +ve) (M+H)
+
: 
281.6/283.6, 303.8/306.0 (+Na) 
 
Synthesis of 2-[(4-bromo-2-methoxy-phenyl)methyl]-5-methyl-oxazole (92): 
 
2-(4-bromo-2-methoxy-phenyl)-N-prop-2-ynyl-acetamide (200 mg, 0.713 mmol) was 
dissolved in 2 ml of 1,2-dichloroethane in a microwave vial. FeCl3 (0.5 eq., 57.6 mg, 0.356 
mmol) was added and the mixture heated to 150
o
C for 90 mins. Water and DCM were added 
to the mixture and the organic layer separated, dried over MgSO4 and concentrated in vacuo. 
The product was purified by column chromatography, MeOH/DCM (1 %), to give a light 
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yellow/orange oil, (108.7 mg, 0.389 mmol, 54.3 %). 
1
H NMR (500 MHz, CDCl3) δ 7.09 – 
7.03 (m, 2H), 7.01 (s, 1H), 6.65 (d, J = 1.1, 1H), 4.04 (s, 2H), 3.82 (s, 3H), 2.26 (d, J = 1.2, 
3H); 
13
C NMR (126 MHz, CDCl3) δ 161.66 (C), 157.87 (C), 148.90 (C), 131.42 (CH), 
123.66 (CH), 123.09 (C), 122.03 (CH), 121.65 (C), 114.31 (CH), 55.83 (CH3), 28.30 (CH2), 
10.88 (CH3); MS (ES +ve) (M+H)
+





To a solution of 2-[(4-bromo-2-methoxy-phenyl)methyl]-5-methyl-oxazole (80 mg, 0.285 
mmol) in dioxane/water (4.5/0.5 ml) was added bis(pinacolato)diboron (1.5 eq., 108.5 mg, 
0.427 mmol), potassium carbonate (1.5 eq., 59.0 mg, 0.427 mmol) and triphenylphosphine 
(20 mol %, 15.0 mg) followed by palladium acetate (5 mol %) and the mixture heated in the 
microwave at 120 
o
C for 30 mins. The mixture was concentrated in vacuo and purified by 
column chromatography, EtOAc/hexane (30-40 %) to give a clear oil, (37.0 mg, 0.1124 
mmol, 39.4 %). 
1
H NMR (500 MHz, MeOD) δ 7.35 – 7.30 (m, 1H), 7.20 – 7.12 (m, 1H), 














To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added 2-[[2-
methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]-5-methyl-oxazole 
(1 eq., 39.7 mg, 0.1205 mmol), potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and 
triphenylphosphine (20 mol %, 9.5 mg) followed by palladium acetate (5 mol %) and the 
mixture heated in the microwave at 120 
o
C for 30 mins. The mixture was concentrated in 
vacuo and purified by column chromatography, MeOH/DCM (10% then 0-30 drops of NEt3 
per 100 ml) to give a pale yellow solid, (36.8 mg, 0.0751 mmol, 62.3 %). 
1
H NMR (500 
MHz, MeOD) δ 8.28 (s, 1H), 7.38 (d, J = 7.6, 1H), 7.29 (s, 1H), 7.26 (dd, J = 7.6, 1.6, 1H), 
6.69 (d, J = 1.2, 1H), 4.57 (t, J = 6.6, 2H), 4.15 (s, 2H), 3.91 (s, 3H), 3.17 (d, J = 7.4, 2H), 
2.96 (t, J = 6.6, 2H), 2.69 (m, 1H), 2.56 (s, 6H), 2.31 (s, 3H), 2.17 (t, J = 11.0, 2H), 1.94 (m, 
2H), 1.54 (m, 2H); 
13
C NMR (126 MHz, MeOD) δ 162.54 (C), 158.55 (C), 157.95 (C), 
155.47 (CH), 154.21 (C), 149.33 (C), 145.01 (C), 133.18 (C), 130.96 (CH), 124.85 (C), 
121.56 (CH), 120.34 (CH), 110.70 (CH), 97.78 (C), 62.77 (CH), 56.03 (CH2), 54.78 (CH3), 
51.82 (2x CH2), 44.08 (CH2), 39.66 (2x CH3), 28.17 (CH2), 26.79 (2x CH2), 9.16 (CH3); MS 
(ES +ve) [M+H]
+
: 491.8; HRMS (ES +ve), C26H35N8O2 [M+H]
+









To a solution of 1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5/0.5 ml) was added 4-
(Cyanomethyl)benzeneboronic acid, (1 eq., 29.1 mg, 0.181 mmol), potassium carbonate (1.5 
eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 mg) followed by 
palladium acetate (5 mol %) and the mixture heated in the microwave at 120 
o
C for 30 mins. 
The mixture was concentrated in vacuo and purified by column chromatography, 
MeOH/DCM (5-10 % then 20 drops of NEt3 per 100 ml) to give a cream solid, (41.8 mg, 
0.1034 mmol, 85.8 %). 
1
H NMR (500 MHz, MeOD) δ 8.27 (s, 1H), 7.79 – 7.70 (m, 2H), 
7.59 (d, J = 8.3, 2H), 4.56 (t, J = 6.4, 2H), 4.03 (s, 2H), 3.18 (d, J = 5.8, 2H), 3.04 – 2.93 (m, 
3H), 2.74 (s, 6H), 2.17 (dd, J = 15.1, 6.9, 2H), 1.99 (d, J = 12.8, 2H), 1.61 – 1.51 (m, 2H); 
13
C NMR (126 MHz, MeOD) δ 158.49 (C), 155.47 (CH), 154.36 (C), 144.35 (C), 132.22 
(C), 128.84 (2x CH), 128.70 (2x CH), 117.95 (C), 110.00 (C), 97.74 (C), 63.27 (CH), 55.84 
(CH2), 51.39 (2x CH2), 44.11 (CH2), 39.27 (2x CH3), 26.32 (2x CH2), 21.98 (CH2); MS (ES 
+ve) [M+H]
+
: 405.0; HRMS (ES +ve), C22H29N8 (M+H)
+








10.6.5 Synthesis of Compounds 96-101 
Synthesis of 3-iodo-1-[2-(4-methylpiperazin-1-yl)ethyl]pyrazolo[3,4-d]pyrimidin-4-amine 
(96): 
 
100 mg, 0.265 mmol of 1-(2,2-diethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine was 
added to a 5 ml microwave tube. 2.5 ml of water and 2.5 ml of TFA were then added and the 
mixture heated to 100 
o
C for 30 mins in the microwave. The solvents were removed in vacuo 
to give a dark brown oil. 0.265 mmol of 2-(4-amino-3-iodo-pyrazolo[3,4-d]pyrimidin-1-
yl)acetaldehyde was suspended in 3 ml of DCM. 1-methylpiperizine (1.5 eq., 0.399 mmol, 
39.8 mg, 44.1 ul) was added followed by a drop of acetic acid and the mixture allowed to stir 
for 10 mins. Sodium triacetoxyborohydride (1.5 eq., 0.399 mmol, 84.6 mg) was added and 
the mixture allowed to stir for 17 hours overnight. The mixture was concentrated in vacuo 
and purified by column chromatography, MeOH/DCM (5-10 % then 0-15 drops of NEt3 per 
100 ml) to give a light orange thick oil, (89.1 mg, 0.2302 mmol, 86.9 %). 
1
H NMR (500 
MHz, MeOD) δ 8.22 (s, 1H), 4.51 (t, J = 6.0, 2H), 3.33 (d, J = 1.7, 4H), 3.20 – 3.04 (m, 4H), 
2.98 (t, J = 6.0, 2H), 2.83 (s, 3H); 
13
C NMR (126 MHz, MeOD) δ 158.05 (C), 155.67 (CH), 
153.80 (C), 103.55 (C), 87.02 (C), 55.51 (CH2), 53.44 (CH2), 49.45 (CH2), 44.18 (CH2), 











Synthesis of 3-iodo-1-[2-(4-methoxy-1-piperidyl)ethyl]pyrazolo[3,4-d]pyrimidin-4-amine 
(97): 
 
100 mg, 0.287 mmol of 1-(2,2-dimethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine 
was added to a 5 ml microwave tube. The mixture was then concentrated in vacuo. 0.287 
mmol of 2-(4-amino-3-iodo-pyrazolo[3,4-d]pyrimidin-1-yl)acetaldehyde was suspended in 3 
ml of DCM. 4-methoxypiperidine (1.5 eq., 0.430 mmol, 49.5 mg) was added followed by a 
drop of acetic acid and the mixture allowed to stir for 10 mins. Sodium 
triacetoxyborohydride (1.5 eq., 0.430 mmol, 91.1 mg) was then added and the mixture 
allowed to stir for 72 hours. The product was concentrated in vacuo and the product purified 
by column chromatography, MeOH/DCM (0-8 %) to give a pale yellow solid, (112 mg, 
0.279 mmol, 97.1 %). 
1
H NMR (500 MHz, MeOD) δ 8.23 (s, 1H), 4.53 (t, J = 6.6, 2H), 3.29 
(s, 1H), 2.98 (t, J = 6.5, 2H), 2.91 (s, 2H), 2.45 (s, 2H), 1.89 (s, 2H), 1.57 (s, 2H); 
13
C NMR 
(126 MHz, MeOD) δ 158.09 (C), 155.71 (CH), 153.68 (C), 103.71 (C), 87.16 (C), 75.13 










100 mg, 0.287 mmol of 1-(2,2-dimethoxyethyl)-3-iodo-pyrazolo[3,4-d]pyrimidin-4-amine 
was added to a 5 ml microwave tube. 2.5 ml of water and 2.5 ml of TFA were then added 
and the mixture heated to 100 
o
C for 30 mins in the microwave. The product was then 
concentrated in vacuo. 0.287 mmol of 2-(4-amino-3-iodo-pyrazolo[3,4-d]pyrimidin-1-
yl)acetaldehyde was suspended in 3 ml of DCM. 3-dimethylaminopiperidine (1.5 eq., 0.430 
mmol, 55.1 mg) was added followed by a drop of acetic acid and the mixture allowed to stir 
for 10 mins. Sodium triacetoxyborohydride (1.5 eq., 0.430 mmol, 91.1 mg) was added and 
the mixture allowed to stir for 18 hours. The mixture was concentrated in vacuo and purified 
by column chromatography, MeOH/DCM (5-10 %) to give a cream solid, (117.5 mg, 0.283 
mmol, 98.6 %). 
1
H NMR (500 MHz, MeOD) δ 8.22 (s, 1H), 4.54 – 4.43 (m, 2H), 3.08 (m, 
1H), 2.99 – 2.90 (m, 3H), 2.84 (s, 6H), 2.65  (m, 2H), 2.38 (m, 1H), 1.88 (m, 1H), 1.75 – 
1.65 (m, 2H), 1.55 – 1.47 (m, 1H); 
13
C NMR (126 MHz, MeOD) δ 158.13 (C), 155.80 (CH), 
153.62 (C), 103.65 (C), 87.01 (C), 62.48 (CH), 56.37 (CH2), 52.78 (CH2), 52.75 (CH2), 




Synthesis of tert-butyl N-[4-[4-amino-1-[2-(4-methylpiperazin-1-yl)ethyl]pyrazolo[3,4-
d]pyrimidin-3-yl]-2-methoxy-phenyl]carbamate (99): 
 
To a solution 3-iodo-1-[2-(4-methylpiperazin-1-yl)ethyl]pyrazolo[3,4-d]pyrimidin-4-amine 
(50 mg, 0.129 mmol) in dioxane/water (4.5 ml/0.5 ml) was added [4-(tert-
butoxycarbonylamino)-3-methoxy-phenyl]boronic acid (1.5 eq., 51.8 mg, 0.194 mmol), 
potassium carbonate (1.5 eq., 26.8 mg, 0.194 mmol) and triphenylphosphine (20 mol %, 10.2 
mg) followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 
120 
o
C for 30 mins. The mixture was concentrated in vacuo and purified by column 
224 
 
chromatography, MeOH/DCM (10 % then 0-20 drops of NEt3 per 100 ml) to give a brown 
solid, (55.4 mg, 0.115 mmol, 89.0 %). 
1
H NMR (500 MHz, MeOD) δ 8.25 (s, 1H), 8.06 (d, J 
= 8.2, 1H), 7.29 (d, J = 1.8, 1H), 7.24 (dd, J = 8.2, 1.8, 1H), 4.55 (t, J = 6.5, 2H), 3.97 (s, 
3H), 2.95 (t, J = 6.5, 2H), 2.57 (s, 8H), 2.35 (s, 3H), 1.55 (s, 9H); 
13
C NMR (126 MHz, 
MeOD) δ 158.54 (C), 155.42 (CH), 154.21 (C), 153.48 (C), 149.29 (C), 145.02 (C), 128.80 
(C), 127.42 (C), 120.44 (CH), 119.61 (CH), 110.16 (CH), 97.74 (C), 80.21 (C), 56.21 (CH2), 
55.10 (CH3), 54.16 (2x CH2), 51.64 (2x CH2), 44.06 (CH3), 43.84 (CH2), 27.21 (3x CH3); 
MS (ES +ve) (M+H)
+
: 483.6; HRMS (ES +ve), C24H35N8O3 (M+H)
+
: calculated 483.28266, 
found 483.28200. 
 
Synthesis of tert-butyl N-[4-[4-amino-1-[2-(4-methoxy-1-piperidyl)ethyl]pyrazolo[3,4-
d]pyrimidin-3-yl]-2-methoxy-phenyl]carbamate (100): 
 
To a solution of 3-iodo-1-[2-(4-methoxy-1-piperidyl)ethyl]pyrazolo[3,4-d]pyrimidin-4-
amine (50 mg, 0.124 mmol) in dioxane/water (4.5 ml/0.5 ml) was added [4-(tert-
butoxycarbonylamino)-3-methoxy-phenyl]boronic acid (1.5 eq., 49.8 mg, 0.187 mmol), 
potassium carbonate (1.5 eq., 25.8 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 6.5 
mg) followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 
120 
o
C for 30 mins. The mixture was concentrated in vacuo and purified by column 
chromatography, MeOH/DCM (0-10 %) to give a cream coloured solid, (60.0 mg, 0.121 
mmol, 97.3 %). 
1
H NMR (500 MHz, MeOD) δ 8.29 (s, 1H), 8.08 (d, J = 8.2, 1H), 7.31 (d, J 
= 1.8, 1H), 7.27 (dd, J = 8.2, 1.8, 1H), 4.63 (t, J = 6.6, 2H), 3.98 (s, 3H), 3.34 (s, 3H), 3.12 





(126 MHz, MeOD) δ 158.53 (C), 155.46 (CH), 154.22 (C), 153.42 (C), 149.28 (C), 145.17 
(C), 128.73 (C), 127.38 (C), 120.44 (CH), 119.50 (CH), 110.33 (CH), 97.94 (C), 80.15 (C), 
75.12 (CH), 56.21 (CH2), 55.10 (CH3), 54.79 (CH3), 50.02 (2x CH2), 43.60 (CH2), 29.69 (2x 
CH2), 27.21 (3x CH3); MS (ES +ve) [M+H]
+
: 498.2; HRMS (ES +ve), C25H35N7O4 [M+H]
+
: 
calculated 498.28233, found 498.2850. 
 
Synthesis of tert-butyl N-[4-[4-amino-1-[2-[3-(dimethylamino)-1-
piperidyl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxy-phenyl]carbamate (101): 
 
To a solution of 1-[2-[3-(dimethylamino)-1-piperidyl]ethyl]-3-iodo-pyrazolo[3,4-
d]pyrimidin-4-amine  (50 mg, 0.1205 mmol) in dioxane/water (4.5 ml/0.5 ml) was added [4-
(tert-butoxycarbonylamino)-3-methoxy-phenyl]boronic acid (1.5 eq., 48.3 mg, 0.181 mmol), 
potassium carbonate (1.5 eq., 25.0 mg, 0.181 mmol) and triphenylphosphine (20 mol %, 9.5 
mg) followed by palladium acetate (5 mol %)  and the mixture heated in the microwave at 
120 
o
C for 30 mins. The mixture was concentrated in vacuo and purified by column 
chromatography, MeOH/DCM (5-10 %) to give a dark red solid, (60.5 mg, 0.119 mmol, 98.4 
%). 
1
H NMR (500 MHz, MeOD) δ 8.25 (s, 1H), 8.05 (d, J = 8.2, 1H), 7.26 (d, J = 1.8, 1H), 
7.22 (dd, J = 8.2, 1.8, 1H), 4.58 – 4.48 (m, 2H), 3.94 (s, 3H), 3.13 (m, 1H), 2.97 (m, 3H), 
2.82 (s, 6H), 2.66 (m, 2H), 2.42 (m, 1H), 1.86 (m, 1H), 1.71 (m, 2H), 1.52 (m, 10H); 
13
C 
NMR (126 MHz, MeOD) δ 158.61 (C), 155.59 (CH), 154.11 (C), 153.49 (C), 149.33 (C), 
145.10 (C), 128.93 (C), 127.24 (C), 120.44 (CH), 119.66 (CH), 110.28 (CH), 97.76 (C), 
80.24 (C), 62.58 (CH), 56.39 (CH2), 55.12 (CH3), 52.86 (CH2), 52.73 (CH2), 44.28 (CH2), 
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40.32 (2x CH3), 27.20 (3x CH3), 24.59 (CH2), 21.84 (CH2); MS (ES +ve) [M+H]
+
: 511.0; 
HRMS (ES +ve), C26H39N8O3 (M+H)
+
: calculated 511.31396, found 511.31140. 
 
10.6.6 Synthesis of Compounds 102-104 
Synthesis of 1-(2,2-dimethoxyethyl)-3-iodo-pyrazole (102): 
 
To a solution of 3-iodo-1H-pyrazole (500 mg, 2.578 mmol) in DMF (10 ml) was added 
sodium hydride (1.5 eq., 3.867 mmol, 60% dispersion in mineral oil, 154.7 mg) and the 
suspension allowed to stir for 30 mins until the gas evolution had subsided. 
Bromoacetaldehyde dimethyl acetal (1.5 eq. 3.867 mmol, 649.6 mg, 0.454 ml) was then 
added dropwise and the mixture heated at 150 
o
C in the microwave for an hour. The mixture 
was concentrated in vacuo in order to remove as much DMF as possible. EtOAc and water 
were then added to the mixture and the organic layer separated. The aqueous layer was 
washed twice with EtOAc and organics combined, dried over MgSO4 and concentrated in 
vacuo. The product was purified by column chromatography, MeOH/DCM (0-1 %) to give a 
light orange solid, (519.2 mg, 1.841 mmol, 71.4 %). 
1
H NMR (500 MHz, CDCl3) δ 7.28 (d, 
J = 2.3, 1H), 6.40 (d, J = 2.3, 1H), 4.62 (t, J = 5.4, 1H), 4.20 (d, J = 5.4, 2H), 3.37 (d, J = 
2.4, 6H); 
13
C NMR (126 MHz, CDCl3) δ 132.61 (CH), 114.84 (CH), 103.29 (CH2), 94.49 
(C), 55.20 (2x CH3), 54.55 (CH); MS (ES +ve) (M+H)
+









Synthesis of 1-[2-(3-iodopyrazol-1-yl)ethyl]-N,N-dimethyl-piperidin-4-amine (103): 
 
1-(2,2-dimethoxyethyl)-3-iodo-pyrazole (250 mg, 0.887 mmol) was added to a microwave 
vial followed by water (0.25 ml) and TFA (0.25 ml) and the mixture heated to 100 
o
C in the 
microwave for an hour. The product was concentrated in vacuo and used without further 
purification. 0.887 mmol of 2-(3-iodopyrazol-1-yl)acetaldehyde was suspended in 5 ml of 
DCM. N,N-dimethylpiperidine-4-amine (1.5 eq., 1.33 mmol, 170.5 mg) was added followed 
by a drop of acetic acid and the mixture allowed to stir for 10 mins. Sodium 
triacetoxyborohydride (1.5 eq., 1.33 mmol, 281.9 mg) was added and the mixture allowed to 
stir for 72 hours. The mixture was concentrated in vacuo and purified by column 
chromatography, MeOH/DCM (5-10 % then 10-20 drops of NEt3 per 100 ml) to give a thick 
light orange oil, (306.3 mg, 0.880 mmol, 99.2 %). 
1
H NMR (500 MHz, MeOD) δ 7.54 (d, J 
= 2.3, 1H), 6.43 (d, J = 2.3, 1H), 4.27 (t, J = 6.4, 2H), 3.10 – 3.05 (m, 1H), 3.05 – 2.99 (m, 
2H), 2.85 – 2.76 (m, 8H), 2.17 (td, J = 12.0, 2.3, 2H), 2.01 (d, J = 13.2, 2H), 1.67 (tt, J = 
12.1, 6.1, 2H); 
13
C NMR (126 MHz, MeOD) δ 132.70 (CH), 114.34 (CH), 93.40 (C), 63.39 












Synthesis of tert-butyl N-[4-[1-[2-[4-(dimethylamino)-1-piperidyl]ethyl]pyrazol-3-yl]-2-
methoxy-phenyl]carbamate (104): 
 
To a solution of 1-[2-(3-iodopyrazol-1-yl)ethyl]-N,N-dimethyl-piperidin-4-amine (50 mg, 
0.1436 mmol) in dioxane/water (4.5 ml/0.5 ml) was added [4-(tert-butoxycarbonylamino)-3-
methoxy-phenyl]boronic acid (1.5 eq., 57.6 mg, 0.215 mmol), potassium carbonate (1.5 eq., 
29.7 mg, 0.215 mmol) and triphenylphosphine (20 mol %, 7.5 mg) followed by palladium 
acetate (5 mol %)  and the mixture heated in the microwave at 120 
o
C for an hour. The 
reaction was concentrated in vacuo and purified by column chromatography, MeOH/DCM 
(5-10 %) to give a dark orange solid, (42.7 mg, 0.0963 mmol, 67.1 %). 
1
H NMR (500 MHz, 
MeOD) δ 7.88 (s, 1H), 7.69 (d, J = 2.3, 1H), 7.42 (d, J = 1.7, 1H), 7.33 (dd, J = 8.3, 1.8, 1H), 
6.62 (d, J = 2.3, 1H), 4.33 (t, J = 6.4, 2H), 3.96 (s, 3H), 3.22 – 3.15 (m, 1H), 3.11 (s, 2H), 
2.94 (s, 2H), 2.85 (d, J = 14.6, 6H), 2.26 (s, 2H), 2.05 (s, 2H), 1.73 (d, J = 8.3, 2H), 1.55 (d, 
J = 4.2, 9H); 
13
C NMR (126 MHz, MeOD) δ 153.56 (C), 151.55 (C), 149.10 (C), 131.77 
(CH), 128.50 (C), 127.36 (C), 123.00 (C), 119.24 (CH), 117.75 (CH), 107.31 (CH), 102.25 
(CH), 63.48 (CH), 56.69 (CH2), 54.95 (CH3), 51.21 (2x CH2), 49.11 (CH2), 39.19 (2x CH3), 
27.23 (3x CH3), 26.22 (2x CH2); MS (ES +ve) (M+H)
+
: 444.2; HRMS (ES +ve), 
C24H38N5O3 (M+H)
+






10.7 Biology Methods 
 
10.7.1 Cell Culture General 
MCF7, MDA-MB-231 and SYF cells were grown in Dulbecco’s Modified Eagle medium 
(DMEM) and PC3 cells were grown in Roswell Park Memorial Institute medium (RPMI), 
supplemented with serum (10% fetal bovine serum) and L-glutamine (2 mM) and incubated 
in a Heracell 240i tissue culture incubator at 37 °C and 5 % CO2.  
 
10.7.2 Cell Viability Assay 
Cells were plated in 96-well plates at 2000 cells/well in 100 µl of DMEM medium 
containing 10% FBS and 2 mM L-glutamine and incubated for 48 h in an incubator at 37 
o
C 
and 5% CO2. After 48 hours, the media was aspirated from each well and replaced with 95 µl 
of fresh medium. Compounds, including DMSO, were prepared at 20X in DMEM medium 
in a separate 96-well intermediate plate. 5 µl from the intermediate plate was then added to 
each well containing cells. Untreated cells were incubated with DMSO (0.1% v/v). After 5 
days, PrestoBlue™ cell viability reagent (10 µl) was added to each well and the plates 
incubated for 60 - 90 min. Fluorescence emission was detected using a fluorescence plate 
reader (excitation 540 nm, emission 590 nm). All conditions were normalised to the 
untreated cells (100%) and curves were fitted using a four parameter logistic fit with 
minimum value constrained to zero using GraphPad Prism software, to calculate EC50 
values. 
 
10.7.3 Apoptosis Assay - Using the IncuCyte 
Cells were plated in 96-well Nunc™ black optical-bottom plates (Thermo Scientific) at 3000 
cells/well in 100 µl of DMEM medium containing 10% FBS and 2 mM L-glutamine and 
incubated for 48h in an incubator at 37 
o
C and 5% CO2. The media was replaced with 95 µl 
of fresh media containing NucView™ 488 from Biotium, at 1 µM concentration and drugs 
or DMSO added along a concentration gradient, as described in the cell viability assay, and 
the plates placed in the IncuCyte for incubation. Cell growth was monitored over 5 days 
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using phase and green fluorescence (excitation 460 nm, emission 524 nm) microscopy. Cell 
confluence and apoptotic (green) count was performed by the IncuCyte software. 
 
10.7.4 Cell Cycle Assay 
Cells were plated at 5000 cell/well in 100 µl of DMEM or RPMI medium containing 10% 
FBS and 2 mM L-glutamine in 96-well Nunc™ black optical-bottom plates and incubated at 
37 
o
C with 5% CO2. After 48 hours, the media was aspirated off and replaced with 95 µl of 
fresh media. Compounds, including DMSO, were prepared at 20X in DMEM or RMPI 
medium in a separate plate and 5 µl then added to each well containing cells. Untreated cells 
were incubated with DMSO (0.1% v/v). The cells were incubated for 24 hours at 37 
o
C then 
100 µl of 8% PFA in PBS was added to each well and left to incubate at room temperature 
for 20 mins. The media/PFA was removed and wells washed with 100 µl of PBS (x3). 100 µl 
of blocking buffer (PBS containing 1.1% BSA and 0.2% Trixton X100) was added to each 
well and left for 30 minutes. 30 µl of a primary antibody solution containing anti-Cyclin B1 
mixed mouse monoclonal antibody (1:300) and anti-pHH3 rabbit polyclonal antibody 
(1:800) was added to each well and plates incubated for an hour at room temperature. The 
solution was then removed and wells washed with 100 µl of blocking buffer (x3). 100 µl of 
blocking buffer was added to each well and plates incubated for 30 minutes at room 
temperature. 30 µl of a secondary antibody solution containing 4 µg/ml of DAPI, 
AlexaFluor® 488 Donkey anti-mouse antibody (1:500) and AlexaFluor® 594 Goat anti-
rabbit antibody (1:500) was added to each well and left to incubate for 45 mins at room 
temperature in the dark. The solution was then removed and plates washed with 100 µl of 
PBS (x3) and stored in 100 µl PBS in the dark until imaged. Images were acquired using the 
scan^R fluorescence microscope from Olympus or ImageXpress System from Molecular 
Devices and analysed using scan^R or ImageXpress software. Cells were sorted according to 
their cell cycle state by DNA content and intensity. 
 
10.7.5 Western Blotting Protocol 
Cells were plated at 1x10
6
 cells/well in 2 ml of DMEM medium containing 10% FBS and 2 
mM L-glutamine in 6-well plates and incubated at 37 
o
C with 5% CO2. After 24 hours, the 
media was aspirated and replaced with 2 ml of DMEM medium containing 0.1 % FBS and 2 
mM L-glutamine and the cells incubated for a further 24 hours. 2 µl of compounds dissolved 
in DMSO at appropriate concentration was then added to each well and plates incubated for 
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30 mins. 222 µl of FBS was then added to each well (giving a final concentration of 10%) 
and cells incubated for one hour. Cell lysates were then prepared using 100 µl of MD 
Anderson lysate buffer per well. The total cell protein concentration in each lysate was 
determined using Precision Red Advanced Protein Reagent #2 from Cytoskeleton. 25 µl of 
SDS-PAGE sample loading buffer, 10 µl of 1M DDT, lysate and water up to 100 µl to give 
solutions of 2-3 mg/ml were boiled at 100 
o
C for 3 mins. Samples were subjected to SDS-
PAGE on BioRad 4-15% precast gels over 60 mins at 140 V and transferred to PVDF 
membranes over 150 mins at 210 mA. Membranes were blocked for an hour at room 
temperature using Roche’s blocking buffer then primary antibodies added in 0.5 % blocking 
buffer at 4
o
C overnight. Membranes were washed with TBS/T (x3, 5 mins) then secondary 
antibody linked to horseradish peroxidase (HRP) added for an hour at room temperature. 
Following further washing with TBS/T (x3, 5 mins) and TBS (x2, 5 mins) HRP was detected 
by peroxidase enhanced chemiluminescence (POD ECL from Roche) and bands visualised 
using X-ray film or the ChemiDoc™ MP Imaging System from BioRad. 
 
10.7.6 Cell Migration Assay 
Cells were plated at 50000 cells/well in 100 µl of DMEM medium containing 10% FBS and 
2 mM L-glutamine in a 96-well ImageLock plate from Essen BioScience and left overnight 
to adhere in an incubator at 37 
o
C and 5% CO2. Scratch wounds were created in each well 
using the WoundMaker™ supplied by Essen BioScience and each well washed with media 
(100 µl, x2) to remove floating cells. 95 µl of fresh media was added in each well. 
Compounds, including DMSO, were prepared at 20X in DMEM medium in a separate plate 
and 5 µl then added to each well containing cells. Untreated cells were incubated with 
DMSO (0.1% v/v). Images were recorded every 30 mins using the IncuCyte-ZOOM™ for 
24 hours. Analysis was performed using the IncuCyte software. 
 
10.7.7 Zebra Fish Toxicology Assay (Work performed by Dr Liz Patton and Reece Dowling, 
The University of Edinburgh) 
Wild-type zebrafish embryos were collected from AB-TPL breeding pairs and reared at 28 
°C in E3 embryo media. The embryos, 2 days post fertilisation (dpf), were treated with 
compound 52 or Dasatinib at 100µM, and DMSO (0.1 % v/v) as negative control, for 2 
hours prior to tail amputation. The tails were then clipped from the 
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embryos. The embryos were incubated with drug for a further 2 hours before being washed 
off and replaced with fresh E3 media. For PP20 treatment, the fish were incubated for 1 hour 
pre-amputation and 1 hour post-amputation then replaced with fresh E3 media. The embryos 
were left to develop in E3 media at 28 
o
C for 2 days, after which, they were imaged by light 
microscopy. 
 
10.7.8 hERG Channel Inhibition (Work performed by CYPROTEX DISCOVERY LIMITED) 
The experiments are performed on an IonWorks™ HT Instrument (Molecular Devices 
Corporation), which automatically performs electrophysiology measurements in 48 single 
cells simultaneously. In a specialised 384-well plate (PatchPlate™), all cell suspensions, 
buffers and test compound solutions are at room temperature during the experiment. The 
cells used are Chinese hamster ovary (CHO) cells stably transfected with hERG (cell-line 
obtained from Cytomyx, UK). A single-cell suspension is prepared in extracellular solution 
(Dulbecco's phosphate buffered saline with calcium and magnesium pH 7-7.2) and aliquots 
added automatically to each well of a PatchPlate™. The cells are then positioned over a 
small hole at the bottom of each well by applying a vacuum beneath the plate to form an 
electrical seal. The vacuum is applied through a single compartment common to all wells 
which is filled with intracellular solution (buffered to pH 7.2 with HEPES). The resistance of 
each seal is measured via a common ground-electrode in the intracellular compartment and 
individual electrodes placed into each of the upper wells. Electrical access to the cells is then 
achieved by circulating a perforating agent, amphotericin, underneath the PatchPlate™ and 
then measuring the pre-compound hERG current. An electrode is positioned in the 
extracellular compartment and a holding potential of -80 mV applied for 15 sec. The hERG 
channels are then activated by applying a depolarising step to +40 mV for 5 sec and then 
clamped at -50 mV for 4 sec to elicit the hERG tail current, before returning to -80 mV for 
0.3 s. The compound is then added automatically to the upper wells of the PatchPlate™ from 
a 96-well microtitre plate containing a range of concentrations of each compound. Solutions 
are prepared by diluting 10 mM DMSO solutions of the test compound into extracellular 
buffer such that the final concentrations tested are 0.008, 0.04, 0.2, 1, 5 and 25 µM (final 
DMSO concentration 0.25%). The test compound is left in contact with the cells for 300 sec 
before recording currents using the some voltage-step protocol as in the pre-compound scan. 
Quinidine, an established hERG inhibitor, is included as a positive control and buffer 
containing 0.25% DMSO is included as a negative control. The results for all compounds on 
the plate are rejected and the experiment repeated if the IC50 value for quinidine or the 
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negative control is outside quality-control limits. Each concentration is tested in 4 replicate 
wells on the PatchPlate™. However, only cells with a seal resistance greater than 50 MOhm 
and a pre-compound current of at least 0.1 nA are used to evaluate hERG blockade. Post-
compound currents are then expressed as a percentage of pre-compound currents and plotted 
against concentration for each compound. Where concentration-dependent inhibition is 
observed, the data are fitted to the following equation and an IC50 value calculated: 
Y = (Vmax-Vmin)/(1+X/X50)
3
 + Ymin 
 
10.7.9 Cytochrome P450 Enzyme Inhibition (Work performed by Dr Scott Webster, The 
University of Edinburgh) 
The P450-Glo screening system (Promega) was used to determine any effects of compounds 
on the activity of the CYP450 enzymes responsible for drug metabolism.  The substrates 
used in this system are converted to a luciferin product by the CYP enzymes; luminescence 
is measured and represents the activity of the relevant enzyme.  The hit compounds were 
assayed at a concentration of 10 µM.  Assay buffer, substrate, positive inhibitor control and 
incubation times varied for each CYP enzyme assayed, these variables and concentrations 
for each are summarised in Table 2.3.  Each compound was added at 40 µM to a separate 
well of a white walled 96 well plate in a volume of 12.5 µL.  Compounds were prepared in 
luciferin-free water (with a final DMSO concentration of 1%) and assayed in duplicate.  
High controls contained luciferin-free water with DMSO (final concentration 1%) and low 
controls contained luciferin-free water only.  Positive control inhibitors were assayed at a 
final concentration of 10 µM.  Reaction mixture containing 12.5 µL of the relevant assay 
buffer, substrate and CYP membranes were added to the hit compounds, positive inhibitor 
and high control wells.  To the low control wells, 12.5 µL of reaction mixture was added 
which contained CYP-free control membranes.  The plates were sealed and placed on a plate 
shaker briefly to mix the contents of each well.  Plates were then pre-incubated at the assay 
reaction temperature of 37 °C for ten minutes.  The reaction was initiated by the addition of 
25 µL of NADPH regeneration system.  Plates were incubated at 37 °C for the duration of 
the activity assay (incubation time for each enzyme are shown in Table 2.3).  Following 
incubation, luciferin detection reagent was added at a volume of 50 µL per well and the 
luminescence signal was left to stabilize for twenty minutes at room temperature.  The 
luminescence signal in each well was read using a TECAN M1000 Infinite plate reader with 
an integration time of 1 second.  The signal detected in the low control wells was averaged 
and subtracted from the average signal from all other wells.  The signal was represented in 
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relative light units (RLU).  Measurements obtained in the high control (vehicle only) wells 
were used to calculate the % inhibition of CYP activity for each compound tested.  
10.7.10 Plasma Protein Binding (Work performed by Dr Scott Webster, The University of 
Edinburgh) 
The degree of plasma protein binding was determined for each compound using rapid 
equilibrium dialysis (RED) device inserts in their corresponding base plates according to the 
protocol reported by Waters et al (2008).  Each compound was diluted separately to a 
concentration of 10 µM in 200 µL of human plasma and transferred to the sample chamber 
of the RED device (indicated by red ring).  350 µL of PBS was added to the buffer chamber 
before the plate was sealed and incubated for 24 hours at 37˚C with rotation at 100 rpm.  
Following equilibrium dialysis, a 50 µL sample was obtained from both chambers of the 
RED device for each compound tested.  50 µL of PBS was added to the plasma samples 
(from the sample chamber) and 50 µL of plasma was added to the PBS samples (from the 
buffer chamber).  To precipitate protein in the samples, 300 µL of ice-cold 90:10 
acetonitrile:water with 0.1% formic acid (F.A.) was added to each sample.  Samples were 
vortexed briefly then incubated on ice for 30 minutes.  Samples were subject to 
centrifugation at 13,000 rpm for 10 minutes before the supernatant fraction was transferred 
to a 96 well deep well block.  The supernatant was dried down under nitrogen and re-
constituted in 70 µL of solvent (90:10 acetonitrile:water with 0.1% F.A.) before being 
transferred to a U-bottom 96 well plate for MS analysis.  Zero time point samples for each 
compound (no 24 hour dialysis) were prepared and used as controls.  Plates were frozen at -
20˚C prior to MS analysis.  LC-MS/MS was used to quantify the peak area of each 
compound in each compartment of the RED devices using MS tune settings established and 
validated for each compound. The peak areas detected in the 0 and 24 hour time point 
samples were utilised to calculate the % of compound which is bound to plasma protein. 
 
10.7.11 Human Liver Microsome Stability (Work performed by Dr Scott Webster, The 
University of Edinburgh) 
The microsomal stability of each compound was determined using human (or rat) liver 
microsomes.  Microsomes were thawed and diluted to a concentration of 2 mg/mL in 50 mM 
NaPO4 buffer pH 7.4.  Each compound was diluted in 4 mM NADPH (made in the 
phosphate buffer above) to a concentration of 10 µM.  Two identical incubation plates were 
prepared to act as a 0 minute and a 30 minute time point assay.  30 µL of each compound 
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dilution was added in duplicate to the wells of a U-bottom 96 well plate and warmed at 37˚C 
for approximately 5 minutes.  Verapamil, lidocaine and propranolol were utilised as 
reference compounds in this experiment.  Microsomes were also pre-warmed at 37˚C before 
the addition of 30 µL to each well of the plate resulting in a final concentration of 1 mg/mL.  
The reaction was terminated at the appropriate time point (0 or 30 minutes) by addition of 60 
µL of ice-cold 0.3M trichloroacetic acid (TCA) per well.  The plates were centrifuged for 10 
minutes at 1000 rpm and the supernatant fraction transferred to a fresh U-bottom 96 well 
plate.  Plates were sealed and frozen at -20˚C prior to MS analysis.  LC-MS/MS was used to 
quantify the peak area response of each compound before and after incubation with human 
liver microsomes using MS tune settings established and validated for each compound.  
These peak intensity measurements were used to calculate the % remaining after incubation 
with human microsomes for each hit compound. 
 
10.7.12 Human, Mouse and Rat Plasma Stability (Work performed by CYPROTEX 
DISCOVERY LIMITED) 
Plasma is adjusted to pH 7.4 using either hydrochloric acid or sodium hydroxide depending 
on the initial pH of the plasma. Incubations are performed at a test or control compound 
concentration of 1 µM in plasma, pH 7.4, at 37oC. The final DMSO concentration in the 
incubation is 2.5%. Reactions are terminated following 0, 15, 30, 60 and 120min by 
methanol containing internal standard. The sampling plate is centrifuged (2500rpm, 45min, 
4
o
C) and the supernatants from each time point pooled in cassettes of up to 4 compounds. 
Samples are analysed for parent compound by LC-MS/MS using Cyprotex generic analytical 
conditions. The percentage of parent compound remaining at each time point relative to the 0 
min sample is then calculated from LC-MS/MS peak area ratios (compound peak 
area/internal standard peak area). 
 
10.7.13 Hepatocyte Stability (Work performed by CYPROTEX DISCOVERY LIMITED) 
Cryopreserved pooled hepatocytes are purchased from a reputable commercial supplier and 
stored in liquid nitrogen prior to use. Williams E media supplemented with 2 mM L-
glutamine and 25 mM HEPES and test compound (final substrate concentration 3 µM; final 
DMSO concentration 0.25 %) are pre-incubated at 37°C prior to the addition of a suspension 
of cryopreserved hepatocytes (final cell density 0.5 x l0
6
 viable cells/ml in Williams E media 
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supplemented with 2 mM L-glutamine and 25 mM HEPES) to initiate the reaction. The final 
incubation volume Is 500 µl. A control incubation is included for each compound tested 
where lysed cells are added instead of viable cells. Two control compounds are included 
with each species. The reactions are stopped by transferring 50 µl of incubate to 100 µl 
methanol containing internal standard at the appropriate time points. The control (lysed cells) 
is incubated for 60 min only. The termination plates are centrifuged at 2500 rpm at 4 °C for 
30 min to precipitate the protein. Following protein precipitation, the sample supernatants 
are combined in cassettes of up to 4 compounds and analysed using Cyprotex generic LC-
MS/MS conditions. From a plot of in peak area ratio (compound peak area/internal standard 
peak area) against time, the gradient of the line is determined. Subsequently, half-life (t1/2) 
and intrinsic clearance (CLint) are calculated using the equations below: 
 
Elimination rate constant (k) = (-gradient) 
Half-life (t1/2) (min) = 0693/k 
Intrinsic clearance (CLint) (µl/min/million cells) = (V x 0.393)/t1/2 
 
Where V = incubation volume (µl)/number of cells. 
 
10.7.14 Pharmacokinetic Analysis (Work performed by CYPROTEX DISCOVERY 
LIMITED) 
Three female CD1 mice, 25-30g, were dosed per administration route per time point, per 
compound. The test compound was administered either orally or intravenously (typical dose 
level of 10 mg compound per kg body weight). Animals were given free access to food 
throughout the study. At the following time points, the animals were anaesthetised, blood 
collected in heparinised tubes and animals sacrificed: 
Oral dosing: 0.08, 0.25, 0.5, 1, 2, 4 and 8 hour post dose. 
IV dosing: 0.08, 0.25, 0.5, 1, 2, 4 and 8 hour post dose.  
 
10.7.15 Kinase Screening Assay (Work performed by Reaction Biology Corp.) 
 
Compound IC50 values were determined from 10-point, 1:3 dilution curves starting at either 
100 μM or 10 μM with 10μM ATP, by Reaction Biology Corp. For the whole kinome screen 
237 
 
compounds were screened against 340 wild type kinases at a single dose of 10 or 1 μM, in 
duplicate, with 10 μM of ATP. The data was averaged and plotted as percentage enzyme 
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ABL1 CHK1 FLT4/VEGFR3 MEK3 PKA STK38L/NDR2 
ABL2/ARG CHK2 FMS MEKK1 PKAcb STK39/STLK3 
ACK1 CK1a1 FRK/PTK5 MEKK2 PKAcg SYK 
AKT1 CK1d FYN MEKK3 PKCa TAK1 
AKT2 CK1epsilon GCK/MAP4K2 MELK PKCb1 TAOK1 
AKT3 CK1g1 GLK/MAP4K3 MINK/MINK1 PKCb2 TAOK2/TAO1 
ALK CK1g2 GRK1 MKK4 PKCd TAOK3/JIK 
ALK1/ACVRL1 CK1g3 GRK2 MKK6 PKCepsilon TBK1 
ALK2/ACVR1 CK2a GRK3 MLCK/MYLK PKCeta TEC 
ALK3/BMPR1A CK2a2 GRK4 MLCK2/MYLK2 PKCg TESK1 
ALK4/ACVR1B CLK1 GRK5 MLK1/MAP3K9 PKCiota TGFBR2 
ALK5/TGFBR1 CLK2 GRK6 MLK2/MAP3K10 PKCmu/PRKD1 TIE2/TEK 
ARAF CLK3 GRK7 MLK3/MAP3K11 PKCnu/PRKD3 TLK1 
ARK5/NUAK1 CLK4 GSK3a MNK1 PKCtheta TLK2 
ASK1/MAP3K5 COT1/MAP3K8 GSK3b MNK2 PKCzeta TNIK 
Aurora A CSK Haspin MRCKa/CDC42BPA PKD2/PRKD2 TNK1 
Aurora B DAPK1 HCK MRCKb/CDC42BPB PKG1a TRKA 
Aurora C DAPK2 HGK/MAP4K4 MSK1/RPS6KA5 PKG1b TRKB 
AXL DCAMKL1 HIPK1 MSK2/RPS6KA4 PKG2/PRKG2 TRKC 
BLK DCAMKL2 HIPK2 MSSK1/STK23 PKN1/PRK1 TSSK2 
BMPR2 DDR1 HIPK3 MST1/STK4 PKN2/PRK2 TSSK3/STK22C 
BMX/ETK DDR2 HIPK4 MST2/STK3 PKN3/PRK3 TTBK1 
BRAF DLK/MAP3K12 HPK1/MAP4K1 MST3/STK24 PLK1 TTBK2 
BRK DMPK IGF1R MST4 PLK2 TXK 
BRSK1 DMPK2 IKKa/CHUK MUSK PLK3 TYK1/LTK 
BRSK2 DRAK1/STK17A IKKb/IKBKB MYLK3 PLK4/SAK TYK2 
BTK DYRK1/DYRK1A IKKe/IKBKE MYO3b PRKX TYRO3/SKY 
c-Kit DYRK1B IR NEK1 PYK2 ULK1 
c-MER DYRK2 IRAK1 NEK11 RAF1 ULK2 
c-MET DYRK3 IRAK4 NEK2 RET ULK3 
c-Src DYRK4 IRR/INSRR NEK3 RIPK2 VRK1 
CAMK1a EGFR ITK NEK4 RIPK3 VRK2 
CAMK1b EPHA1 JAK1 NEK5 RIPK5 WEE1 
CAMK1d EPHA2 JAK2 NEK6 ROCK1 WNK1 
CAMK1g EPHA3 JAK3 NEK7 ROCK2 WNK2 
CAMK2a EPHA4 JNK1 NEK9 RON/MST1R WNK3 
CAMK2b EPHA5 JNK2 NLK ROS/ROS1 YES/YES1 
CAMK2d EPHA6 JNK3 OSR1/OXSR1 RSK1 ZAK/MLTK 
CAMK2g EPHA7 KDR/VEGFR2 P38a/MAPK14 RSK2 ZAP70 
CAMK4 EPHA8 KHS/MAP4K5 P38b/MAPK11 RSK3 ZIPK/DAPK3 
CAMKK1 EPHB1 LATS1 P38d/MAPK13 RSK4  
CAMKK2 EPHB2 LATS2 P38g SGK1  
CDC7/DBF4 EPHB3 LCK p70S6K/RPS6KB1 SGK2  
CDK1/cyclin A EPHB4 LCK2/ICK p70S6Kb/RPS6KB2 SGK3/SGKL  
CDK1/cyclin B ERBB2/HER2 LIMK1 PAK1 SIK1  
CDK1/cyclin E ERBB4/HER4 LIMK2 PAK2 SIK2  
CDK16/cyclin Y 
(PCTAIRE) 
ERK1 LKB1 PAK3 SIK3  
CDK2/cyclin A ERK2/MAPK1 LOK/STK10 PAK4 SLK/STK2  
CDK2/Cyclin A1 ERK5/MAPK7 LRRK2 PAK5 SNARK/NUAK2  
CDK2/cyclin E ERK7/MAPK15 LYN PAK6 SRMS  
CDK3/cyclin E FAK/PTK2 LYN B PASK SRPK1  
CDK4/cyclin D1 FER MAPKAPK2 PBK/TOPK SRPK2  
CDK4/cyclin D3 FES/FPS MAPKAPK3 PDGFRa SSTK/TSSK6  
CDK5/p25 FGFR1 MAPKAPK5/PRAK PDGFRb STK16  
CDK5/p35 FGFR2 MARK1 PDK1/PDPK1 STK22D/TSSK1  
CDK6/cyclin D1 FGFR3 MARK2/PAR-1Ba PHKg1 STK25/YSK1  
CDK6/cyclin D3 FGFR4 MARK3 PHKg2 STK32B/YANK2  
CDK7/cyclin H FGR MARK4 PIM1 STK32C/YANK3  
CDK9/cyclin K FLT1/VEGFR1 MEK1 PIM2 STK33  
CDK9/cyclin T1 FLT3 MEK2 PIM3 STK38/NDR1  
 






















PI3K (p110a/p65a) SPHK2 
PI3K (p110a/ (E542K)/p85a) PI4K2A 
PI3K (p110a (E545K)/p85a) PIP5K1A 
PI3K (p110a (H1047R)/p85a) PIP5K1C 
PI3KC2aPIK3C2A 
 















Synthesis of PP20: a) 2-iodopropane, NaH, DMF, mw, 150 
o
C. b) [4-(tert-
butoxycarbonylamino)-3-methoxy-phenyl]boronic acid, K2CO3, Pd(OAc)2, PPh3, 1,4-
dioxane/water (10:1), 120 
o
C, mw. 
